патент
№ US 0008148380
МПК A61K31/497

Antibacterial amide and sulfonamide substituted heterocyclic urea compounds

Авторы:
Joseph Guiles Thale Jarvis Sarah Strong
Все (18)
Правообладатель:
Все (15)
Номер заявки
12669634
Дата подачи заявки
23.07.2008
Опубликовано
03.04.2012
Страна
US
Дата приоритета
07.02.2026
Номер приоритета
Страна приоритета
Как управлять
интеллектуальной собственностью
Реферат

The present invention provides novel amide and sulfonamide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.

Формула изобретения

1. A compound of Formula (I):

in which:

R1is selected from the group consisting of a substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroaryl;

X is selected from the group consisting of a C and N atom;

Y is selected from the group consisting of CO and SO2;

R2, R3and R4are independently selected from the group consisting of H, OH, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted linear, cyclic or branched alkyl, cyano, and perfluoroalkyl; and

R5is selected from the group consisting of H, halogen, alkyl, cyano and null, wherein R5is null when X is N;

wherein R2, R4, Y and N or R2, R3, CH and N do not form a substituted or unsubstituted 4-7 member saturated ring.

2. A compound of Formula (I):

in which:

R1is selected from the group consisting of a substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroaryl;

X is selected from the group consisting of a C and N atom;

Y is selected from the group consisting of CO and SO2;

R3is selected from the group consisting of H, OH, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted linear, cyclic or branched alkyl, cyano, and perfluoroalkyl; and

R5is selected from the group consisting of H, halogen, alkyl, cyano and null, wherein R5is null when X is N,

wherein R2, R4, Y and N form a substituted or unsubstituted 4-7 member saturated ring.

3. A compound of Formula (I):

in which:

R1is selected from the group consisting of a substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroaryl;

X is selected from the group consisting of a C and N atom;

Y is selected from the group consisting of CO and SO2;

R4is selected from the group consisting of H, OH, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted linear, cyclic or branched alkyl, cyano, and perfluoroalkyl; and

R5is selected from the group consisting of H, halogen, alkyl, cyano and null, wherein R5is null when X is N,

wherein R2, R3, CH and N form a substituted or unsubstituted 4-7 member saturated ring.

4. The compound of claim 1, wherein R1is a substituted or unsubstituted phenyl or thiophene group.

5. The compound of claim 4, wherein R1is a phenyl group having one or more substituents selected from the group consisting of halogen, cyano, (C1-6)alkyl, mono to perfluoro(C1-3)alkyl, (C3-7)cycloalkyl, (C2-6)alkenyl, (C1-6)alkoxy, (C2-6)alkenoxy, hydroxy, amino, mono- or di-(C1-6)alkylamino, acylamino, nitro, carboxy, (C1-6)alkoxycarbonyl, (C1-6)alkenyloxycarbonyl, (C1-6)alkoxycarbonyl(C1-6)alkyl, carboxy(C1-6)alkyl, (C1-6)alkylcarbonyloxy, carboxy(C1-6)alkyloxy, (C1-6)alkoxycarbonyl(C1-6)alkoxy, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)-alkylsulphamoyl, and carbamoyl.

6. The compound of claim 1, wherein R1is selected from the group consisting of 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3-iodophenyl, 4-iodophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-4-methylendioxyphenyl, 3-4-difluorophenyl, 3-4-dichlorophenyl, 3-4-dibromophenyl, 3-4-dimethylphenyl, 3-4-(—CH2CH2CH2—)phenyl, 3-4-(—OCH2CH2O—)phenyl, 3-chloro-4-fluorophenyl, benzo[1,3]dioxyl-5-yl, and 3-3-cyanophenyl, 3,5-difluorophenyl, thiophen-2-yl, thiophen-3-yl, 4,5-di-bromo-thiophen-2yl, 5-chloro-thiophen-2yl, and 5-bromo-thiophen-2yl, 5-fluoro-thiophen-2-yl, 5-chloro-thiophen-3-yl, 1,1,-difluoro-benzo[1,3]dioxyl-5-yl, 7-chlorobenzo[1,3]dioxol-5-yl, 3-nitrophenyl, 2,1,3-benzoxadiazol-5-yl, and 4-nitrophenyl.

7. The compound of claim 1, wherein Y is a CO group.

8. The compound of claim 7, wherein X is C atom.

9. The compound of claim 7, wherein X is N atom.

10. The compound of claim 1, wherein Y is a SO2group.

11. The compound of claim 10, wherein X is a C atom.

12. The compound of claim 10, wherein X is an N atom.

13. The compound of claim 1, wherein R2is selected from the group consisting of H, methyl, ethyl, 2-hydroxyethyl, 2-methoxyethyl, 2-aminoethyl, propyl, cyclopropyl, isopropyl, 2,4-dimethoxybenzyl, 2-methanesulfonylaminoethyl, 2,2-Difluoro-ethyl, and 3,5-dimethylisoxazole-4-yl-methyl.

14. The compound of claim 1, wherein R3is selected from the group consisting of H, methyl, ethyl, 2-hydroxyethyl, 2-hydroxymethyl, 2-methoxyethyl, 2-aminoethyl, propyl, cyclopropyl, isopropyl, 2,4-dimethoxybenzyl, and 2-methanesulfonylaminoethyl.

15. The compound of claim 1, wherein R4is selected from the group consisting of methyl, 2-(2-methoxyethoxy)-methyl, 2-methoxymethyl, 4-methylisoxazole-5-yl, isoxazole-5-yl, 3-phenylpropanyl, furan-2-yl, 4-phenoxybutanyl, 1,1-dioxo-tetrahydro-1-lamda6-thiophen-3-ylmethylaminoyl, 3,5-dimethylisoxazole-4-yl, 1-methyl-1H-imidazole-5-yl, furan-3-yl, 3-methylfuran-2-yl, 5-methyl-3-phenylisoxazole-4-yl, 5-methyl-2-phenyl-2H-1,2,3-triazole-4-yl, 5-methylisoxazole-3-yl, 3-methyl-5-phenylisoxazole-4-yl, 3-methyl-5-(4-methyl-1,2,3-thiadiazol-5-yl)isoxazole-4-yl, 2-(2H-tetrazol-5-yl)methyl, benzofuran-2-yl, 1,2,5-oxadiazole-3-yl, (3,5-dimethylisoxazol-4-yl)-methyl, 3-methylisoxazole-4-yl, 5-methylisoxazole-4-yl, 5-cyclopropyl-isoxazole-4-yl, 2,6-dimethylphenyl, 5-(furan-2-yl)-isoxazole-3-yl, 2,5-dimethyloxazole-4-yl, 2-phenylthiazole-4-yl, 2-(thiophen-2-yl)thiazole-4-yl, 3-hydroxy-isoxazole-5-yl, 5-phenyl-1,3,4-oxadiazole-2-yl, 5-methylfuran-2-yl, 4-methyl-1,2,5-oxadiazole-3-yl, 4-methyl-2-(pyrazin-2-yl)thiazole-5-yl, 2,4-dimethoxy-phenyl, 4-methoxy-phenyl, 3,4-dimethoxy-phenyl, benzo[1,3]dioxole-5-yl, 3,4,5-trimethoxy-phenyl, 5-methyl-3-(trifluoromethyl)isoxazole-4-yl, pyridin-3-ylmethyl, 2,4-dimethylpyridine-3-yl, 2,4,6-trimethylphenyl, 5-(methoxymethyl)-3-methylisoxazole-4-yl, 2-methoxy-methyl, 2-methoxyformyl, 3-ethyl-5-methylisoxazole-4-yl, pyrimidine-5-yl, pyrazine-2-yl, 5-methylpyrazine-2-yl, furan-3-yl, 4-methyloxazole-5-yl, 2-tosylmethyl, 3-ethylcarboxy-5-methylisoxazole-4-yl, 3-carboxy-5-methylisoxazole-4-yl, 2-methylpyridine-3-yl, 4-methylpyridine-3-yl, 3-chloro-4-(methylsulfonyl)thiophene-2-yl, 4-methylthiazole-5-yl, 5-oxo-3,5-dihydro-2H-thiazolo[3,2-a]pyrimidine-6-yl, 4-methyl-2-(methylthio)pyrimidine-5-yl, 2-methylprop-1-enyl, 2-methylphenyl, quinoxaline-2,3-methylpyridine-4-yl, 3-methylisoxazole-4-yl, 4-amino-pyrimidine-5-yl, 2-amino-4-methylpyrimidine-5-yl, 4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-yl, 2,4,6-trimethylpyrimidine-5-yl, 3-methylpyrazine-2-yl, 4-Boc-amino-1-methyl-1H-imidazole-2-yl, 4-amino-1-methyl-1H-imidazole-2-yl, 4-acetamido-1-methyl-1H-imidazole-2-yl, 4,6-dimethylpyrimidine-5-yl, 3-(hydroxymethyl)-5-methylisoxazole-4-yl, 3-methylpyridine-2-yl, 2-amino-4,6-dimethylpyrimidine-5-yl, 2-methylimidazo[1,2-a]pyridine-3-yl, tetrahydrofuran-2-yl, 2-methoxypyridine-3-yl, tetrahydrofuran-3-yl, methoxyformyl, 2-chloropyridine-3-yl, 1,3,5-tetramethyl-1H-pyrazole-4-yl, (S)-tetrahydrofuran-2-yl, (R)-tetrahydrofuran-2-yl, 3-propoxypyridine-4-yl, N-Boc-morpholine-2-yl, morpholine-2-yl, pyridazine-4-yl, 3,5-dimethyl-1H-pyrazole-4-yl, pyridazine-3-yl, tetrahydro-2H-pyran-4-yl, 1,5-dimethyl-1H-pyrazole-4-yl, morpholine-3-yl, 4-methylpyrrolidine-3-yl, (S)-pyrrolidine-2-yl, 1,1-Dioxo-tetrahydro-1-lamda6-thiophene-3-yl, 4-methylphenyl, methyl, ethyl, propyl, butyl, cyclopropyl, and 1,1-Dioxo-1-isothiazolidin-2-yl, 2-methyl-5,6-dihydro-4H-pyran-3-yl, 2-methyl-5-morpholin-4-ylmethyl-furan-3-yl, 2-methyl-but-2-enyl, [1,2,3]thiadiazole-4-yl, 2-pyridin-3-yl-thiazole-4-yl, 2,5-dimethyl-2H-pyrazole-3-yl, 4-methyl-furazan-3-yl, 2-morpholin-4-ylmethyl-furan-3-yl, 1-methyl-pyrrolidine-2-yl, 1-methyl-1H-pyrrole-2-yl, 1,5-dimethyl-1H-[1,2,3]triazole-4-yl, 5-fluoro-thiophene-2-yl, 4-methyl-pyrimidine-5-yl, 4-methyl-2-phenyl-pyrimidine-5-yl, 2-methylsulfanyl-nicotinyl, acetonitrile, 6-morpholin-4-yl-nicotinyl, 4-methyl-thiazole-5-yl, 3-methyl-1H-pyrazole-4-yl, 2,4-dimethyl-pyrimidine-5-yl, 2-methyl-[1,6]naphthyridine-3-yl, 6-(4-methoxy-phenyl)-pyridazine-3-yl, 2,6-bis-dimethylamino-pyrimidine-4-yl, 2,6-di-morpholin-4-yl-pyrimidine-4-yl, 3-pyridin-3-yl-acrylonitrile-2-yl, 2-methyl-[1,8]naphthyridine-3-yl, 2-dimethylamino-6-methyl-pyrimidine-4-yl, acetic acid 1-yl-ethyl ester, 1-ethyl-3-methyl-1H-pyrazole-4-yl, 2-methyl-pyrazolo[1,5-a]pyrimidine-3-yl, 1-hydroxy-ethyl, 1-ethyl-5-methyl-1H-pyrazole-4-yl, 5,7-dimethyl-pyrazolo[1,5-a]pyrimidine-3-yl, 1-methyl-1H-indole-3-yl, 1-methyl-1H-indazole-3-yl, pyrazolo[1,5-a]pyridine-3-yl, 2-furan-2-yl-oxo, 5-oxo-pyrrolidine-2-yl, 4-methyl-pyridazine-3-yl, 5-methyl-pyridazine-4-yl, 3-amino-1H-pyrazole-4-yl, 3,6-dimethoxy-pyridazine-4-yl, 3,6-dichloro-pyridazine-4-yl, pyridine-3-yl, pyridine-2-yl, 1-methyl-1H-imidazole-4-yl, 1,2-dimethyl-1H-imidazole-4-yl, pyridin-3-yl-methyl, 3-chloro-6-methoxy-pyridazin-4-yl, 3,5-dimethyl-pyridazin-4-yl, 1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl, 3-chloro-6-hydroxy-pyridazin-4-yl, 2-methyl-tetrahydrofuran-2-yl, 4-chloro-1-methyl-1H-pyrazol-3-yl, 5-chloro-1-methyl-1H-pyrazol-4-yl, 4-chloro-2-methyl-2H-pyrazol-3-yl, 4-chloro-1H-pyrazol-3-yl, 1,3,6-trimethyl-1H-pyrazolo[3,4-b]pyridin-3-yl, 2-methyl-5-sulfamoyl-phenyl, 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl, 1-phenyl-cyclobutyl, 3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl, 7-chloro-benzo[1,3]dioxol-5-yl, 6-[1,2,4]triazol-1-yl-pyridin-3-yl, 1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl, 2-(2,4-dioxo-3,4-dihydropyrimidin-1-(2H)-yl)methyl, 6-chloro-3-hydroxy-pyridazin-4-yl, 3-cyano-2-hydroxy-6-methyl-pyridin-4-yl, 1-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazol-4-yl, 4-oxo-3,4-dihydrophthalazin-1-yl, 4,6-dimethyl-2-oxo-2H-pyran-5-yl, 1-methyl-4-sulfamoyl-1H-pyrrol-2-yl, (5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)methyl, 3,6-dimethyl-4-oxo-3,4-dihydrofuro[2,3-d]pyrimidin-5-yl, 5-methyl-4-oxo-3,4-dihydrothieno[2,3-b]pyrimidin-6-yl, phenyl-difluoromethyl, 4-hydroxyl-1-carbamoyl-pyrrolidin-2-yl, 2-(1-morpholino)-pyridin-3-yl, 1-(3-fluorophenyl)-cyclobutyl, 1-methyl-5-trifluoromethyl-1H-pyrazol-4-yl, (S)-1-methoxyethyl, 3-methyl-5,6-dihydro-1,4-dioxin-2-yl, (R)-5-oxo-tetrahydrofuran-2-yl, 5-chloro-1,3-dimethyl-1H-pyraozol-4-yl, 2-methoxy-ethyl, 1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl, (R)-1-methoxy-ethyl, 1-(2-methoxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl, tetrahydro-2H-pyran-2-yl, 3,6-dimethylisoxazolo[5,4-b]pyridine-4-yl, 5-methoxy-tetrahydrofuran-2-yl, 1-(4-methoxybutyl)-3,5-dimethyl-1H-pyrazol-4-yl, 1-(3-methoxypropyl)-3,5-dimethyl-1H-pyrazol-4-yl, 1-(4-fluorophenyl)-cyclobutyl, 5-methyl-tetrahydrofuran-2-yl, 3-methyl-oxetan-3-yl, 5-chloro-1H-pyrazol-4-yl, (R)-2,2-dimethyl-1,3-dioxolan-4-yl, (S)-2,2-dimethyl-1,3-dioxolan-4-yl, 3,6-dichloro-5-methyl-pyridazin-4-yl, 6-methoxyl-3-methyl-pyridazin-4-yl, 1-methyl-5-nitro-1H pyrazol-4-yl, 2,3-dihydrobenzofuran-2-yl, 6-hydroxy-3-methyl-pyridazin-4-yl, 2-(1-pyrrolidinyl)-pyridin-3-yl, 3-oxo-3-(2-thiophenyl)-propyl, 3-oxo-3-phenyl-propyl, 3-fluoro-4-methoxy-benzyl, 3,4-dimethoxy-benzyl, 4-(hydroxymethyl)-phenoxy-methyl, 3-methylsulfonyl-benzyl, 2-mercapto-4-methyl-thiazol-5-yl, 5-trifluoromethyl-furan-2-yl, 6-hydroxy-3-methylamino-pyridazin-4-yl, 3-(dimethylamino)-6-methoxy-pyridazin-4-yl, 2,2-dimethyl-tetrahydro-2H-pyran-4-yl, 4-(dimethylamino)-benzyl, 7-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl, 1H-benzoimidazol-2-yl, naphthalene-2-yl-methyl, 4-methoxy-3-methyl-benzyl, 1-amino-2-benzyloxy-ethyl, 1,4-dioxo-1,2,3,4-tetrahydrophthalazin-6-yl, 2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-methyl, 5-nitro-1H-pyrazol-4-yl, (S)-3,3-difluoro-tetrahydrofuran-2-yl, chroman-2-yl, 3,5-dimethyl-1H-pyrazol-4-yl, 4-butynyl, 2-methyl-1,2,34-tetrahydroisoquinolin-3-yl, (S)-2-(4-pyridinyl), 1-amino-ethyl, cis-3-methoxy-tetrahydrofuran-2-yl, 1-cyano-cyclopropyl, ethynyl, 1-ethoxy-ethyl, 1-(4-methoxy-phenoxy)ethyl, 1-(cyclopropylmethoxy)ethyl, 1,4-diamino-butyl, 1-(2-phenoxyethoxy)ethyl, cyclopropylmethyl, 3-ethyl-3-oxetan-3-yl, 1-(2,2-difluoroethoxy)ethyl, 1-(4-fluoro-benzyloxy)ethyl, 1-(2,2,2-trifluoroethoxy)ethyl, 1-(prop-2-ynyloxy)ethyl, 5-methyl-isoxazol-3-yl, 1-((1-methyl-pyrrolidin-3-yl)oxy)ethyl, 1-(2-hydroxyethoxy)ethyl, cyclopentyl, 1-hydroxy-cyclopropyl, cyclohexyl, 2-methyl cyclohexyl, 2-oxo-2,3-dihydrobenzoxazol-6-yl, 2,2,2-trifluoroethyl, 1-hydroxy-1-methyl-ethyl, (R)-5-(hydroxymethyl)tetrahydrofuran-2-yl, (4-hydroxy-2-oxo-pyrrolidin-1-yl)methyl, 1,2,2,2-tetrafluoroethyl, 1-carbamoyl-cyclopropyl, 2-methyl-cyclopropyl, 5-chloro-1,3-dimethyl-1H-pyrazol-4-yl, 5-isopropyl-3-methyl-isoxazol-4-yl, and 1,3,5-trimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl.

16. The compound of claim 2, wherein R2, R4, Y and N together form 2,4-dioxothiazolidin-3-yl.

17. The compound of claim 2, wherein R2, R4, Y and N together form 2-oxooxazolidin-3-yl.

18. The compound of claim 3, wherein R2, R3, CH and N together form 4-aceoxy-1-(methylsulfonyl)pyrrolidin-2-yl.

19. The compound of claim 3, wherein R2, R3, CH and N together form 4-hydroxy-1-(methylsulfonyl)pyrrolidin-2-yl.

20. A compound selected from the group consisting of:

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-methoxyethyl)acetamide;

3-(N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)acetamido)propylphosphonic acid;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-2-(2-methoxyethoxy)-N-methylacetamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylacetamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylisoxazole-5-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylisoxazole-5-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-3-phenylpropanamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylfuran-2-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-phenoxybutanamide;

1-(3,4-Dichloro-benzyl)-3-{4-[3-(1,1-dioxo-tetrahydro-1,6-thiophen-3-ylmethyl)-1-methyl-ureidomethyl]-thiazol-2-yl}-urea;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-1H-imidazole-5-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylfuran-3-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylfuran-2-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-3-phenylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-ethyl-3,5-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-isopropyl-3,5-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-3-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyl-5-phenylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyl-5-(4-methyl-1,2,3-thiadiazol-5-yl)isoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(2H-tetrazol-5-yl)acetamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbenzofuran-2-carboxamide;

N-(1-(2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)ethyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-1,2,5-oxadiazole-3-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-2-(3,5-dimethylisoxazol-4-yl)-N-methylacetamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-3-ethyl-N,5-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-4-carboxamide;

5-cyclopropyl-N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,6-trimethylbenzamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-5-(furan-2-yl)-N-methylisoxazole-3-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,5-trimethyloxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-phenylthiazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2,4-dimethoxybenzyl)-3,5-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-methoxyethyl)-3,5-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(thiophen-2-yl)thiazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-3-hydroxy-N-methylisoxazole-5-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-phenyl-1,3,4-oxadiazole-2-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylfuran-2-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethyl-1,2,5-oxadiazole-3-carboxamide;

4-Methyl-2-pyrazin-2-yl-thiazole-5-carboxylic acid {2-[3-(3,4-dichlorobenzyl)ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-2,4-dimethoxy-N-methylbenzamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-4-methoxy-N-methylbenzamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-3,4-dimethoxy-N-methylbenzamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbenzo[1,3]dioxole-5-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-3,4,5-trimethoxy-N-methylbenzamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-3-(trifluoromethyl)isoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(pyridin-3-yl)acetamide;

N-(1-(2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)-2-(methylamino)-2-oxoethyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,4-trimethylnicotinamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,4,6-tetramethylbenzamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-hydroxyethyl)-3,5-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-(methoxymethyl)-N,3-dimethylisoxazole-4-carb oxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-5-(methoxymethyl)-N,3-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylacetamide;

methyl 2-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)amino)-2-oxoacetate;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylisoxazole-4-carboxamide;

3-ethyl-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,4-trimethylnicotinamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrazine-2-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrimidine-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrimidine-5-carboxamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrazine-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylpyrazine-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylfuran-3-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethyloxazole-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-3-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-tosylacetamide;

Ethyl 4-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)-5-methylisoxazole-3-carboxylate;

4-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)-5-methylisoxazole-3-carboxylic acid;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylnicotinamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylnicotinamide;

3-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-(methylsulfonyl)thiophene-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylthiazole-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-oxo-3,5-dihydro-2H-thiazolo[3,2-a]pyrimidine-6-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethyl-2-(methylthio)pyrimidine-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylbut-2-enamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylbenzamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylquinoxaline-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylpicolinamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-((4-methoxybenzyloxy)methyl)-N,3-dimethylisoxazole-4-carboxamide;

N-(2-Aminoethyl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3,5-dimethylisoxazole-4-carboxamide;

4-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrimidine-5-carboxamide;

2-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylpyrimidine-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3,5-dimethyl-N-(2-(methylsulfonamido)ethyl)isoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethyl-2-oxo-1,2-dihydropyridine-3-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,4,6-tetramethylpyrimidine-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide;

tert-butyl 2-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)-1-methyl-1H-imidazol-4-ylcarbamate;

4-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-1H-imidazole-2-carboxamide;

4-acetamido-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-1H-imidazole-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethylpyrimidine-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-(hydroxymethyl)-N,5-dimethylisoxazole-4-carboxamide;

N-((2-(3-(4-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(3,5-difluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylisonicotinamide;

N-((2-(3-(3-chlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(benzo[1,3]dioxol-5-ylmethyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

2-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethylpyrimidine-5-carboxamide;

N-((2-(3-((2,2-difluorobenzo[1,3]dioxol-5-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylimidazo[1,2-a]pyridine-3-carboxamide;

N,3,5-trimethyl-N-((2-(3-(3-(N-methylacetamido)benzyl)ureido)thiazol-4-yl)methyl)isoxazole-4-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;

1-(4-((2,4-dioxothiazolidin-3-yl)methyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylnicotinamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-3-carboxamide;

N,3,5-trimethyl-N-((2-(3-(thiophen-3-ylmethyl)ureido)thiazol-4-yl)methyl)isoxazole-4-carboxamide;

methyl (2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl(2-hydroxyethyl)carbamate;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-hydroxyethyl)-3-methylisonicotinamide;

1-(3-fluorobenzyl)-3-(4-((2-oxooxazolidin-3-yl)methyl)thiazol-2-yl)urea;

2-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylnicotinamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1,3,5-tetramethyl-1H-pyrazole-4-carboxamide;

(S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;

(R)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-3-propoxypicolinamide;

tert-butyl 2-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)morpholine-4-carboxylate;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylmorpholine-2-carboxamide;

N-((2-(3-(3,5-difluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide;

N-((2-(3-(3,5-difluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylisonicotinamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyridazine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyridazine-3-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydro-2H-pyran-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1,5-trimethyl-1H-pyrazole-4-carboxamide;

N-((2-(3-((5-chlorofuran-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylmorpholine-3-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylpyrrolidine-3-carboxamide;

(S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrrolidine-2-carboxamide;

2-Methyl-5,6-dihydro-4H-pyran-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2-Methyl-5-morpholin-4-ylmethyl-furan-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2-Methyl-but-2-enoic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1,2,3-Thiadiazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {2-[3-(5-fluoro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2-Pyridin-3-yl-thiazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2,5-Dimethyl-2H-pyrazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

4-Methyl-furazan-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2-Morpholin-4-ylmethyl-furan-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1-Methyl-pyrrolidine-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1-Methyl-1H-pyrrole-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1,5-Dimethyl-1H-[1,2,3]triazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

5-Fluoro-thiophene-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

4-Methyl-pyrimidine-5-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-2-methylsulfanyl-nicotinamide;

2-Cyano-N-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-acetamide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {5-bromo-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-6-morpholin-4-yl-nicotinamide;

4-Methyl-thiazole-5-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3-Methyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2,4-Dimethyl-pyrimidine-5-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2-Methyl-[1,6]naphthyridine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

6-(4-Methoxy-phenyl)-pyridazine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3-Methyl-pyrazine-2-carboxylic acid {5-bromo-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3-Methyl-pyrazine-2-carboxylic acid {5-chloro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2,6-Bis-dimethylamino-pyrimidine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2,6-Di-morpholin-4-yl-pyrimidine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2-Cyano-N-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-3-pyridin-3-yl-acrylamide;

2-Methyl-[1,8]naphthyridine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2-Dimethylamino-6-methyl-pyrimidine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-2-methoxy-N-methyl-2-phenyl-acetamide;

3-Methyl-pyrazine-2-carboxylic acid {2-[3-(5-fluoro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3-Methyl-pyrazine-2-carboxylic acid methyl-[2-(3-thiophen-3-ylmethyl-ureido)-thiazol-4-ylmethyl]-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {5-cyano-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

Acetic acid 1-({2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-carbamoyl)-ethyl ester;

1-Ethyl-3-methyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2-Methyl-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-2-hydroxy-N-methyl-propionamide;

3,5-Dimethyl-isoxazole-4-carboxylic acid (1-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-yl}-ethyl)-amide;

1-Ethyl-5-methyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

5,7-Dimethyl-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid (1-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-yl}-2-hydroxy-ethyl)-amide;

1-Methyl-1H-indole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1-Methyl-1H-indazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

Pyrazolo[1,5-a]pyridine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-2-furan-2-yl-N-methyl-2-oxo-acetamide;

3,5-Dimethyl-isoxazole-4-carboxylic acid [2-(3-benzyl-ureido)-thiazol-4-ylmethyl]-methyl-amide;

3-Methyl-pyrazine-2-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-5-isopropyl-thiazol-4-ylmethyl}-methyl-amide;

5-Oxo-pyrrolidine-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3-Methyl-pyrazine-2-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid (2,2-difluoro-ethyl)-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-amide;

4-Methyl-pyridazine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

5-Methyl-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3-Amino-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,6-Dimethoxy-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

(3,5-Dimethyl-isoxazol-4-ylmethyl)-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-carbamic acid methyl ester;

(R)-Tetrahydro-furan-2-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

5-Methyl-pyridazine-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,5-Dimethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

5-Methyl-pyridazine-4-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

Tetrahydro-furan-2-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,5-Dimethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,6-Dichloro-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3-Chloro-6-methoxy-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {5-fluoro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

(R)-Tetrahydro-furan-2-carboxylic acid {5-fluoro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,5-Dimethyl-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{5-Fluoro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-acetamide;

1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid {5-fluoro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3-Chloro-6-hydroxy-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

2-Methyl-tetrahydro-furan-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

4-Chloro-1-methyl-1H-pyrazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

4-Chloro-2-methyl-2H-pyrazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

4-Chloro-1H-pyrazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid (cyano-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-yl}-methyl)-methyl-amide;

1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1,3,6-Trimethyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{2-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-2,N-dimethyl-5-sulfamoyl-benzamide;

1-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1-Phenyl-cyclobutanecarboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

3-Methyl-4-oxo-3,4-dihydro-phthalazine-1-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

7-Chloro-benzo[1,3]dioxole-5-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{2-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-6-[1,2,4]triazol-1-yl-nicotinamide;

1-(2-Methoxy-ethyl)-6-oxo-1,6-dihydro-pyridazine-3-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-methylacetamide;

1,1-Dioxo-tetrahydrothiophene-3-carboxylic acid {2-[3-(5-chlorothiophen-2-yl)methyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

6-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-hydroxy-N-methylpyridazine-4-carboxamide;

5-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1,3-trimethyl-1H-pyrazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-isopropyl-N,3-dimethylisoxazole-4-carboxamide;

3-cyano-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-hydroxy-N,6-dimethylisonicotinamide;

6-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-3-oxo-2,3-dihydropyridazine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethyl-5-sulfamoylbenzamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-1-phenylcyclobutanecarboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-oxo-3,4-dihydrophthalazine-1-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethyl-2-oxo-2H-pyran-5-carboxamide;

7-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbenzo[1,3]dioxole-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-4-sulfamoyl-1H-pyrrole-2-carboxamide;

2-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,6-trimethyl-4-oxo-3,4-dihydrofuro[2,3-d]pyrimidine-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxamide;

2,2-difluoro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-phenylacetamide;

N2-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-4-hydroxy-N2-methylpyrrolidine-1,2-dicarboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-morpholinonicotinamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-oxo-3,4-dihydrophthalazine-1-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethyl-2-oxo-2H-pyran-5-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-4-sulfamoyl-1H-pyrrole-2-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-N-methylacetamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-1-(3-fluorophenyl)-N-methylcyclobutanecarboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2,2-difluoro-N-methyl-2-phenylacetamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;

(S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyl-5,6-dihydro-1,4-dioxine-2-carboxamide;

(R)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-oxotetrahydrofuran-2-carboxamide;

5-chloro-N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,1,3-trimethyl-1H-pyrazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyl-4-oxo-3,4-dihydrophthalazine-1-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,6-trimethyl-4-oxo-3,4-dihydrofuro[2,3-d]pyrimidine-5-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-methoxy-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(2-hydroxyethyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;

(R)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(2-methoxyethyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydro-2H-pyran-2-carboxamide;

N-(cyano(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide;

N-(cyano(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,6-trimethylisoxazolo[5,4-b]pyridine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-methoxy-N-methyltetrahydrofuran-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(4-methoxybutyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(3-methoxypropyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;

N-((5-fluoro-2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylpyridazine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-morpholinonicotinamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,6-trimethylisoxazolo[5,4-b]pyridine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(4-fluorophenyl)-N-methylcyclobutanecarboxamide;

1,1-Dioxo-tetrahydrothiophene-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyltetrahydrofuran-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyloxetane-3-carboxamide;

5-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-1H-pyrazole-4-carboxamide;

(R)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,2-trimethyl-1,3-dioxolane-4-carboxamide;

(S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,2-trimethyl-1,3-dioxolane-4-carboxamide;

N-(2-amino-1-(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)ethyl)-N-methyltetrahydrofuran-2-carboxamide;

(R)—N-((2-(3-((5-fluorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;

3,6-dichloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylpyridazine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-methoxy-N,3-dimethylpyridazine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1,3,6-tetramethyl-1H-pyrazolo[3,4-b]pyridine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-nitro-1H-pyrazole-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2,3-dihydrobenzofuran-2-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-2,3-dihydrobenzofuran-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-hydroxy-N,3-dimethylpyridazine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(pyrrolidin-1-yl)nicotinamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-oxo-4-(thiophen-2-yl)butanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-oxo-4-phenylbutanamide;

2-(3-fluoro-4-methoxyphenyl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;

2-(3,4-dimethoxyphenyl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-(hydroxymethyl)phenoxy)-N-methylacetamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(3-(methylsulfonyl)phenyl)acetamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(2-mercapto-4-methylthiazol-5-yl)-N-methylacetamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-(trifluoromethyl)furan-2-carboxamide;

(R)—N-((5-fluoro-2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-hydroxy-N-methyl-3-(methylamino)pyridazine-4-carboxamide;

3-(dimethylamino)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-methoxy-N-methylpyridazine-4-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(2-methoxyethyl)-N-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(pyrrolidin-1-yl)nicotinamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,2-trimethyltetrahydro-2H-pyran-4-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,2,2-trimethyltetrahydro-2H-pyran-4-carboxamide;

N-((2-(3-((1H-indol-5-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(benzo[1,2,5]oxadiazol-5-ylmethyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(benzo[1,2,5]thiadiazol-5-ylmethyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

2-(4-(dimethylamino)phenyl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-7-hydroxy-N-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;

3-(1H-benzoimidazol-2-yl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(naphthalen-2-yl)acetamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-methoxy-3-methylphenyl)-N-methylacetamide;

2-amino-3-(benzyloxy)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-1,4-dioxo-1,2,3,4-tetrahydrophthalazine-6-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-6-(1H-1,2,4-triazol-1-yl)nicotinamide;

2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-1,4-dioxo-1,2,3,4-tetrahydrophthalazine-6-carboxamide;

N2-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-4-hydroxy-N2-methylpyrrolidine-1,2-dicarboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-nitro-1H-pyrazole-4-carboxamide;

(S)-3,3-difluoro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylchroman-2-carboxamide;

4-(3,5-dimethyl-1H-pyrazol-4-yl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbenzamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpent-4-ynamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;

(S)-2-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-3-(pyridin-4-yl)propanamide;

cis-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-methoxy-N-methyltetrahydrofuran-2-carboxamide;

1-cyano-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropanecarboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropiolamide;

N-((2-(3-((1H-indol-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((2-(3-(benzoxazol-6-ylmethyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

2-ethoxy-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-methoxyphenoxy)-N-methylpropanamide;

2-(cyclopropylmethoxy)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;

2,5-diamino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpentanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(2-phenoxyethoxy)propanamide;

2-cyclopropyl-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;

N,3,5-trimethyl-N-((2-(3-(4-nitrobenzyl)ureido)thiazol-4-yl)methyl)isoxazole-4-carboxamide;

N,3,5-trimethyl-N-((2-(3-(3-nitrobenzyl)ureido)thiazol-4-yl)methyl)isoxazole-4-carboxamide;

3-ethyl-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyloxetane-3-carboxamide;

2-(2,2-difluoroethoxy)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-fluorobenzyloxy)propanamide;

2-(2,2,2-trifluoroethoxy)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(prop-2-ynyloxy)propanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-((5-methylisoxazol-3-yl)methoxy)propanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(1-methylpyrrolidin-3-yloxy)propanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(2-hydroxyethoxy)propanamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopentanecarboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-1-hydroxy-N-methylcyclopropanecarboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methylcyclohexanecarboxamide;

1-cyano-N-((5-fluoro-2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropanecarboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopentanecarboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylcyclohexanecarboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclohexanecarboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-oxo-2,3-dihydrobenzoxazole-6-carboxamide;

3,3,3-trifluoro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-hydroxy-N,2-dimethylpropanamide;

2,3-cis-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyltetrahydrofuran-2-carboxamide;

(5R)-—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-(hydroxymethyl)-N-methyltetrahydrofuran-2-carboxamide;

N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2-hydroxy-N,2-dimethylpropanamide;

N-((2-(3-(5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-oxo-2,3-dihydrobenzoxazole-6-carboxamide;

(S)—N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)-N-methylacetamide;

(R)—N-((2-(3-(benzo[1,2,5]oxadiazol-5-ylmethyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;

(R)—N-((2-(3-((7-chlorobenzo[1,3]dioxol-5-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;

2,3,3,3-tetrafluoro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropanecarboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropane-1,1-dicarboxamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylcyclopropanecarboxamide;

(S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)-N-methylacetamide;

N-((5-(3-(3-fluorobenzyl)ureido)-1,2,4-thiadiazol-3-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;

N-((5-(3-(3-fluorobenzyl)ureido)-1,2,4-thiadiazol-3-yl)methyl)-N,2,6-trimethylbenzamide;

N-((5-(3-(3-fluorobenzyl)ureido)-1,2,4-thiadiazol-3-yl)methyl)-N,3-dimethylisonicotinamide;

N-((5-(3-(3-fluorobenzyl)ureido)-1,2,4-thiadiazol-3-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide;

1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

5-Chloro-1,3-dimethyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

5-Isopropyl-3-methyl-isoxazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1,3,5-Trimethyl-1H-pyrazolo[4,3-b]pyridine-7-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Methyl-5-pyrrol-1-yl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

3-Methyl-4-oxo-3,4-dihydro-phthalazine-1-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2,4-Dimethyl-6-oxo-6H-pyran-3-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

3,6-Dimethyl-isoxazolo[5,4-b]pyridine-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2-(5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-N-{5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-acetamide;

3,6-Dimethyl-4-oxo-3,4-dihydro-furo[2,3-d]pyrimidine-5-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-6-[1,2,4]triazol-1-yl-nicotinamide;

1-(2-Methoxy-ethyl)-6-oxo-1,6-dihydro-pyridazine-3-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Methyl-4-sulfamoyl-1H-pyrrole-2-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-N-methyl-acetamide;

3,6-Dimethyl-4-oxo-3,4-dihydro-furo[2,3-d]pyrimidine-5-carboxylic acid{5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

(R)-Tetrahydro-furan-2-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1,3,5-Trimethyl-1H-pyrazolo[4,3-b]pyridine-7-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-3-cyano-2-hydroxy-6,N-dimethyl-isonicotinamide;

6-Chloro-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

7-Chloro-benzo[1,3]dioxole-5-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

5-Methyl-4-oxo-3,4-dihydro-thieno[2,3-d]pyrimidine-6-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Methyl-5-pyrrol-1-yl-1H-pyrazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

3-Methyl-4-oxo-3,4-dihydro-phthalazine-1-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2,4-Dimethyl-6-oxo-6H-pyran-3-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

5-Methyl-4-oxo-3,4-dihydro-thieno[2,3-d]pyrimidine-6-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-6-[1,2,4]triazol-1-yl-nicotinamide;

1-(2-Methoxy-ethyl)-6-oxo-1,6-dihydro-pyridazine-3-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2,2-difluoro-N-methyl-2-phenyl-acetamide;

(R)-Tetrahydro-furan-2-carboxylic acid [5-(3-benzo[1,2,5]oxadiazol-5-ylmethyl-ureido)-[1,2,4]thiadiazol-3-ylmethyl]-methyl-amide;

3,5-Dimethyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

3,5-Dimethyl-pyridazine-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

5-Isopropyl-3-methyl-isoxazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2,N-dimethyl-5-sulfamoyl-benzamide;

1,1-Dioxo-tetrahydrothiophene-3-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-morpholin-4-yl-nicotinamide;

1-Phenyl-cyclobutanecarboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

4-Oxo-3,4-dihydro-phthalazine-1-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

7-Chloro-benzo[1,3]dioxole-5-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-(4-Fluoro-phenyl)-cyclobutanecarboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

5-Chloro-1,3-dimethyl-1H-pyrazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Phenyl-cyclobutanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

4-Oxo-3,4-dihydro-phthalazine-1-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-(4-Fluoro-phenyl)-cyclobutanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2,2-Difluoro-N-{5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-phenyl-acetamide;

1,1-Dioxo-tetrahydro-llambda*6*-thiophene-3-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2,2-Dimethyl-tetrahydro-pyran-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2,3-Dihydro-benzofuran-2-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

(R)-Tetrahydro-furan-2-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2,2-Dimethyl-tetrahydro-pyran-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Methyl-5-nitro-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Methyl-5-nitro-1H-pyrazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2,3-Dihydro-benzofuran-2-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

(R)—N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-methoxy-N-methyl-propionamide;

(R)—N-{5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-methoxy-N-methyl-propionamide;

N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-morpholin-4-yl-nicotinamide;

N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-pyrrolidin-1-yl-nicotinamide;

N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2,N-dimethyl-5-sulfamoyl-benzamide;

N-{5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-pyrrolidin-1-yl-nicotinamide;

2,2-Difluoro-N-{5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-pyridin-2-yl-acetamide;

1-Methyl-4-sulfamoyl-1H-pyrrole-2-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

4-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-amide 2-({5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide);

Cyclopentanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2-Methyl-cyclohexanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

Cyclohexanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2,6-Dioxo-hexahydro-pyrimidine-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Cyano-cyclopropanecarboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

1-Hydroxy-cyclopropanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

2-Oxo-2,3-dihydro-benzooxazole-6-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-hydroxy-2,N-dimethyl-propionamide;

1-Cyano-cyclopropanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;

N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-((S)-4-hydroxy-2-oxo-pyrrolidin-1-yl)-N-methyl-acetamide;

1,1-Dioxo-tetrahydro-116-thiophene-3-sulfonic acid {2-[3-(3,4-dichloro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylbenzenesulfonamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-sulfonamide;

N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylmethanesulfonamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylmethanesulfonamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropane-1-sulfonamide;

1-(3,4-dichlorobenzyl)-3-(4-(4-hydroxy-1-(methylsulfonyl)pyrrolidin-2-yl)thiazol-2-yl)urea;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbutane-1-sulfonamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylethanesulfonamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-sulfonamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropanesulfonamide;

N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-(methylsulfonamido)ethyl)methanesulfonamide;

1-[4-(1,1-Dioxo-116-isothiazolidin-2-ylmethyl)-thiazol-2-yl]-3-(3-fluoro-benzyl)-urea;

Ethanesulfonic acid {5-bromo-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-4-morpholin-4-yl-benzenesulfonamide;

Furan-2-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

Thiophene-2-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

Pyridine-3-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

Pyridine-2-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1-Methyl-1H-imidazole-4-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

1,2-Dimethyl-1H-imidazole-4-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;

N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-C-pyridin-3-yl-methanesulfonamide;

N-(3,5-Dimethyl-isoxazol-4-ylmethyl)-N-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methanesulfonamide.

21. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt of a compound of claim 1.

22. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 20 or a pharmaceutically acceptable salt of a compound of claim 20.

23. The compound of claim 3, selected from the group consisting of 5-(2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)-1-(methylsulfonyl)pyrrolidin-3-yl acetate and 1-(3-Fluoro-benzyl)-3-{4-[1-(propane-1-sulfonyl)-pyrrolidin-2-yl]-thiazol-2-yl}-urea.

Описание

RELATED APPLICATIONS

[0001]

This application is a 35 U.S.C. §371 national phase application of PCT/US2008/070893 (WO 2009/015208), filed on Jul. 23, 2008, entitled “Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds”, which application claims the benefit of U.S. Provisional Application Ser. No. 60/961,634, filed Jul. 23, 2007, and claims benefit of U.S. Provisional Application Ser. No. 61/022,725, filed Jan. 22, 2008, each of which is incorporated herein by reference in its entirety.

TECHNICAL FIELD

[0002]

The present invention relates to novel heterocyclic urea compounds and in particular to novel amide and sulfonamide substituted heterocyclic urea compounds and to their uses in the treatment of bacterial infections.

BACKGROUND OF THE INVENTION

[0003]

Antibacterials kill or inhibit the growth of bacteria by interfering with major processes of cellular function that are essential for survival. The development of antibacterial agents has significantly reduced the morbidity and mortality associated with bacterial infections over the last century, particularly in developed countries. However, the emergence of drug-resistant bacterial strains threatens the resurgence of bacterial-borne diseases long thought to have been conquered.

[0004]

Resistance to antibacterials can occur when the target of a drug mutates so that it can still function, but is no longer inhibited by the drug (e.g., mutations in the quinolone resistance determining regions of bacterial gyrases and topisomerase enzymes that confer resistance to the fluoroquinolones). In a recent congressional report, the General Accounting Office (GAO) has summarized the current and future public health burden resulting from drug-resistant bacteria (Antimicrobial Resistance (1999). General Accounting Office (GAO/RCED-99-132)). According to this report, the number of patients treated in a hospital setting for an infection with drug-resistant bacteria has doubled from 1994 to 1996 and again almost doubled from 1996 to 1997. The same GAO report also provides clear evidence that previously susceptible bacteria are increasingly becoming resistant and spreading around the world. As a consequence of the increase and prevalence of resistant bacteria there is a growing need to identify new antibacterial agents.

SUMMARY OF THE INVENTION

[0005]

It has now been found that amide and sulfonamide substituted heterocyclic urea compounds are useful in the treatment of bacterial infections. The present invention relates to these antibacterial compounds and salts thereof, pharmaceutical compositions comprising these compounds and methods of use thereof in the treatment of bacterial infections, including resistant bacterial infections.

[0006]

In one aspect the invention provides compounds of Formula (I):

[0007]


in which:

[0008]

R1is selected from the group consisting of a substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl and substituted or unsubstituted heteroaryl;

[0009]

X is selected from the group consisting of a C and N atom;

[0010]

Y is selected from the group consisting of CO and SO2;

[0011]

R2, R3and R4are independently selected from the group consisting of, H, OH, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted linear, cyclic or branched alkyl, cyano, and perfluoroalkyl;

[0012]

and further, optionally

[0013]

wherein R2, R4, Y, and N together can form a substituted or unsubstituted 4-7 member saturated ring;

[0014]

or alternatively, optionally

[0015]

wherein R2, R3and N together can form a substituted or unsubstituted 4-7 member saturated ring; and

[0016]

R5is selected from the group consisting of H, halogen, alkyl, cyano and null, wherein R5is null when X is N.

[0017]

These and various other features as well as advantages which characterize the invention will be apparent from a reading of the following detailed description and a review of the appended claims.

DETAILED DESCRIPTION OF THE INVENTION

[0018]

The present invention relates to antibacterial compounds and salts thereof, pharmaceutical compositions comprising these compounds and methods of use thereof. The compounds of the present invention are useful in the protection of patients from bacterial infections, including antibiotic resistant bacterial infections.

[0019]

In particular, antibacterial compounds of the invention include amide and sulfonamide substituted heterocyclic urea compounds.

[0020]

In one embodiment, the invention provides compounds of Formula (I):

[0021]

[0022]

In one embodiment, R1is preferably a substituted or unsubstituted phenyl or thiophene group, for example, a phenyl group which has one or more substituents independently selected from halogen, cyano, (C1-6)alkyl, mono to perfluoro(C1-3)alkyl, (C3-7)cycloalkyl, (C2-6)alkenyl, (C1-6)alkoxy, (C2-6)alkenoxy, hydroxy, amino, mono- or di-(C1-6)alkylamino, acylamino, nitro, carboxy, (C1-6)alkoxycarbonyl, (C1-6)alkenyloxycarbonyl, (C1-6)alkoxycarbonyl(C1-6)alkyl, carboxy(C1-6)alkyl, (C1-6)alkylcarbonyloxy, carboxy(C1-6)alkyloxy, (C1-6)alkoxycarbonyl(C1-6)alkoxy, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)-alkylsulphamoyl, and carbamoyl.

[0023]

Suitable identities for R1include, but are not limited to, 3-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-bromophenyl, 4-bromophenyl, 3-iodophenyl, 4-iodophenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 3-4-methylendioxyphenyl, 3-4-difluorophenyl, 3-4-dichlorophenyl, 3-4-dibromophenyl, 3-4-dimethylphenyl, 3-4-(—CH2CH2CH2—)phenyl, 3-4-(—OCH2CH2O—)phenyl, 3-chloro-4-fluorophenyl, benzo[1,3]dioxyl-5-yl, and 3-3-cyanophenyl, 3-5 difluorophenyl, thiophen-2-yl, thiophen-3-yl, 4,5-di-bromo-thiophen-2-yl, 5-chloro-thiophen-2-yl, and 5-bromo-thiophen-2-yl, 5-fluoro-thiophen-2-yl, 5-chloro-thiophen-3-yl, 1,1,-difluoro-benzo[1,3]dioxyl-5-yl, 7-chlorobenzo[1,3]dioxol-5-yl, 3-nitrophenyl, 2,1,3-benzoxadiazol-5-yl, and 4-nitrophenyl.

[0024]

X is selected from the group consisting of C and N atom.

[0025]

Y is selected from the group consisting of CO, and SO2.

[0026]

R5is selected from the group consisting of H, halogen, alkyl, cyano and null, wherein R5is null when X is N.

[0027]

R2, R3and R4are independently selected from the group consisting of, H, OH, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted linear, cyclic or branched alkyl, cyano, and perfluoroalkyl.

[0028]

Suitable identities for R2, and R3, include, but are not limited to, H, methyl, ethyl, 2-hydroxyethyl, 2-hydroxymethyl, 2,2-Difluoro-ethyl, 2-methoxyethyl, 2-aminoethyl, propyl, cyclopropyl, isopropyl, 2,4-dimethoxybenzyl, 2-methanesulfonylaminoethyl and 3,5-dimethylisoxazole-4-yl-methyl.

[0029]

Suitable identities for R4, include, but are not limited to methyl, 2-(2-methoxyethoxy)-methyl, 2-methoxymethyl, 4-methylisoxazole-5-yl, isoxazole-5-yl, 3-phenylpropanyl, furan-2-yl, 4-phenoxybutanyl, 1,1-dioxo-tetrahydro-1-lamda6-thiophen-3-ylmethylaminoyl, 3,5-dimethylisoxazole-4-yl, 1-methyl-1H-imidazole-5-yl, furan-3-yl, 3-methylfuran-2-yl, 5-methyl-3-phenylisoxazole-4-yl, 5-methyl-2-phenyl-2H-1,2,3-triazole-4-yl, 5-methylisoxazole-3-yl, 3-methyl-5-phenylisoxazole-4-yl, 3-methyl-5-(4-methyl-1,2,3-thiadiazol-5-yl)isoxazole-4-yl, 2-(2H-tetrazol-5-yl)methyl, benzofuran-2-yl, 1,2,5-oxadiazole-3-yl, (3,5-dimethylisoxazol-4-yl)-methyl, 3-methylisoxazole-4-yl, 5-methylisoxazole-4-yl, 5-cyclopropyl-isoxazole-4-yl, 2,6-dimethylphenyl, 5-(furan-2-yl)-isoxazole-3-yl, 2,5-dimethyloxazole-4-yl, 2-phenylthiazole-4-yl, 2-(thiophen-2-yl)thiazole-4-yl, 3-hydroxy-isoxazole-5-yl, 5-phenyl-1,3,4-oxadiazole-2-yl, 5-methylfuran-2-yl, 4-methyl-1,2,5-oxadiazole-3-yl, 4-methyl-2-(pyrazin-2-yl)thiazole-5-yl, 2,4-dimethoxy-phenyl, 4-methoxy-phenyl, 3,4-dimethoxy-phenyl, benzo[1,3]dioxole-5-yl, 3,4,5-trimethoxy-phenyl, 5-methyl-3-(trifluoromethyl)isoxazole-4-yl, pyridin-3-ylmethyl, 2,4-dimethylpyridine-3-yl, 2,4,6-trimethylphenyl, 5-(methoxymethyl)-3-methylisoxazole-4-yl, 2-methoxy-methyl, 2-methoxyformyl, 3-ethyl-5-methylisoxazole-4-yl, pyrimidine-5-yl, pyrazine-2-yl, 5-methylpyrazine-2-yl, furan-3-yl, 4-methyloxazole-5-yl, 2-tosylmethyl, 3-ethylcarboxy-5-methylisoxazole-4-yl, 3-carboxy-5-methylisoxazole-4-yl, 2-methylpyridine-3-yl, 4-methylpyridine-3-yl, 3-chloro-4-(methylsulfonyl)thiophene-2-yl, 4-methylthiazole-5-yl, 5-oxo-3,5-dihydro-2H-thiazolo[3,2-a]pyrimidine-6-yl, 4-methyl-2-(methylthio)pyrimidine-5-yl, 2-methylprop-1-enyl, 2-methylphenyl, quinoxaline-2,3-methylpyridine-4-yl, 3-methylisoxazole-4-yl, 4-amino-pyrimidine-5-yl, 2-amino-4-methylpyrimidine-5-yl, 4,6-dimethyl-2-oxo-1,2-dihydropyridine-3-yl, 2,4,6-trimethylpyrimidine-5-yl, 3-methylpyrazine-2-yl, 4-Boc-amino-1-methyl-1H-imidazole-2-yl, 4-amino-1-methyl-1H-imidazole-2-yl, 4-acetamido-1-methyl-1H-imidazole-2-yl, 4,6-dimethylpyrimidine-5-yl, 3-(hydroxymethyl)-5-methylisoxazole-4-yl, 3-methylpyridine-2-yl, 2-amino-4,6-dimethylpyrimidine-5-yl, 2-methylimidazo[1,2-a]pyridine-3-yl, tetrahydrofuran-2-yl, 2-methoxypyridine-3-yl, tetrahydrofuran-3-yl, methoxyformyl, 2-chloropyridine-3-yl, 1,3,5-tetramethyl-1H-pyrazole-4-yl, (S)-tetrahydrofuran-2-yl, (R)-tetrahydrofuran-2-yl, 3-propoxypyridine-4-yl, N-Boc-morpholine-2-yl, morpholine-2-yl, pyridazine-4-yl, 3,5-dimethyl-1H-pyrazole-4-yl, pyridazine-3-yl, tetrahydro-2H-pyran-4-yl, 1,5-dimethyl-1H-pyrazole-4-yl, morpholine-3-yl, 4-methylpyrrolidine-3-yl, (S)-pyrrolidine-2-yl, 1,1-Dioxo-tetrahydro-1-lamda6-thiophene-3-yl, 4-methylphenyl, methyl, ethyl, propyl, butyl, cyclopropyl, and 1,1-Dioxo-1-isothiazolidin-2-yl, 2-methyl-5,6-dihydro-4H-pyran-3-yl, 2-methyl-5-morpholin-4-ylmethyl-furan-3-yl, 2-methyl-but-2-enyl, [1,2,3]thiadiazole-4-yl, 2-pyridin-3-yl-thiazole-4-yl, 2,5-dimethyl-2H-pyrazole-3-yl, 4-methyl-furazan-3-yl, 2-morpholin-4-ylmethyl-furan-3-yl, 1-methyl-pyrrolidine-2-yl, 1-methyl-1H-pyrrole-2-yl, 1,5-dimethyl-1H-[1,2,3]-triazole-4-yl, 5-fluoro-thiophene-2-yl, 4-methyl-pyrimidine-5-yl, 4-methyl-2-phenyl-pyrimidine-5-yl, 2-methylsulfanyl-nicotinyl, acetonitrile, 6-morpholin-4-yl-nicotinyl, 4-methyl-thiazole-5-yl, 3-methyl-1H-pyrazole-4-yl, 2,4-dimethyl-pyrimidine-5-yl, 2-methyl-[1,6]naphthyridine-3-yl, 6-(4-methoxy-phenyl)-pyridazine-3-yl, 2,6-bis-dimethylamino-pyrimidine-4-yl, 2,6-di-morpholin-4-yl-pyrimidine-4-yl, 3-pyridin-3-yl-acrylonitrile-2-yl, 2-methyl-[1,8]naphthyridine-3-yl, 2-dimethylamino-6-methyl-pyrimidine-4-yl, acetic acid 1-yl-ethyl ester, 1-ethyl-3-methyl-1H-pyrazole-4-yl, 2-methyl-pyrazolo[1,5-a]pyrimidine-3-yl, 1-hydroxy-ethyl, 1-ethyl-5-methyl-1H-pyrazole-4-yl, 5,7-dimethyl-pyrazolo[1,5-a]pyrimidine-3-yl, 1-methyl-1H-indole-3-yl, 1-methyl-1H-indazole-3-yl, pyrazolo[1,5-a]pyridine-3-yl, 2-furan-2-yl-oxo, 5-oxo-pyrrolidine-2-yl, 4-methyl-pyridazine-3-yl, 5-methyl-pyridazine-4-yl, 3-amino-1H-pyrazole-4-yl, 3,6-dimethoxy-pyridazine-4-yl, 3,6-dichloro-pyridazine-4-yl, pyridine-3-yl, pyridine-2-yl, 1-methyl-1H-imidazole-4-yl, 1,2-dimethyl-1H-imidazole-4-yl, pyridin-3-yl-methyl, 3-chloro-6-methoxy-pyridazin-4-yl, 3,5-dimethyl-pyridazin-4-yl, 1-methyl-3-trifluoromethyl-1H-pyrazol-4-yl, 3-chloro-6-hydroxy-pyridazin-4-yl, 2-methyl-tetrahydrofuran-2-yl, 4-chloro-1-methyl-1H-pyrazol-3-yl, 5-chloro-1-methyl-1H-pyrazol-4-yl, 4-chloro-2-methyl-2H-pyrazol-3-yl, 4-chloro-1H-pyrazol-3-yl, 1,3,6-trimethyl-1H-pyrazolo[3,4-b]pyridin-3-yl, 2-methyl-5-sulfamoyl-phenyl, 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl, 1-phenyl-cyclobutyl, 3-methyl-4-oxo-3,4-dihydrophthalazin-1-yl, 7-chloro-benzo[1,3]dioxol-5-yl, 6-[1,2,4]triazol-1-yl-pyridin-3-yl, 1-(2-methoxyethyl)-6-oxo-1,6-dihydropyridazin-3-yl, 2-(2,4-dioxo-3,4-dihydropyrimidin-1-(2H)-yl)methyl, 6-chloro-3-hydroxy-pyridazin-4-yl, 3-cyano-2-hydroxy-6-methyl-pyridin-4-yl, 1-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazol-4-yl, 4-oxo-3,4-dihydrophthalazin-1-yl, 4,6-dimethyl-2-oxo-2H-pyran-5-yl, 1-methyl-4-sulfamoyl-1H-pyrrol-2-yl, (5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)methyl, 3,6-dimethyl-4-oxo-3,4-dihydrofuro[2,3-d]pyrimidin-5-yl, 5-methyl-4-oxo-3,4-dihydrothieno[2,3-b]pyrimidin-6-yl, phenyl-difluoromethyl, 4-hydroxyl-1-carbamoyl-pyrrolidin-2-yl, 2-(1-morpholino)-pyridin-3-yl, 1-(3-fluorophenyl)-cyclobutyl, 1-methyl-5-trifluoromethyl-1H-pyrazol-4-yl, (S)-1-methoxyethyl, 3-methyl-5,6-dihydro-1,4-dioxin-2-yl, (R)-5-oxo-tetrahydrofuran-2-yl, 5-chloro-1,3-dimethyl-1H-pyraozol-4-yl, 2-methoxy-ethyl, 1-(2-hydroxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl, (R)-1-methoxy-ethyl, 1-(2-methoxyethyl)-3,5-dimethyl-1H-pyrazol-4-yl, tetrahydro-2H-pyran-2-yl, 3,6-dimethylisoxazolo[5,4-b]pyridine-4-yl, 5-methoxy-tetrahydrofuran-2-yl, 1-(4-methoxybutyl)-3,5-dimethyl-1H-pyrazol-4-yl, 1-(3-methoxypropyl)-3,5-dimethyl-1H-pyrazol-4-yl, 1-(4-fluorophenyl)-cyclobutyl, 5-methyl-tetrahydrofuran-2-yl, 3-methyl-oxetan-3-yl, 5-chloro-1H-pyrazol-4-yl, (R)-2,2-dimethyl-1,3-dioxolan-4-yl, (S)-2,2-dimethyl-1,3-dioxolan-4-yl, 3,6-dichloro-5-methyl-pyridazin-4-yl, 6-methoxyl-3-methyl-pyridazin-4-yl, 1-methyl-5-nitro-1H pyrazol-4-yl, 2,3-dihydrobenzofuran-2-yl, 6-hydroxy-3-methyl-pyridazin-4-yl, 2-(1-pyrrolidinyl)-pyridin-3-yl, 3-oxo-3-(2-thiophenyl)-propyl, 3-oxo-3-phenyl-propyl, 3-fluoro-4-methoxy-benzyl, 3,4-dimethoxy-benzyl, 4-(hydroxymethyl)-phenoxy-methyl, 3-methylsulfonyl-benzyl, 2-mercapto-4-methyl-thiazol-5-yl, 5-trifluoromethyl-furan-2-yl, 6-hydroxy-3-methylamino-pyridazin-4-yl, 3-(dimethylamino)-6-methoxy-pyridazin-4-yl, 2,2-dimethyl-tetrahydro-2H-pyran-4-yl, 4-(dimethylamino)-benzyl, 7-hydroxy-1,2,3,4-tetrahydroisoquinolin-3-yl, 1H-benzoimidazol-2-yl, naphthalene-2-yl-methyl, 4-methoxy-3-methyl-benzyl, 1-amino-2-benzyloxy-ethyl, 1,4-dioxo-1,2,3,4-tetrahydrophthalazin-6-yl, 2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-methyl, 5-nitro-1H-pyrazol-4-yl, (S)-3,3-difluoro-tetrahydrofuran-2-yl, chroman-2-yl, 3,5-dimethyl-1H-pyrazol-4-yl, 4-butynyl, 2-methyl-1,2,34-tetrahydroisoquinolin-3-yl, (S)-2-(4-pyridinyl), 1-amino-ethyl, cis-3-methoxy-tetrahydrofuran-2-yl, 1-cyano-cyclopropyl, ethynyl, 1-ethoxy-ethyl, 1-(4-methoxy-phenoxy)ethyl, 1-(cyclopropylmethoxy)ethyl, 1,4-diamino-butyl, 1-(2-phenoxyethoxy)ethyl, cyclopropylmethyl, 3-ethyl-3-oxetan-3-yl, 1-(2,2-difluoroethoxy)ethyl, 1-(4-fluoro-benzyloxy)ethyl, 1-(2,2,2-trifluoroethoxy)ethyl, 1-(prop-2-ynyloxy)ethyl, 5-methyl-isoxazol-3-yl, 1-((1-methyl-pyrrolidin-3-yl)oxy)ethyl, 1-(2-hydroxyethoxy)ethyl, cyclopentyl, 1-hydroxy-cyclopropyl, cyclohexyl, 2-methyl cyclohexyl, 2-oxo-2,3-dihydrobenzoxazol-6-yl, 2,2,2-trifluoroethyl, 1-hydroxy-1-methyl-ethyl, (R)-5-(hydroxymethyl)tetrahydrofuran-2-yl, (4-hydroxy-2-oxo-pyrrolidin-1-yl)methyl, 1,2,2,2-tetrafluoroethyl, 1-carbamoyl-cyclopropyl, 2-methyl-cyclopropyl, 5-chloro-1,3-dimethyl-1H-pyrazol-4-yl, 5-isopropyl-3-methyl-isoxazol-4-yl, and 1,3,5-trimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl.

[0030]

In alternative embodiments, R2, R4, Y, and N together form a substituted or unsubstituted 4-7 member saturated ring. Suitable identities for such a substituted or unsubstituted 4-7 member saturated rings include, but are not limited to, 2,4-dioxothiazolidin-3-yl and 2-oxooxazolidin-3-yl.

[0031]

In other alternative embodiments, R2, R3and N together form a substituted or unsubstituted 4-7 member saturated ring. Suitable identities for such a substituted or unsubstituted 4-7 member saturated rings include, but are not limited to, 4-acetoxy-1-(methylsulfonyl)pyrrolidin-2-yl and 4-hydroxy-1-(methylsulfonyl)pyrrolidin-2-yl.

[0032]

When used herein, the term “alkyl” and similar terms such as “alkoxy” include all straight chain, branched, and cyclic isomers. Representative examples thereof include methyl, ethyl, n-propyl, iso-propyl, cyclobutyl, cyclopropyl, cyclopentyl, cyclohexyl, n-butyl, sec-butyl, iso-butyl, t-butyl, n-pentyl and n-hexyl. Optionally fluorosubstituted alkyls may have 1 or more substitutions of F for H on the alkyl chain. A representative example of an optionally fluorosubstituted alkyl is trifluoromethyl.

[0033]

When used herein, the terms “alkenyl” and “alkynyl” include all straight chain, branched and cyclic isomers. Representative examples thereof include vinyl, ethynyl and 1-propynyl. Optionally fluorosubstituted alkenyls may have 1 or more substitutions of F for H on the alkenyl chain. A representative example of an optionally fluorosubstituted alkenyl is fluorovinyl.

[0034]

Preferred substituents for alkyl and alkenyl groups include, for example, and unless otherwise defined, halogen, cyano, azido, nitro, carboxy, (C1-6)alkoxycarbonyl, carbamoyl, mono- or di-(C1-6)alkylcarbamoyl, sulpho, sulphamoyl, mono- or di-(C1-6)alkylsulphamoyl, amino, mono- or di-(C1-6)alkylamino, acylamino (e.g., pyridyloxy), ureido, (C1-6)alkoxycarbonylamino, 2,2,2-trichloroethoxycarbonylamino, aryl, heteroaryl, heterocyclyl, hydroxy, (C1-6)alkoxy (e.g., ethoxy, isopropoxy), acyloxy (e.g., phenyloxy, benzyloxy, phenethoxy), oxo, acyl, 2-thienoyl, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, hydroxyimino, (C1-6)alkoxyimino, hydrazino, hydrazono, benzohydroximoyl, guanidino, amidino and iminoalkylamino Also preferred are 4-formyl-piperazin-1-yl, 4-methylpiperazin-1-yl-, 4-ethylpiperazin-1-yl-, 4-phenylpiperazin-1-yl-, 4-pyrimidin-2-yl-piperazin-1-yl, Hexahydroxy-pyrrolo[1,2-a]imidazole-1-yl, Morpholin-4-yl, 3-(2-methoxy-ethyl)-methyl-amino, and 3-(2-methoxy-ethyl)-methyl-amino. Other appropriate substituents include alkylthio meaning an alkyl-S— group in which the alkyl group is as previously described. Non-limiting examples of suitable alkylthio groups include methylthio and ethylthio. The bond to the parent moiety is through the sulfur. Substituents further include alkoxycarbonyl meaning an alkyl-O—CO— group. Non-limiting examples of suitable alkoxycarbonyl groups include methoxycarbonyl and ethoxycarbonyl. The bond to the parent moiety is through the carbonyl. Another suitable substituent is alkylsulfonyl meaning an alkyl-SO2group. Preferred alkylsulfonyl groups are those in which the alkyl group is a lower alkyl. The bond to the parent moiety is through the sulfonyl.

[0035]

When used herein, the term “aryl” means an aromatic monocyclic or multicyclic ring system with each ring comprising from about 6 to about 14 carbon atoms, preferably about 6 to about 10 carbon atoms. The aryl group can be optionally substituted with one or more “ring system substituents” and optionally substituted with up to five, preferably up to three substituents which may be the same or different, and are as defined herein. Non-limiting examples of suitable aryl groups include phenyl, naphthyl, anthracenyl, phenanthrenyl, indanyl, indenyl, and the like. Aryl moieties are well known and described, for example, in Hawley's Condensed Chemical Dictionary (13 ed.), R. J. Lewis, ed., J. Wiley & Sons, Inc., New York (1997). Aryl groups can be substituted or unsubstituted.

[0036]

When substituted, an aryl group may have up to three substituents. Preferred substituents for an aryl group (a “ring system substituent”) include, for example, and unless otherwise defined, halogen, cyano, (C1-6)alkyl, mono to perfluoro(C1-3)alkyl, (C3-7)cycloalkyl, (C2-6)alkenyl, (C1-6)alkoxy, (C2-6)alkenoxy, arylC(1-6)alkoxy, halo(C1-6)alkyl, hydroxy, amino, mono- or di-(C1-6)alkylamino, acylamino, nitro, carboxy, (C1-6)alkoxycarbonyl, (C1-6)alkenyloxycarbonyl, (C1-6)alkoxycarbonyl(C1-6)alkyl, carboxy(C1-6)alkyl, (C1-6)alkylcarbonyloxy, carboxy(C1-6)alkyloxy, (C1-6)alkoxycarbonyl(C1-6)alkoxy, (C1-6)alkylthio, (C1-6)alkylsulphinyl, (C1-6)alkylsulphonyl, sulphamoyl, mono- and di-(C1-6)-alkylsulphamoyl, carbamoyl, mono- and di-(C1-6)alkylcarbamoyl, heteroaryl and heterocyclyl. Other preferred aryl groups include arylalkyl meaning an alkyl substituted aryl group. Other preferred aryl groups include aryloxy meaning an aryl-O— group in which the aryl group is as previously described. Non-limiting examples of suitable aryloxy groups include phenoxy and naphthoxy. The bond to the parent moiety is through the ether oxygen. Arylalkyloxy meaning an arylalkyl-O— group in which the arylalkyl group is as previously described. Non-limiting examples of suitable arylalkyloxy groups include benzyloxy and phenethyloxy. The bond to the parent moiety is through the ether oxygen. Another preferred aryl is an arylthio meaning an aryl-S— group in which the aryl group is as previously described. Non-limiting examples of suitable arylthio groups include phenylthio and naphthylthio. The bond to the parent moiety is through the sulfur. Other preferred aryls include arylalkylthio meaning an arylalkyl-S— group in which the arylalkyl group is as previously described. Non-limiting example of a suitable arylalkylthio group is benzylthio. The bond to the parent moiety is through the sulfur. Other preferred aryls is an aryloxycarbonyl meaning an aryl-O—C(O)— group. Non-limiting examples of suitable aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl. The bond to the parent moiety is through the carbonyl. Another such group is an arylalkoxycarbonyl meaning an arylalkyl-O—C(O)— group. Non-limiting example of a suitable arylkoxycarbonyl group is benzyloxycarbonyl. The bond to the parent moiety is through the carbonyl. Yet another such group is an arylsulfonyl meaning an aryl-SO2— group. The bond to the parent moiety is through the sulfonyl.

[0037]

When used herein, the term “heteroaryl” monocyclic and polycyclic aromatic hydrocarbons include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen alone or in combination. Preferably the heteroaryl ring comprises from 4 to 7, and preferably 5 to 6, ring atoms. Non-limiting examples of suitable heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, isoxazolyl, isothiazolyl, oxazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, pyrazolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxalinyl, phthalazinyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinolinyl, imidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinolinyl, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl, 2,3-dihydrobenzothienyl-5-oxide, 2,3-dihydrobenzothienyl-5-dioxide, benzoxazolin-2-on-yl, indolinyl, benzodioxolanyl, benzodioxane, and the like. Heteroaryl groups can be substituted or unsubstituted. A fused heteroaryl ring system may include carbocyclic rings and need only include one heterocyclic ring.

[0038]

When used herein, the term “heterocyclyl” means an aromatic or non-aromatic saturated monocyclic or multicyclic (preferably bicyclic) ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur, alone or in combination. Suitably the heterocyclic ring comprises from 4 to 7, preferably 5 to 6, ring atoms. A fused heterocyclic ring system may include carbocyclic rings and need only include one heterocyclic ring. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclyls contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Any —NH in a heterocyclyl ring may exist protected such as, for example, as an —N(Boc), —N(CBz), —N(Tos) group and the like; such protected moieties are also considered part of this invention. The heterocyclyl can be optionally substituted by one or more “ring system substituents” which may be the same or different, and are as defined herein. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable monocyclic heterocyclyl rings include piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrimidyl, oxazolidinyl, and the like.

[0039]

When substituted, a heteroaryl or a heterocyclyl group may have up to three substituents. Preferred such substituents include those previously mentioned for an aryl group as well as oxo.

[0040]

When used herein, the terms “halogen” and “halo” include fluorine, chlorine, bromine and iodine and fluoro, chloro, bromo and iodo, respectively.

[0041]

When used herein, the term “acyl” means an H—C(O)—, alkyl-C(O)— or cycloalkyl-C(O)—, group in which the various groups are as previously described. The bond to the parent moiety is through the carbonyl. Preferred acyls contain a lower alkyl. Non-limiting examples of suitable acyl groups include formyl, acetyl and propanoyl.

[0042]

When used herein, the term “substituted” means that one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By “stable compound” or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The term “optionally substituted” means optional substitution with the specified groups, radicals or moieties.

[0043]

It should also be noted that any heteroatom with unsatisfied valences in the text, schemes, examples and Tables herein is assumed to have the hydrogen atom to satisfy the valences. When a functional group in a compound is termed “protected”, this means that the group is in modified form to preclude undesired side reactions at the protected site when the compound is subjected to a reaction. Suitable protecting groups will be recognized by those with ordinary skill in the art as well as by reference to standard textbooks such as, for example, T. W. Greene et al, Protective Groups in Organic Synthesis (1991), Wiley, N.Y.

[0044]

When any variable (e.g., aryl, heterocycle, R2, etc.) occurs more than one time in any constituent or in Formula (I), its definition on each occurrence is independent of its definition at every other occurrence.

[0045]

When used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

[0046]

The compounds according to the invention are suitably provided in substantially pure form, for example at least 50% pure, suitably at least 60% pure, advantageously at least 75% pure, preferably at least 85% pure, more preferably at least 95% pure, especially at least 98% pure, all percentages being calculated as weight/weight. An impure or less pure form of a compound according to the invention may, for example, be used in the preparation of a more pure form of the same compound or of a related compound (for example a corresponding derivative) suitable for pharmaceutical use.

[0047]

It will be appreciated that certain compounds of the present invention may comprise one or more chiral centers so that compounds may exist as stereoisomers, including diastereoisomers and enantiomers. The present invention covers all such stereoisomers, and mixtures thereof, including racemates.

[0048]

In some aspects of the present invention provides compounds of Formula (Ia):

[0049]

[0050]

in which:

[0051]

R1, R2, R3, R4, R5and X are as previously described herein.

[0052]

In addition, aspects of the present invention provide compounds of Formula (Ib):

[0053]

[0054]

in which:

[0000]

R1, R2, R3, R4, R5and X are as previously described herein.

[0000]

Accordingly, the invention provides the following compounds:

[0000]

  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-methoxyethyl)acetamide;
  • 3-(N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)acetamido)propylphosphonic acid;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-2-(2-methoxyethoxy)-N-methylacetamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylacetamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylisoxazole-5-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylisoxazole-5-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-3-phenylpropanamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylfuran-2-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-phenoxybutanamide;
  • 1-(3,4-Dichloro-benzyl)-3-{4-[3-(1,1-dioxo-tetrahydro-116-thiophen-3-ylmethyl)-1-methyl-ureidomethyl]-thiazol-2-yl}-urea;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-1H-imidazole-5-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylfuran-3-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylfuran-2-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-3-phenylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-ethyl-3,5-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-isopropyl-3,5-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-3-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyl-5-phenylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyl-5-(4-methyl-1,2,3-thiadiazol-5-yl)isoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(2H-tetrazol-5-yl)acetamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbenzofuran-2-carboxamide;
  • N-(1-(2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)ethyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-1,2,5-oxadiazole-3-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-2-(3,5-dimethylisoxazol-4-yl)-N-methylacetamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-3-ethyl-N,5-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-4-carboxamide;
  • 5-cyclopropyl-N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,6-trimethylbenzamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-5-(furan-2-yl)-N-methylisoxazole-3-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,5-trimethyloxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-phenylthiazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2,4-dimethoxybenzyl)-3,5-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-methoxyethyl)-3,5-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(thiophen-2-yl)thiazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-3-hydroxy-N-methylisoxazole-5-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-phenyl-1,3,4-oxadiazole-2-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylfuran-2-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethyl-1,2,5-oxadiazole-3-carboxamide;
  • 4-Methyl-2-pyrazin-2-yl-thiazole-5-carboxylic acid {2-[3-(3,4-dichlorobenzyl)ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-2,4-dimethoxy-N-methylbenzamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-4-methoxy-N-methylbenzamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-3,4-dimethoxy-N-methylbenzamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbenzo[1,3]dioxole-5-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-3,4,5-trimethoxy-N-methylbenzamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-3-(trifluoromethyl)isoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(pyridin-3-yl)acetamide;
  • N-(1-(2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)-2-(methylamino)-2-oxoethyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,4-trimethylnicotinamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,4,6-tetramethylbenzamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-hydroxyethyl)-3,5-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-(methoxymethyl)-N,3-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-5-(methoxymethyl)-N,3-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylacetamide;
  • methyl 2-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)amino)-2-oxoacetate;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylisoxazole-4-carboxamide;
  • 3-ethyl-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,4-trimethylnicotinamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrazine-2-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrimidine-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrimidine-5-carboxamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrazine-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylpyrazine-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylfuran-3-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethyloxazole-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-3-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-tosylacetamide;
  • Ethyl 4-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)-5-methylisoxazole-3-carboxylate;
  • 4-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)-5-methylisoxazole-3-carboxylic acid;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylnicotinamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylnicotinamide;
  • 3-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-(methylsulfonyl)thiophene-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylthiazole-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-oxo-3,5-dihydro-2H-thiazolo[3,2-a]pyrimidine-6-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethyl-2-(methylthio)pyrimidine-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylbut-2-enamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylbenzamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylquinoxaline-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylpicolinamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-((4-methoxybenzyloxy)methyl)-N,3-dimethylisoxazole-4-carboxamide;
  • N-(2-Aminoethyl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3,5-dimethylisoxazole-4-carboxamide;
  • 4-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrimidine-5-carboxamide;
  • 2-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylpyrimidine-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3,5-dimethyl-N-(2-(methylsulfonamido)ethyl)isoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethyl-2-oxo-1,2-dihydropyridine-3-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,4,6-tetramethylpyrimidine-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide;
  • tert-butyl 2-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)-1-methyl-1H-imidazol-4-ylcarbamate;
  • 4-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-1H-imidazole-2-carboxamide;
  • 4-acetamido-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-1H-imidazole-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethylpyrimidine-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-(hydroxymethyl)-N,5-dimethylisoxazole-4-carboxamide;
  • N-((2-(3-(4-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3,5-difluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylisonicotinamide;
  • N-((2-(3-(3-chlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(benzo[1,3]dioxol-5-ylmethyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • 2-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethylpyrimidine-5-carboxamide;
  • N-((2-(3-(2,2-difluorobenzo[1,3]dioxol-5-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylimidazo[1,2-a]pyridine-3-carboxamide;
  • N,3,5-trimethyl-N-((2-(3-(3-(N-methylacetamido)benzyl)ureido)thiazol-4-yl)methyl)isoxazole-4-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;
  • 1-(4-((2,4-dioxothiazolidin-3-yl)methyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylnicotinamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-3-carboxamide;
  • N,3,5-trimethyl-N-((2-(3-(thiophen-3-ylmethyl)ureido)thiazol-4-yl)methyl)isoxazole-4-carboxamide;
  • methyl (2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl(2-hydroxyethyl)carbamate;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-hydroxyethyl)-3-methylisonicotinamide;
  • 1-(3-fluorobenzyl)-3-(4-((2-oxooxazolidin-3-yl)methyl)thiazol-2-yl)urea;
  • 2-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylnicotinamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1,3,5-tetramethyl-1H-pyrazole-4-carboxamide;
  • (S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;
  • (R)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-3-propoxypicolinamide;
  • tert-butyl 2-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)morpholine-4-carboxylate;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylmorpholine-2-carboxamide;
  • N-((2-(3-(3,5-difluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide;
  • N-((2-(3-(3,5-difluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylisonicotinamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyridazine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyridazine-3-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydro-2H-pyran-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1,5-trimethyl-1H-pyrazole-4-carboxamide;
  • N-((2-(3-((5-chlorofuran-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylmorpholine-3-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylpyrrolidine-3-carboxamide;
  • (S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpyrrolidine-2-carboxamide;
  • 2-Methyl-5,6-dihydro-4H-pyran-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2-Methyl-5-morpholin-4-ylmethyl-furan-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2-Methyl-but-2-enoic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1,2,3-Thiadiazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid {2-[3-(5-fluoro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2-Pyridin-3-yl-thiazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2,5-Dimethyl-2H-pyrazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 4-Methyl-furazan-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2-Morpholin-4-ylmethyl-furan-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1-Methyl-pyrrolidine-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1-Methyl-1H-pyrrole-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1,5-Dimethyl-1H-[1,2,3]triazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 5-Fluoro-thiophene-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 4-Methyl-pyrimidine-5-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 4-Methyl-2-phenyl-pyrimidine-5-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-2-methylsulfanyl-nicotinamide;
  • 2-Cyano-N-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-acetamide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid {5-bromo-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-6-morpholin-4-yl-nicotinamide;
  • 4-Methyl-thiazole-5-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3-Methyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2,4-Dimethyl-pyrimidine-5-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2-Methyl-[1,6]naphthyridine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 6-(4-Methoxy-phenyl)-pyridazine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3-Methyl-pyrazine-2-carboxylic acid {5-bromo-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3-Methyl-pyrazine-2-carboxylic acid {5-chloro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2,6-Bis-dimethylamino-pyrimidine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2,6-Di-morpholin-4-yl-pyrimidine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2-Cyano-N-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-3-pyridin-3-yl-acrylamide;
  • 2-Methyl-[1,8]naphthyridine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2-Dimethylamino-6-methyl-pyrimidine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-2-methoxy-N-methyl-2-phenyl-acetamide;
  • 3-Methyl-pyrazine-2-carboxylic acid {2-[3-(5-fluoro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3-Methyl-pyrazine-2-carboxylic acid methyl-[2-(3-thiophen-3-ylmethyl-ureido)-thiazol-4-ylmethyl]-amide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid {5-cyano-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • Acetic acid 1-({2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-carbamoyl)-ethyl ester;
  • 1-Ethyl-3-methyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2-Methyl-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-2-hydroxy-N-methyl-propionamide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid (1-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-yl}-ethyl)-amide;
  • 1-Ethyl-5-methyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 5,7-Dimethyl-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid (1-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-yl}-2-hydroxy-ethyl)-amide;
  • 1-Methyl-1H-indole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1-Methyl-1H-indazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • Pyrazolo[1,5-a]pyridine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-2-furan-2-yl-N-methyl-2-oxo-acetamide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid [2-(3-benzyl-ureido)-thiazol-4-ylmethyl]-methyl-amide;
  • 3-Methyl-pyrazine-2-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-5-isopropyl-thiazol-4-ylmethyl}-methyl-amide;
  • 5-Oxo-pyrrolidine-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3-Methyl-pyrazine-2-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid (2,2-difluoro-ethyl)-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-amide;
  • 4-Methyl-pyridazine-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 5-Methyl-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3-Amino-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,6-Dimethoxy-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • (3,5-Dimethyl-isoxazol-4-ylmethyl)-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-carbamic acid methyl ester;
  • (R)-Tetrahydro-furan-2-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 5-Methyl-pyridazine-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 5-Methyl-pyridazine-4-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • Tetrahydro-furan-2-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-3-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,6-Dichloro-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3-Chloro-6-methoxy-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid {5-fluoro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • (R)-Tetrahydro-furan-2-carboxylic acid {5-fluoro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{5-Fluoro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-acetamide;
  • 1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid {5-fluoro-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3-Chloro-6-hydroxy-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 2-Methyl-tetrahydro-furan-2-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 4-Chloro-1-methyl-1H-pyrazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 5-Chloro-1-methyl-1H-pyrazole-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 4-Chloro-2-methyl-2H-pyrazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 4-Chloro-1H-pyrazole-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-isoxazole-4-carboxylic acid (cyano-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-yl}-methyl)-methyl-amide;
  • 1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1,3,6-Trimethyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{2-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-2,N-dimethyl-5-sulfamoyl-benzamide;
  • 1-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1-Phenyl-cyclobutanecarboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 3-Methyl-4-oxo-3,4-dihydro-phthalazine-1-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 7-Chloro-benzo[1,3]dioxole-5-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{2-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-6-[1,2,4]triazol-1-yl-nicotinamide;
  • 1-(2-Methoxy-ethyl)-6-oxo-1,6-dihydro-pyridazine-3-carboxylic acid {2-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-methylacetamide;
  • 1,1-Dioxo-tetrahydrothiophene-3-carboxylic acid {2-[3-(5-chlorothiophen-2-yl)methyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 6-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-hydroxy-N-methylpyridazine-4-carboxamide;
  • 5-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1,3-trimethyl-1H-pyrazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-isopropyl-N,3-dimethylisoxazole-4-carboxamide;
  • 3-cyano-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-hydroxy-N,6-dimethylisonicotinamide;
  • 6-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-3-oxo-2,3-dihydropyridazine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethyl-5-sulfamoylbenzamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-1-phenylcyclobutanecarboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-oxo-3,4-dihydrophthalazine-1-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethyl-2-oxo-2H-pyran-5-carboxamide;
  • 7-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbenzo[1,3]dioxole-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-4-sulfamoyl-1H-pyrrole-2-carboxamide;
  • 2-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,6-trimethyl-4-oxo-3,4-dihydrofuro[2,3-d]pyrimidine-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxamide;
  • 2,2-difluoro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-phenylacetamide;
  • N2-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-4-hydroxy-N2-methylpyrrolidine-1,2-dicarboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-morpholinonicotinamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-oxo-3,4-dihydrophthalazine-1-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,4,6-trimethyl-2-oxo-2H-pyran-5-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-4-sulfamoyl-1H-pyrrole-2-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-N-methylacetamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-1-(3-fluorophenyl)-N-methylcyclobutanecarboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2,2-difluoro-N-methyl-2-phenylacetamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamide;
  • (S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyl-5,6-dihydro-1,4-dioxine-2-carboxamide;
  • (R)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-oxotetrahydrofuran-2-carboxamide;
  • 5-chloro-N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,1,3-trimethyl-1H-pyrazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyl-4-oxo-3,4-dihydrophthalazine-1-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,6-trimethyl-4-oxo-3,4-dihydrofuro[2,3-d]pyrimidine-5-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-methoxy-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(2-hydroxyethyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;
  • (R)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(2-methoxyethyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydro-2H-pyran-2-carboxamide;
  • N-(cyano(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide;
  • N-(cyano(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,6-trimethylisoxazolo[5,4-b]pyridine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-methoxy-N-methyltetrahydrofuran-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(4-methoxybutyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(3-methoxypropyl)-N,3,5-trimethyl-1H-pyrazole-4-carboxamide;
  • N-((5-fluoro-2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylpyridazine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-morpholinonicotinamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,6-trimethylisoxazolo[5,4-b]pyridine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(4-fluorophenyl)-N-methylcyclobutanecarboxamide;
  • 1,1-Dioxo-tetrahydrothiophene-3-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethyltetrahydrofuran-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyloxetane-3-carboxamide;
  • 5-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-1H-pyrazole-4-carboxamide;
  • (R)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,2-trimethyl-1,3-dioxolane-4-carboxamide;
  • (S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,2-trimethyl-1,3-dioxolane-4-carboxamide;
  • N-(2-amino-1-(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)ethyl)-N-methyltetrahydrofuran-2-carboxamide;
  • (R)—N-((2-(3-((5-fluorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;
  • 3,6-dichloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,5-dimethylpyridazine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-methoxy-N,3-dimethylpyridazine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1,3,6-tetramethyl-1H-pyrazolo[3,4-b]pyridine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-nitro-1H-pyrazole-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2,3-dihydrobenzofuran-2-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-2,3-dihydrobenzofuran-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-hydroxy-N,3-dimethylpyridazine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(pyrrolidin-1-yl)nicotinamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-oxo-4-(thiophen-2-yl)butanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-4-oxo-4-phenylbutanamide;
  • 2-(3-fluoro-4-methoxyphenyl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;
  • 2-(3,4-dimethoxyphenyl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-(hydroxymethyl)phenoxy)-N-methylacetamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(3-(methylsulfonyl)phenyl)acetamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(2-mercapto-4-methylthiazol-5-yl)-N-methylacetamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-5-(trifluoromethyl)furan-2-carboxamide;
  • (R)—N-((5-fluoro-2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-methoxy-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-hydroxy-N-methyl-3-(methylamino)pyridazine-4-carboxamide;
  • 3-(dimethylamino)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-methoxy-N-methylpyridazine-4-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-1-(2-methoxyethyl)-N-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(pyrrolidin-1-yl)nicotinamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2,2-trimethyltetrahydro-2H-pyran-4-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,2,2-trimethyltetrahydro-2H-pyran-4-carboxamide;
  • N-((2-(3-((1H-indol-5-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(benzo[1,2,5]oxadiazol-5-ylmethyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(benzo[1,2,5]thiadiazol-5-ylmethyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • 2-(4-(dimethylamino)phenyl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-7-hydroxy-N-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
  • 3-(1H-benzoimidazol-2-yl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(naphthalen-2-yl)acetamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-methoxy-3-methylphenyl)-N-methylacetamide;
  • 2-amino-3-(benzyloxy)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-1,4-dioxo-1,2,3,4-tetrahydrophthalazine-6-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-6-(1H-1,2,4-triazol-1-yl)nicotinamide;
  • 2-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-1,4-dioxo-1,2,3,4-tetrahydrophthalazine-6-carboxamide;
  • N2-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-4-hydroxy-N2-methylpyrrolidine-1,2-dicarboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,1-dimethyl-5-nitro-1H-pyrazole-4-carboxamide;
  • (S)-3,3-difluoro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylchroman-2-carboxamide;
  • 4-(3,5-dimethyl-1H-pyrazol-4-yl)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbenzamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpent-4-ynamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;
  • (S)-2-amino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-3-(pyridin-4-yl)propanamide;
  • cis-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-methoxy-N-methyltetrahydrofuran-2-carboxamide;
  • 1-cyano-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropanecarboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropiolamide;
  • N-((2-(3-((1H-indol-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((2-(3-(benzoxazol-6-ylmethyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • 2-ethoxy-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-methoxyphenoxy)-N-methylpropanamide;
  • 2-(cyclopropylmethoxy)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;
  • 2,5-diamino-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpentanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(2-phenoxyethoxy)propanamide;
  • 2-cyclopropyl-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylacetamide;
  • N,3,5-trimethyl-N-((2-(3-(4-nitrobenzyl)ureido)thiazol-4-yl)methyl)isoxazole-4-carboxamide;
  • N,3,5-trimethyl-N-((2-(3-(3-nitrobenzyl)ureido)thiazol-4-yl)methyl)isoxazole-4-carboxamide;
  • 3-ethyl-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyloxetane-3-carboxamide;
  • 2-(2,2-difluoroethoxy)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-fluorobenzyloxy)propanamide;
  • 2-(2,2,2-trifluoroethoxy)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(prop-2-ynyloxy)propanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-((5-methylisoxazol-3-yl)methoxy)propanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-(1-methylpyrrolidin-3-yloxy)propanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(2-hydroxyethoxy)propanamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopentanecarboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-1-hydroxy-N-methylcyclopropanecarboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methylcyclohexanecarboxamide;
  • 1-cyano-N-((5-fluoro-2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropanecarboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopentanecarboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylcyclohexanecarboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclohexanecarboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-oxo-2,3-dihydrobenzoxazole-6-carboxamide;
  • 3,3,3-trifluoro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-hydroxy-N,2-dimethylpropanamide;
  • 2,3-cis-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3-dimethyltetrahydrofuran-2-carboxamide;
  • (5R)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-5-(hydroxymethyl)-N-methyltetrahydrofuran-2-carboxamide;
  • N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2-hydroxy-N,2-dimethylpropanamide;
  • N-((2-(3-(5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyl-2-oxo-2,3-dihydrobenzoxazole-6-carboxamide;
  • (S)—N-((2-(3-((5-chlorothiophen-2-yl)methyl)ureido)thiazol-4-yl)methyl)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)-N-methylacetamide;
  • (R)—N-((2-(3-(benzo[1,2,5]oxadiazol-5-ylmethyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;
  • (R)—N-((2-(3-((7-chlorobenzo[1,3]dioxol-5-yl)methyl)ureido)thiazol-4-yl)methyl)-N-methyltetrahydrofuran-2-carboxamide;
  • 2,3,3,3-tetrafluoro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropanamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropanecarboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropane-1,1-dicarboxamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,2-dimethylcyclopropanecarboxamide;
  • (S)—N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)-N-methylacetamide;
  • N-((5-(3-(3-fluorobenzyl)ureido)-1,2,4-thiadiazol-3-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide;
  • N-((5-(3-(3-fluorobenzyl)ureido)-1,2,4-thiadiazol-3-yl)methyl)-N,2,6-trimethylbenzamide;
  • N-((5-(3-(3-fluorobenzyl)ureido)-1,2,4-thiadiazol-3-yl)methyl)-N,3-dimethylisonicotinamide;
  • N-((5-(3-(3-fluorobenzyl)ureido)-1,2,4-thiadiazol-3-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide;
  • 1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 5-Chloro-1,3-dimethyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 5-Isopropyl-3-methyl-isoxazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1,3,5-Trimethyl-1H-pyrazolo[4,3-b]pyridine-7-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Methyl-5-pyrrol-1-yl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 3-Methyl-4-oxo-3,4-dihydro-phthalazine-1-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2,4-Dimethyl-6-oxo-6H-pyran-3-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 3,6-Dimethyl-isoxazolo[5,4-b]pyridine-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2-(5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-N-{5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-acetamide;
  • 3,6-Dimethyl-4-oxo-3,4-dihydro-furo[2,3-d]pyrimidine-5-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-6-[1,2,4]triazol-1-yl-nicotinamide;
  • 1-(2-Methoxy-ethyl)-6-oxo-1,6-dihydro-pyridazine-3-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Methyl-4-sulfamoyl-1H-pyrrole-2-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-6-yl)-N-methyl-acetamide;
  • 3,6-Dimethyl-4-oxo-3,4-dihydro-furo[2,3-d]pyrimidine-5-carboxylic acid{5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • (R)-Tetrahydro-furan-2-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1,3,5-Trimethyl-1H-pyrazolo[4,3-b]pyridine-7-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-3-cyano-2-hydroxy-6,N-dimethyl-isonicotinamide;
  • 6-Chloro-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 7-Chloro-benzo[1,3]dioxole-5-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 5-Methyl-4-oxo-3,4-dihydro-thieno[2,3-d]pyrimidine-6-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Methyl-5-pyrrol-1-yl-1H-pyrazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Methyl-6-oxo-1,4,5,6-tetrahydro-pyridazine-3-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 3-Methyl-4-oxo-3,4-dihydro-phthalazine-1-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2,4-Dimethyl-6-oxo-6H-pyran-3-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 5-Methyl-4-oxo-3,4-dihydro-thieno[2,3-d]pyrimidine-6-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-6-[1,2,4]triazol-1-yl-nicotinamide;
  • 1-(2-Methoxy-ethyl)-6-oxo-1,6-dihydro-pyridazine-3-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2,2-difluoro-N-methyl-2-phenyl-acetamide;
  • (R)-Tetrahydro-furan-2-carboxylic acid [5-(3-benzo[1,2,5]oxadiazol-5-ylmethyl-ureido)-[1,2,4]thiadiazol-3-ylmethyl]-methyl-amide;
  • 3,5-Dimethyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 3,5-Dimethyl-pyridazine-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 5-Isopropyl-3-methyl-isoxazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2,N-dimethyl-5-sulfamoyl-benzamide;
  • 1,1-Dioxo-tetrahydrothiophene-3-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-morpholin-4-yl-nicotinamide;
  • 1-Phenyl-cyclobutanecarboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 4-Oxo-3,4-dihydro-phthalazine-1-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 7-Chloro-benzo[1,3]dioxole-5-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-(4-Fluoro-phenyl)-cyclobutanecarboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 5-Chloro-1,3-dimethyl-1H-pyrazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Phenyl-cyclobutanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 4-Oxo-3,4-dihydro-phthalazine-1-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-(4-Fluoro-phenyl)-cyclobutanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2,2-Difluoro-N-{5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-phenyl-acetamide;
  • 1,1-Dioxo-tetrahydro-thiophene-3-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2,2-Dimethyl-tetrahydro-pyran-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2,3-Dihydro-benzofuran-2-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • (R)-Tetrahydro-furan-2-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2,2-Dimethyl-tetrahydro-pyran-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Methyl-5-nitro-1H-pyrazole-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Methyl-5-nitro-1H-pyrazole-4-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2,3-Dihydro-benzofuran-2-carboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • (R)—N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-methoxy-N-methyl-propionamide;
  • (R)—N-{5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-methoxy-N-methyl-propionamide;
  • N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-morpholin-4-yl-nicotinamide;
  • N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-pyrrolidin-1-yl-nicotinamide;
  • N-{5-[3-(5-Chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2,N-dimethyl-5-sulfamoyl-benzamide;
  • N-{5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-pyrrolidin-1-yl-nicotinamide;
  • 2,2-Difluoro-N-{5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-N-methyl-2-pyridin-2-yl-acetamide;
  • 1-Methyl-4-sulfamoyl-1H-pyrrole-2-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 4-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-amide 2-({5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide);
  • Cyclopentanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2-Methyl-cyclohexanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • Cyclohexanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2,6-Dioxo-hexahydro-pyrimidine-4-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Cyano-cyclopropanecarboxylic acid {5-[3-(5-chloro-thiophen-2-ylmethyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 1-Hydroxy-cyclopropanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • 2-Oxo-2,3-dihydro-benzooxazole-6-carboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-hydroxy-2,N-dimethyl-propionamide;
  • 1-Cyano-cyclopropanecarboxylic acid {5-[3-(3-fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-methyl-amide;
  • N-{5-[3-(3-Fluoro-benzyl)-ureido]-[1,2,4]thiadiazol-3-ylmethyl}-2-((S)-4-hydroxy-2-oxo-pyrrolidin-1-yl)-N-methyl-acetamide;
  • 1,1-Dioxo-tetrahydro-1,6-thiophene-3-sulfonic acid {2-[3-(3,4-dichloro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,4-dimethylbenzenesulfonamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-sulfonamide;
  • N-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylmethanesulfonamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylmethanesulfonamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylpropane-1-sulfonamide;
  • 5-(2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)-1-(methylsulfonyl)pyrrolidin-3-yl acetate;
  • 1-(3,4-dichlorobenzyl)-3-(4-(4-hydroxy-1-(methylsulfonyl)pyrrolidin-2-yl)thiazol-2-yl)urea;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylbutane-1-sulfonamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylethanesulfonamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-sulfonamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-methylcyclopropanesulfonamide;
  • N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-N-(2-(methylsulfonamido)ethyl)methanesulfonamide;
  • 1-[4-(1,1-Dioxo-116-isothiazolidin-2-ylmethyl)-thiazol-2-yl]-3-(3-fluoro-benzyl)-urea;
  • 1-(3-Fluoro-benzyl)-3-{4-[1-(propane-1-sulfonyl)-pyrrolidin-2-yl]-thiazol-2-yl}-urea;
  • Ethanesulfonic acid {5-bromo-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-4-morpholin-4-yl-benzenesulfonamide;
  • Furan-2-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • Thiophene-2-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • Pyridine-3-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • Pyridine-2-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1-Methyl-1H-imidazole-4-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • 1,2-Dimethyl-1H-imidazole-4-sulfonic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide;
  • N-{2-[3-(3-Fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-N-methyl-C-pyridin-3-yl-methanesulfonamide; and
  • N-(3,5-Dimethyl-isoxazol-4-ylmethyl)-N-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methanesulfonamide.

[0530]

Prodrugs and solvates of the compounds of the invention are also contemplated herein. The term “prodrug”, as employed herein, denotes a compound that is a drug precursor which, upon administration to a subject, undergoes chemical conversion by metabolic or chemical processes to yield a compound of Formula (I) (note that Formula (I) includes Formula (Ia) and Formula (Ib)) or a salt and/or solvate thereof. A discussion of prodrugs is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems (1987) 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, (1987) Edward B. Roche, ed., American Pharmaceutical Association and Pergamon Press, both of which are incorporated herein by reference thereto.

[0531]

When used herein, the term “solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like.

[0532]

When used herein, the term “hydrate” is a solvate wherein the solvent molecule is H2O.

[0533]

As used herein, the phrases “effective amount” or “therapeutically effective amount” are meant to describe an amount of compound or a composition of the present invention effective in inhibiting bacterial replication and thus producing the desired therapeutic, ameliorative, inhibitory or preventative effect.

[0534]

The compounds of Formula (I) (as defined herein Formula (I) includes Formula (Ia) and (1b)) can form salts which are also within the scope of this invention. Reference to a compound of Formula (I) herein is understood to include reference to salts thereof, unless otherwise indicated. The term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I) contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions (“inner salts”) may be formed and are included within the term “salt(s)” as used herein. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, although other salts are also useful. Salts of the compounds of the Formula (I) may be formed, for example, by reacting a compound of Formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates, or in an aqueous medium followed by lyophilization.

[0535]

Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by S. Berge et al, Journal of Pharmaceutical Sciences (1977) 66(1) 1 19; P. Gould, International J. of Pharmaceutics (1986) 33 201 217; Anderson et al, The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference thereto.

[0536]

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g. methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g. dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g. decyl, lauryl, and stearyl chlorides, bromides and iodides), arylalkyl halides (e.g. benzyl and phenethyl bromides), and others.

[0537]

All such acid and base salts are intended to be pharmaceutically acceptable salts within the scope of the invention and all acid and base salts are considered equivalent to the free forms of the corresponding compounds for purposes of the invention.

[0538]

Compounds of Formula (I) and salts, solvates and prodrugs thereof, may exist in their tautomeric form (for example, as an amide or imino ether). All such tautomeric forms are contemplated herein as part of the present invention. All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts, solvates and prodrugs of the compounds as well as the salts and solvates of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers (such as, for example, 4-pyridyl and 3-pyridyl). Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. The use of the terms “salt”, “solvate” “prodrug” and the like, is intended to equally apply to the salt, solvate and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.

[0539]

Compounds of Formula (I) are inhibitors of PolC, a type II DNA Polymerase III, which is the major replicative polymerase responsible for chromosomal replication in low GC Gram-positive bacteria. Compounds of Formula (I) are generally selective for PolC, showing little or no inhibition of the eukaryotic replicative polymerase, i.e., provides an optimal combination of high activity against various pathogenic bacteria and low or no activity against mammalian calls, allowing the use of compounds of the invention in the treatment of mammals, and in particular humans.

[0540]

Compounds of the present invention show antibacterial activity against clinically relevant Gram-positive pathogens, including S. pyogenes, S. aureus, S. pneumoniae and E. faecalis. Compounds of the present invention demonstrate preferential inhibition of DNA synthesis over RNA, protein, or cell wall synthesis in whole cell assays. Therapeutic compositions of the present invention have antibacterial activity against clinically important Gram-positive pathogens, including staphylococci and streptococci, and particularly including isolates resistant to currently marketed agents.

[0541]

Another aspect of this invention is a method of protecting a patient from a bacterial infection. A patient may be an animal, preferably a mammal and even more preferably a human having or susceptible to a disease or condition associated with a bacterial infection. Protecting may be prophylactic, i.e., administering a compound of the present invention in the absence of a diagnosed bacterial infection, or therapeutic, i.e., administering a compound of the present invention upon diagnosis of a bacterial infection. Protection may be achieved by administering a therapeutically effective amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate of said compound to the patient. A preferred dosage is about 0.001 to 500 mg/kg of body weight/day of the compound of Formula (I) or a pharmaceutically acceptable salt or solvate of said compound. An especially preferred dosage is about 0.01 to 25 mg/kg of body weight/day of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate of said compound.

[0542]

Methods to diagnose bacterial infection in patients are known in the art. Preferred bacterial infections to treat include bacterial infections caused by any bacteria type or species against which the compounds of the present invention have an antibacterial effect. Particularly preferred bacteria types or species include Gram-positive and Gram-negative bacteria and most preferred bacterial types include Gram-positive bacteria.

[0543]

In order to protect an animal from bacterial infection, a therapeutic or prophylactic composition of the present invention is administered to the animal in an effective manner such that bacterial infection is minimized and/or reduced. Preferably, the bacterial infection and/or bacterial burden of the infectious bacteria is reduced by at least about 50%, at least about 70%, and more preferably at least about 90%, 95% or 97%.

[0544]

Suitable patients to treat include humans; birds such as chickens, ostriches, quail, and turkeys; other mammals such as companion animals (including dogs, cats, and rodents) and economic food and/or fur or other product animals, such as horses, cattle, llamas, chinchillas, ferrets, goats, sheep, rodents, minks, rabbits, raccoons, and swine.

[0545]

The compounds of this invention can also be useful in combination (administered together or sequentially) with one or more of antibacterial treatments, such as, for example, treatment with other known antibacterial drug classes such as, for example, β-lactams, glycopeptides, oxazolidinones, macrolides, ketolides, quinolones, fluoroquinolones, aminoglycosides, tetracyclines, and lipopeptides. If formulated as a fixed dose, such combination products employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active agent or treatment within its dosage range. Compounds of Formula (I) may also be administered sequentially with known antibacterial agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of Formula (I) may be administered either prior to or after administration of the known antibacterial agent. Such techniques are within the skills of persons skilled in the art as well as attending physicians.

[0546]

Accordingly, in an aspect, this invention includes combinations comprising an amount of at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and an amount of one or more antibacterial agents or treatments listed above wherein the amounts of the compounds/treatments result in desired therapeutic effect. The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological assays. The exemplified pharmacological assays which are described herein have been carried out with compounds according to the invention and/or their salts.

[0547]

In another aspect, the invention includes pharmaceutical compositions which comprise at least one compound of Formula (I), or a pharmaceutically acceptable salt or solvate of said compound, and at least one pharmaceutically acceptable carrier. Accordingly, the present invention further includes compositions comprising one or more compounds of Formula (I) and a pharmaceutically acceptable carrier.

[0548]

When used herein, the phrase “pharmaceutically acceptable carrier” refers to media generally accepted in the art for the delivery of biologically active agents to patients, in particular, mammals Pharmaceutically acceptable carriers are typically formulated according to a number of factors well within the purview of those of ordinary skill in the art. These include, without limitation: the type and nature of the active agent being formulated; the subject to which the agent-containing composition is to be administered; the intended route of administration of the composition; and, the therapeutic indication being targeted. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, e.g., stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, are found in a variety of readily available sources such as, for example, Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, which is incorporated herein by reference in its entirety.

[0549]

Preparation of Pharmaceutical Compositions of the Invention Include inclusion of inert, solid or liquid pharmaceutically acceptable carriers. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, e.g., magnesium carbonate, magnesium stearate, talc, silica, sucrose, lactose, starch, or cellulose derivatives. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), Remington's Pharmaceutical Sciences, 18th Edition, (1990), Mack Publishing Co., Easton, Pa. incorporated herein by reference.

[0550]

Liquid form preparations include solutions, suspensions and emulsions. As an example, water or water-propylene glycol solutions for parenteral injection or addition of sweeteners and opacifiers for oral solutions, suspensions and emulsions, can be used. Liquid form preparations may also include solutions for intranasal administration. Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as, but not limited to, lactose, starch, magnesium stearate, steric acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar-coated or film-coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract. Liquid dose forms for oral administration can also contain coloring or flavoring agents to increase patient acceptance.

[0551]

Typically, water, pharmaceutically acceptable oils, saline, aqueous dextrose, and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for parenteral solutions. Solutions for parenteral administration can contain, for example, a water soluble salt of the active ingredient and suitable stabilizing agent(s). Antioxidizing agents, such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, can act as suitable stabilizing agents. Also suitable as stabilizing agents are citric acid and its salts, and EDTA. In addition, parenteral solutions can contain preservatives such as, for example, benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

[0552]

Oral compositions are preferred and will generally include an inert diluent or an edible carrier and may be compressed into tablets or enclosed in gelatin capsules. The oral dosage forms are administered to the patient weekly, twice weekly, three times weekly, four times weekly, five times weekly, six times weekly, or 1, 2, 3, or 4 times daily. It is preferred that the compounds of the invention be administered either three or fewer times daily, more preferably once or twice daily. For purposes of oral therapeutic administration, the active compound or compounds can be incorporated with excipients and used in the form of tablets, capsules, lozenges, or troches. Pharmaceutically compatible binding agents and adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches, and the like can contain any of the following ingredients or compounds of a similar nature: a binder such as, but not limited to, gum tragacanth, acacia, corn starch, or gelatin; an excipient such as microcrystalline cellulose, starch, or lactose; a disintegrating agent such as, but not limited to, alginic acid and corn starch; a lubricant such as, but not limited to, magnesium stearate; a glidant, such as, but not limited to, colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; and a flavoring agent such as peppermint, or fruit flavoring.

[0553]

When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials, which modify the physical form of the dosage unit, for example, coatings of sugar and other enteric agents. The compounds can also be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings, and flavors. The active materials can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action.

[0554]

Solutions or suspensions used for parenternal, intradermal, subcutaneous, or topical application can include any of the following components: a sterile diluent such as water for injection, saline solution, fixed oil, a naturally occurring vegetable oil such as sesame oil, coconut oil, peanut oil, cottonseed oil, and the like, or a synthetic fatty vehicle such as ethyl oleate, and the like, polyethylene glycol, glycerine, propylene glycol, or other synthetic solvent; antimicrobial agents such as benzyl alcohol and methyl parabens; antioxidants such as ascorbic acid and sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates, and phosphates; and agents for the adjustment of tonicity such as sodium chloride and dextrose. Parenternal preparations can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass, plastic, or other suitable material. Buffers, preservatives, antioxidants, and the like can be incorporated as required.

[0555]

Where administered intravenously, suitable carriers include physiological saline, phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents such as glucose, polyethylene glycol, polypropyleneglycol, and mixtures thereof. Liposomal suspensions including tissue-targeted liposomes may also be suitable as pharmaceutically acceptable carriers. These may be prepared according to methods known, for example, as described in U.S. Pat. No. 4,522,811, which is incorporated by reference herein.

[0556]

The active compounds may be prepared with carriers that protect the compound against rapid elimination from the body, such as time-release formulations or coatings such as enteric coatings to protect the compounds of the present invention from the acidic environment of the stomach. Enteric coated tablets are well known to those skilled in the art. In addition, capsules filled with small spheres, each coated to protect from the acidic stomach, are also well known to those skilled in the art. Other such carriers include controlled release formulations, such as, but not limited to, implants and microencapsulated delivery systems, and biodegradable, biocompatible polymers such as collagen, ethylene vinyl acetate, polyanhydrides, polyglycolic acid, polyorthoesters, polylactic acid, and the like. Methods for preparation of such formulations are known to those skilled in the art.

[0557]

The compounds of the invention can be administered orally, parenterally (IV, IM, depo-IM, SQ, and depo-SQ), sublingually, intranasally (inhalation), intrathecally, topically, or rectally. Dosage forms known to those skilled in the art are suitable for delivery of the compounds of the invention.

[0558]

When administered orally, compounds of the invention can be administered in usual dosage forms for oral administration as is well known to those skilled in the art and are described more fully herein. These dosage forms include the usual solid unit dosage forms of tablets and capsules as well as liquid dosage forms such as solutions, suspensions, and elixirs. When the solid dosage forms are used, it is preferred that they be of the sustained release type so that the compounds of the invention need to be administered only once or twice daily.

[0559]

The compounds of the invention can be administered parenterally, for example, by IV, IM, depo-IM, SC, or depo-SC. When administered parenterally, a therapeutically effective amount for humans of about 0.5 to about 100 mg/day, preferably from about 5 to about 50 mg daily should be delivered. When a depot formulation is used for injection once a month or once every two weeks, the dose for humans should be about 0.5 mg/day to about 50 mg/day, or a monthly dose of from about 15 mg to about 1,500 mg. Dosing for other types of patients can be estimated from the appropriate human dose.

[0560]

The compounds of the invention can be administered sublingually. When given sublingually, the compounds of the invention should be given one to four times daily in the amounts described above for IM administration.

[0561]

The compounds of the invention can also be administered intranasally. When given by this route, the appropriate dosage forms are a nasal spray or dry powder, as is known to those skilled in the art. The dosage of the compounds of the invention for intranasal administration is the amount described above for IM administration.

[0562]

The compounds of the invention can be administered intrathecally. When given by this route the appropriate dosage form can be a parenteral dosage form as is known to those skilled in the art. The dosage of the compounds of the invention for intrathecal administration is the amount described above for IM administration.

[0563]

The compounds of the invention can be administered topically. When given by this route, the appropriate dosage form is a cream, ointment, or patch. When administered topically, the dosage is from about 0.5 mg/day to about 200 mg/day. The compounds of the invention can be administered rectally by suppository as is known to those skilled in the art. When administered by suppository, the therapeutically effective amount is from about 0.5 mg to about 500 mg for humans. The compounds of the invention can be administered by implants as is known to those skilled in the art. When administering a compound of the invention by implant, the therapeutically effective amount is the amount described above for depot administration.

[0564]

The invention herein is the novel compounds of the invention and new methods of using the compounds of the invention. Given a particular compound of the invention and a desired dosage form, one skilled in the art would know how to prepare and administer the appropriate dosage form.

[0565]

Where the compounds of the invention exhibit insufficient solubility, methods for solubilizing may be used. Such methods are known and include, but are not limited to, using cosolvents such as dimethylsulfoxide (DMSO), using surfactants such as polysorbates including Tween® and dissolution in aqueous sodium bicarbonate. Derivatives of the compounds, such as salts or prodrugs may also be used in formulating effective pharmaceutical compositions.

[0566]

The concentration of the compound is effective for delivery of an amount upon administration that lessens or ameliorates at least one symptom of the disorder for which the compound is administered. Typically, the compositions are formulated for single dosage administration. A suitable single dose is a dose that is capable of reducing bacterial infection and/or bacterial burden with the infectious bacteria when administered one or more times over a suitable time period. For example, a preferred single dose of a compound of Formula (I) ranges from about 1 microgram to about 10 milligrams, but can range up to 100 milligrams of the composition per kilogram body weight of the patient.

[0567]

The active compound is typically included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful effect in the absence of undesirable side effects on the patient treated. The therapeutically effective concentration may be determined empirically by testing the compounds in known in vitro and in vivo model systems for the treated disorder.

[0568]

The compounds and compositions of the invention can be enclosed in multiple or single dose containers. The enclosed compounds and compositions can be provided in kits, for example, including component parts that can be assembled for use. For example, a compound of the invention in lyophilized form, and a suitable diluent, may be provided as separated components for combination prior to use. A kit may include a compound of the invention and a second therapeutic agent for co-administration. The compound of the invention and second therapeutic agent may be provided as separate component parts.

[0569]

A kit herein may include a plurality of containers, each container holding one or more unit dose of the compound of the invention. The containers are preferably adapted for the desired mode of administration, including, but not limited to tablets, gel capsules, sustained-release capsules, and the like for oral administration; depot products, pre-filled syringes, ampules, vials, and the like for parenternal administration; and patches, medipads, creams, ointments, and the like for topical administration.

[0570]

The concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the active compound, the dosage schedule, and amount administered as well as other factors known to those of skill in the art. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at intervals of time. It is understood that the precise dosage and duration of treatment is a function of the disease being treated and may be determined empirically using known testing protocols or by extrapolation from in vivo or in vitro test data.

[0571]

It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the composition(s), and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

[0572]

Compounds of the invention can be prepared as described in the following Examples.

[0573]

The invention disclosed herein is exemplified by the following preparations and examples which should not be construed to limit the scope of the disclosure. Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art.

EXAMPLES

Examples 1-478

[0574]

The following abbreviations are used throughout the Example section and are not meant to limit the scope of the disclosure.

[0000]

TLC=thin layer chromatography

[0000]

eq.=equivalents

[0000]

equiv.=equivalents

[0000]

THF=tetrahydrofuran

[0000]

DIPEA=diisopropylethylamine

[0000]

DIEA=diisopropylethylamine

[0000]

DCM=dichloromethane

[0000]

MeOH=methanol

[0000]

EtOAc=ethyl acetate

[0000]

BOC2O=di-tert-butyl dicarbonate

[0000]

mCPBA=3-chloroperbenzoic acid

[0000]

DMAP=4-(Dimethylamino)pyridine

[0000]

TFA=trifluoroacetic acid

[0000]

DMA=N,N-dimethylacetamide

[0000]

TBTU=O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate

[0000]

DMSO=dimethyl sulfoxide

[0000]

Et2O=diethyl ether

[0000]

MeCN=acetonitrile

[0000]

DMF=N,N-dimethylformamide

[0000]

NMP=1-Methyl-2-pyrrolidinone

[0575]

The compounds of Examples 1-475, shown below in Tables 1 (thiazoyl amides), 2 (thiadiazolyl amides) and 3 (thiazoyl sulfonamides) were prepared by the methods described in Example 477 as indicated in the Tables using intermediates described in Example 476.

[0576]

Preparation of Thiazolyl Amides
EX #NAMEMOL FORMULAMOL WEIGHTMASSMETHODStarting Material 1 (SM1)Starting Material 2 (SM2)
1N-((2-(3-(3,4-dichlorobenzyl)C17H20Cl2N4O3S431.3431,3Int. 12Acetyl chloride
ureido)thiazol-4-yl)methyl)-N-433
(2-methoxyethyl)acetamide
23-(N-((2-(3-(3,4-dichlorobenzyl)ureido)C17H21Cl2N4O5PS495.3495,3Int. 23Acetyl chloride
thiazol-4-yl)methyl) acetamido) propylphosphonic acid497
3N-((2-(3-(3,4-dichlorobenzyl)C18H22Cl2N4O4S461.4461,3Int. 32-(2-Methoxyethoxy)acetyl chloride
ureido)thiazol-4-yl)methyl)-2-463
(2-methoxyethoxy)-N-methylacetamide
4N-((2-(3-(3,4-dichlorobenzyl)C16H18Cl2N4O3S417.3417,3Int. 32-Methoxyacetyl chloride
ureido)thiazol-4-yl)methyl)-2-419
methoxy-N-methylacetamide
5N-((2-(3-(3,4-dichlorobenzyl)C18H17Cl2N5O3S454.3454,3Int. 34-Methyl-isoxazole-5-
ureido)thiazol-4-yl)methyl)-456carboxylic acid chloride
N,4-dimethylisoxazole-5-carboxamide
6N-((2-(3-(3,4-dichlorobenzyl)C17H15Cl2N5O3S440.3440,3Int. 3Isoxazole-5-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-442chloride
methylisoxazole-5-carboxamide
7N-((2-(3-(3,4-dichlorobenzyl)C22H22Cl2N4O2S477.4477,3Int. 33-Phenylpropionyl chloride
ureido)thiazol-4-yl)methyl)-N-479
methyl-3-phenylpropanamide
8N-((2-(3-(3,4-dichlorobenzyl)C18H16Cl2N4O3S439.3439,3Int. 32-Furoyl chloride
ureido)thiazol-4-yl)methyl)-N-441
methylfuran-2-carboxamide
9N-((2-(3-(3,4-dichlorobenzyl)C23H24Cl2N4O3S507.4507,3Int. 34-Phenoxy-butyryl chloride
ureido)thiazol-4-yl)methyl)-N-509
methyl-4-phenoxybutanamide
101-(3,4-Dichloro-benzyl)-3-{4-C19H23Cl2N5O4S2520.5520,3Int. 3N-(1,1-Dioxo-tetrahydrothiophen-3-yl-
[3-(1,1-dioxo-tetrahydro-1l6-522methyl)carbamoyl chloride
thiophen-3-ylmethyl)-1-
methyl-ureidomethyl]-thiazol-2-yl}-urea
11N-((2-(3-(3,4-dichlorobenzyl)C19H19Cl2N5O3S468.4468,3Int. 33,5-Dimethyl-isoxazole-4-
ureido)thiazol-4-yl)methyl)-470carboxylic acid chloride
N,3,5-trimethylisoxazole-4-carboxamide
12N-((2-(3-(3,4-dichlorobenzyl)C18H18Cl2N6O2S453.4453,3Int. 31-Methyl-imidazole-5-
ureido)thiazol-4-yl)methyl)-455carboxylic acid chloride
N,1-dimethyl-1H-imidazole-5-carboxamide
13N-((2-(3-(3,4-dichlorobenzyl)C18H16Cl2N4O3S439.3439,3Int. 33-Furoyl chloride
ureido)thiazol-4-yl)methyl)-N-441
methylfuran-3-carboxamide
14N-((2-(3-(3,4-dichlorobenzyl)C19H18Cl2N4O3S453.3453,3Int. 33-Methyl-2-furoyl chloride
ureido)thiazol-4-yl)methyl)-455
N,3-dimethylfuran-2-carboxamide
15N-((2-(3-(3,4-dichlorobenzyl)C24H21Cl2N5O3S530.4530,3Int. 35-Methyl-3-phenyl-isoxazole-
ureido)thiazol-4-yl)methyl)-5324-carboxylic acid chloride
N,5-dimethyl-3-phenylisoxazole-4-carboxamide
16N-((2-(3-(3,4-dichlorobenzyl)C20H21Cl2N5O3S482.4482,3Int. 83,5-Dimethyl-isoxazole-4-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-484chloride
ethyl-3,5-dimethylisoxazole-4-carboxamide
17N-((2-(3-(3,4-dichlorobenzyl)C21H23Cl2N5O3S496.4496,3Int. 93,5-Dimethyl-isoxazole-4-
ureido)thiazol-4-yl)methyl)-N-isopropyl-3,5-498carboxylic acid chloride
dimethylisoxazole-4-carboxamide
18N-((2-(3-(3,4-dichlorobenzyl)C23H21Cl2N7O2S530.4530,3Int. 35-Methyl-2-phenyl-2H-1,2,3-
ureido)thiazol-4-yl)methyl)-532triazole-4-carboxylic acid
N,5-dimethyl-2-phenyl-2H-chloride
1,2,3-triazole-4-carboxamide
19N-((2-(3-(3,4-C18H17Cl2N5O3S454.3454,3Int. 35-Methylisoxazole-3-carboxylic acid
dichlorobenzyl)ureido)thiazol-4-yl)methyl)-456chloride
N,5-dimethylisoxazole-3-carboxamide
20N-((2-(3-(3,4-dichlorobenzyl)C24H21Cl2N5O3S530.4530,3Int. 33-Methyl-5-phenylisoxazole-
ureido)thiazol-4-yl)methyl)-5324-carboxylic acid chloride
N,3-dimethyl-5-phenylisoxazole-4-carboxamide
21N-((2-(3-(3,4-dichlorobenzyl)C21H19Cl2N7O3S2552.5552,3Int. 33-Methyl-5-(4-methyl-1,2,3-
ureido)thiazol-4-yl)methyl)-554thiadiazol-5-yl)isoxazole-4-
N,3-dimethyl-5-(4-methyl-carboxylic acid chloride
1,2,3-thiadiazol-5-yl)isoxazole-4-carboxamide
22N-((2-(3-(3,4-dichlorobenzyl)C16H16Cl2N8O2S455.3455/4572Int. 32-(2H-Tetrazol-5-yl)acetic
ureido)thiazol-4-yl)methyl)-N-acid
methyl-2-(2H-tetrazol-5-yl)acetamide
23N-((2-(3-(3,4-dichlorobenzyl)C22H18Cl2N4O3S489.4489,3Int. 3Benzofuran-2-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-491chloride
methylbenzofuran-2-carboxamide
24N-(1-(2-(3-(3,4-C20H21Cl2N5O3S482.4482/4843Int. 10a3,5-Dimethyl-isoxazole-4-
dichlorobenzyl)carboxylic acid chloride
ureido)thiazol-4-yl)ethyl)-
N,3,5-trimethylisoxazole-4-carboxamide
25N-((2-(3-(3,4-dichlorobenzyl)C16H14Cl2N6O3S441.3441/4432Int. 31,2,5-Oxadiazole-3-carboxylic
ureido)thiazol-4-yl)methyl)-N-acid chloride
methyl-1,2,5-oxadiazole-3-carboxamide
26N-((2-(3-(3,4-dichlorobenzyl)C20H21Cl2N5O3S482.4482,2Int. 32-(3,5-Dimethylisoxazol-4-
ureido)thiazol-4-yl)methyl)-2-484yl)acetic acid
(3,5-dimethylisoxazol-4-yl)-N-methylacetamide
27N-((2-(3-(3,4-dichlorobenzyl)C20H21Cl2N5O3S482.4482,2Int. 33-Ethyl-5-methylisoxazole-4-
ureido)thiazol-4-yl)methyl)-3-484carboxylic acid
ethyl-N,5-dimethylisoxazole-4-carboxamide
28N-((2-(3-(3,4-dichlorobenzyl)C18H17Cl2N5O3S454.3454,2Int. 33-Methylisoxazole-4-
ureido)thiazol-4-yl)methyl)-456carboxylic acid
N,3-dimethylisoxazole-4-carboxamide
29N-((2-(3-(3,4-dichlorobenzyl)C18H17Cl2N5O3S454.3454,2Int. 35-Methylisoxazole-4-
ureido)thiazol-4-yl)methyl)-456carboxylic acid chloride
N,5-dimethylisoxazole-4-carboxamide
305-cyclopropyl-N-((2-(3-(3,4-C20H19Cl2N5O3S480.4480,2Int. 35-Cyclopropylisoxazole-4-
dichlorobenzyl)ureido)thiazol-482carboxylic acid
4-yl)methyl)-N-methylisoxazole-4-carboxamide
31N-((2-(3-(3,4-dichlorobenzyl)C22H22Cl2N4O2S477.4477,3Int. 32,6-Dimethylbenzoyl chloride
ureido)thiazol-4-yl)methyl)-479
N,2,6-trimethylbenzamide
32N-((2-(3-(3,4-dichlorobenzyl)C21H17Cl2N5O4S506.4506,3Int. 35-(Furan-2-yl)isoxazole-3-
ureido)thiazol-4-yl)methyl)-5-508carboxylic acid chloride
(furan-2-yl)-N-methylisoxazole-3-carboxamide
33N-((2-(3-(3,4-dichlorobenzyl)C19H19Cl2N5O3S468.4468,3Int. 32,5-Dimethyloxazole-4-
ureido)thiazol-4-yl)methyl)-470carboxylic acid chloride
N,2,5-trimethyloxazole-4-carboxamide
34N-((2-(3-(3,4-dichlorobenzyl)C23H19Cl2N5O2S2532.5532,3Int. 32-Phenylthiazole-4-carboxylic
ureido)thiazol-4-yl)methyl)-N-534acid chloride
methyl-2-phenylthiazole-4-
carboxamide
35N-((2-(3-(3,4-dichlorobenzyl)C27H27Cl2N5O5S604.5604,3Int. 113,5-Dimethyl-isoxazole-4-
ureido)thiazol-4-yl)methyl)-N-606carboxylic acid chloride
(2,4-dimethoxybenzyl)-3,5-
dimethylisoxazole-4-
carboxamide
36N-((2-(3-(3,4-dichlorobenzyl)C21H23Cl2N5O4S512.4512,3Int. 123,5-Dimethyl-isoxazole-4-
ureido)thiazol-4-yl)methyl)-N-514carboxylic acid chloride
(2-methoxyethyl)-3,5-
dimethylisoxazole-4-
carboxamide
37N-((2-(3-(3,4-dichlorobenzyl)C21H17Cl2N5O2S3538.5538,3Int. 32-(Thiophen-2-yl)thiazole-4-
ureido)thiazol-4-yl)methyl)-N-540carboxylic acid chloride
methyl-2-(thiophen-2-
yl)thiazole-4-carboxamide
38N-((2-(3-(3,4-dichlorobenzyl)C17H15Cl2N5O4S456.3456/4582Int. 33-Hydroxyisoxazole-5-
ureido)thiazol-4-yl)methyl)-3-carboxylic acid
hydroxy-N-methylisoxazole-
5-carboxamide
39N-((2-(3-(3,4-dichlorobenzyl)C22H18Cl2N6O3S517.4517,3Int. 35-Phenyl-1,3,4-oxadiazole-2-
ureido)thiazol-4-yl)methyl)-N-519carboxylic acid chloride
methyl-5-phenyl-1,3,4-
oxadiazole-2-carboxamide
40N-((2-(3-(3,4-dichlorobenzyl)C19H18Cl2N4O3S453.3453,3Int. 35-Methyl-2-furoyl chloride
ureido)thiazol-4-yl)methyl)-455
N,5-dimethylfuran-2-
carboxamide
41N-((2-(3-(3,4-dichlorobenzyl)C17H16Cl2N6O3S455.3455,2Int. 34-Methyl-1,2,5-oxadiazole-3-
ureido)thiazol-4-yl)methyl)-457carboxylic acid
N,4-dimethyl-1,2,5-
oxadiazole-3-carboxamide
424-Methyl-2-pyrazin-2-yl-C22H19Cl2N7O2S2548.5548,3Int. 32-(Pyrazin-2-yl)4-
thiazole-5-carboxylic acid {2-550methylthiazole-5-carboxylic
[3-(3,4-dichlorobenzyl)acid chloride
ureido]-thiazol-4-ylmethyl}-
methyl-amide
43N-((2-(3-(3,4-dichlorobenzyl)C22H22Cl2N4O4S509.4509,3Int. 32,4-Dimethoxybenzoyl
ureido)thiazol-4-yl)methyl)-511chloride
2,4-dimethoxy-N-
methylbenzamide
44N-((2-(3-(3,4-dichlorobenzyl)C21H20Cl2N4O3S497.4479,3Int. 34-Methoxybenzoyl chloride
ureido)thiazol-4-yl)methyl)-4-481
methoxy-N-methylbenzamide
45N-((2-(3-(3,4-dichlorobenzyl)C22H22Cl2N4O4S509.4509,3Int. 33,4-Dimethoxybenzoyl
ureido)thiazol-4-yl)methyl)-511chloride
3,4-dimethoxy-N-
methylbenzamide
46N-((2-(3-(3,4-dichlorobenzyl)C21H18Cl2N4O4S493.4493,3Int. 33,4-Methylenedioxybenzoyl
ureido)thiazol-4-yl)methyl)-N-495chloride
methylbenzo[1,3]dioxole-5-
carboxamide
47N-((2-(3-(3,4-dichlorobenzyl)C23H24Cl2N4O5S539.4539,3Int. 33,4,5-Trimethoxybenzoyl
ureido)thiazol-4-yl)methyl)-541chloride
3,4,5-trimethoxy-N-
methylbenzamide
48N-((2-(3-(3,4-dichlorobenzyl)C19H16Cl2F3N5O3S522.3522,2Int. 35-Methyl-3-trifluoromethyl-
ureido)thiazol-4-yl)methyl)-524isoxazole-4-carboxylic acid
N,5-dimethyl-3-
(trifluoromethyl)isoxazole-4-
carboxamide
49N-((2-(3-(3,4-dichlorobenzyl)C20H19Cl2N5O2S464.4464,2Int. 32-(Pyridin-3-yl)acetic acid
ureido)thiazol-4-yl)methyl)-N-466
methyl-2-(pyridin-3-yl)
acetamide
50N-(1-(2-(3-(3,4-C21H22Cl2N6O4S525.4525,3Int. 133,5-Dimethyl-isoxazole-4-
dichlorobenzyl)ureido)thiazol-527carboxylic acid chloride
4-yl)-2-(methylamino)-2-
oxoethyl)-N,3,5-
trimethylisoxazole-4-
carboxamide
51N-((2-(3-(3,4-dichlorobenzyl)C21H21Cl2N5O2S478.4478,2Int. 32,4-Dimethylnicotinic acid
ureido)thiazol-4-yl)methyl)-480
N,2,4-trimethylnicotinamide
52N-((2-(3-(3,4-dichlorobenzyl)C23H24Cl2N4O2S491.4491,3Int. 32,4,6-Trimethylbenzoyl
ureido)thiazol-4-yl)methyl)-493chloride
N,2,4,6-tetramethylbenzamide
53N-((2-(3-(3,4-dichlorobenzyl)C20H21Cl2N5O4S498.4498,3Int. 143,5-Dimethyl-isoxazole-4-
ureido)thiazol-4-yl)methyl)-N-500carboxylic acid chloride
(2-hydroxyethyl)-3,5-
dimethylisoxazole-4-
carboxamide
54N-((2-(3-(3-fluorobenzyl)C19H20FN5O3S417.54183Int. 53,5-Dimethyl-isoxazole-4-
ureido)thiazol-4-yl)methyl)-carboxylic acid chloride
N,3,5-trimethylisoxazole-4-
carboxamide
55N-((2-(3-(3-fluorobenzyl)C20H22FN5O4S447.54482Int. 5Int. 31
ureido)thiazol-4-yl)methyl)-5-
(methoxymethyl)-N,3-
dimethylisoxazole-4-
carboxamide
56N-((2-(3-(3,4-dichlorobenzyl)C20H21Cl2N5O4S498.4498,2Int. 3Int. 31
ureido)thiazol-4-yl)methyl)-5-500
(methoxymethyl)-N,3-
dimethylisoxazole-4-
carboxamide
57N-((2-(3-(3-fluorobenzyl)C16H19FN4O3S366.43673Int. 52-Methoxyacetyl chloride
ureido)thiazol-4-yl)methyl)-2-
methoxy-N-methylacetamide
58methyl 2-(((2-(3-(3-C16H17FN4O4S380.43813Int. 5Methyl chlorooxoacetate
fluorobenzyl)ureido)thiazol-4-
yl)methyl)(methyl)amino)-2-
oxoacetate
59N-((2-(3-(3-fluorobenzyl)C18H18FN5O3S403.44042Int. 53-Methylisoxazole-4-
ureido)thiazol-4-yl)methyl)-carboxylic acid
N,3-dimethylisoxazole-4-
carboxamide
603-ethyl-N-((2-(3-(3-C20H22FN5O3S431.54322Int. 53-Ethyl-5-methylisoxazole-4-
fluorobenzyl)ureido)thiazol-4-carboxylic acid
yl)methyl)-N,5-
dimethylisoxazole-4-
carboxamide
61N-((2-(3-(3-fluorobenzyl)C21H22FN5O2S427.54282Int. 52,4-Dimethylnicotinic acid
ureido)thiazol-4-yl)methyl)-
N,2,4-trimethylnicotinamide
62N-((2-(3-(3-fluorobenzyl)C18H17FN6O2S400.44012Int. 5Pyrazine-2-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-
methylpyrazine-2-
carboxamide
63N-((2-(3-(3,4-dichlorobenzyl)C18H16Cl2N6O2S451.3451,2Int. 3Pyrimidine-5-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-453
methylpyrimidine-5-
carboxamide
64N-((2-(3-(3-fluorobenzyl)C18H17FN6O2S400.44012Int. 5Pyrimidine-5-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-
methylpyrimidine-5-
carboxamide
65N-((2-(3-(3,4-dichlorobenzyl)C18H16Cl2N6O2S451.3451,2Int. 3Pyrazine-2-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-453
methylpyrazine-2-
carboxamide
66N-((2-(3-(3-fluorobenzyl)C15H17FN4O2S336.43373Int. 5Acetyl chloride
ureido)thiazol-4-yl)methyl)-N-
methylacetamide
67N-((2-(3-(3-fluorobenzyl)C19H19FN6O2S414.54152Int. 55-Methylpyrazine-2-
ureido)thiazol-4-yl)methyl)-carboxylic acid
N,5-dimethylpyrazine-2-
carboxamide
68N-((2-(3-(3-fluorobenzyl)C18H17FN4O3S388.43893Int. 53-Furoyl chloride
ureido)thiazol-4-yl)methyl)-N-
methylfuran-3-carboxamide
69N-((2-(3-(3-fluorobenzyl)C18H18FN5O3S403.44043Int. 54-Methyloxazole-5-carboxylic
ureido)thiazol-4-yl)methyl)-acid chloride
N,4-dimethyloxazole-5-
carboxamide
70N-((2-(3-(3-fluorobenzyl)C18H18FN5O3S403.44043Int. 55-Methylisoxazole-3-
ureido)thiazol-4-yl)methyl)-carboxylic acid chloride
N,5-dimethylisoxazole-3-
carboxamide
71N-((2-(3-(3-fluorobenzyl)C22H23FN4O4S2490.64912Int. 52-(4-
ureido)thiazol-4-yl)methyl)-N-Methylphenylsulfonyl)acetic
methyl-2-tosylacetamideacid
72Ethyl 4-(((2-(3-(3-C21H22FN5O5S475.54762Int. 5Int. 35
fluorobenzyl)ureido)thiazol-4-
yl)methyl)(methyl)carbamoyl)-
5-methylisoxazole-3-
carboxylate
734-(((2-(3-(3-fluorobenzyl)C19H18FN5O5S447.44489Ethyl 4-(((2-(3-(3-None
ureido)thiazol-4-yl)methyl)fluorobenzyl)ureido)thiazol-
(methyl)carbamoyl)-5-4-yl)methyl)(methyl)
methylisoxazole-3-carboxyliccarbamoyl)-5-
acidmethylisoxazole-3-
carboxylate (EX# 72)
74N-((2-(3-(3-fluorobenzyl)C20H20FN5O2S413.54142Int. 52-Methylnicotinic acid
ureido)thiazol-4-yl)methyl)-
N,2-dimethylnicotinamide
75N-((2-(3-(3-fluorobenzyl)C18H18FN5O3S403.44042Int. 55-Methylisoxazole-4-
ureido)thiazol-4-yl)methyl)-carboxylic acid
N,5-dimethylisoxazole-4-
carboxamide
76N-((2-(3-(3-fluorobenzyl)C20H20FN5O2S413.54142Int. 54-Methylnicotinic acid
ureido)thiazol-4-yl)methyl)-
N,4-dimethylnicotinamide
773-chloro-N-((2-(3-(3-C19H18ClFN4O4S3517.0517,3Int. 53-Methyl-4-(methylsulfonyl)-
fluorobenzyl)ureido)thiazol-4-519thiophene-2-carboxylic acid
yl)methyl)-N-methyl-4-chloride
(methylsulfonyl)thiophene-2-
carboxamide
78N-((2-(3-(3-fluorobenzyl)C18H18FN5O2S2419.54213Int. 54-Methylthiazole-5-carboxylic
ureido)thiazol-4-yl)methyl)-acid chloride
N,4-dimethylthiazole-5-
carboxamide
79N-((2-(3-(3-fluorobenzyl)C20H19FN6O3S2474.54752Int. 55-Oxo-3,5-dihydro-5H-
ureido)thiazol-4-yl)methyl)-N-thiazolo[3,2-a]pyrimidine-6-
methyl-5-oxo-3,5-dihydro-2H-carboxylic acid
thiazolo[3,2-a]pyrimidine-6-
carboxamide
80N-((2-(3-(3-fluorobenzyl)C20H21FN6O2S2460.64612Int. 54-methyl-2-methylthio-
ureido)thiazol-4-yl)methyl)-pyrimidine-5-carboxylic acid
N,4-dimethyl-2-
(methylthio)pyrimidine-5-
carboxamide
81N-((2-(3-(3-fluorobenzyl)C18H21FN4O2S376.53773Int. 53-Methyl-but-2-enoyl chloride
ureido)thiazol-4-yl)methyl)-
N,3-dimethylbut-2-enamide
82N-((2-(3-(3-fluorobenzyl)C21H21FN4O2S412.54133Int. 52-Methylbenzoyl chloride
ureido)thiazol-4-yl)methyl)-
N,2-dimethylbenzamide
83N-((2-(3-(3-fluorobenzyl)C22H19FN6O2S450.54512Int. 5Quinoxaline-2-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-
methylquinoxaline-2-
carboxamide
84N-((2-(3-(3-fluorobenzyl)C20H20FN5O2S413.54142Int. 53-Methylpicolinic acid
ureido)thiazol-4-yl)methyl)-
N,3-dimethylpicolinamide
85N-((2-(3-(3-fluorobenzyl)C27H28FN5O5S553.65542Int. 55-((4-methoxybenzyloxy)
ureido)thiazol-4-yl)methyl)-5-methyl)-3-methylisoxazole-4-
((4-methoxybenzyloxy)carboxylic acid
methyl)-N,3-
dimethylisoxazole-4-
carboxamide
86N-(2-Aminoethyl)-N-((2-(3-C20H23FN6O3S446.54473; 1 Int. 153,5-Dimethyl-isoxazole-4-
(3-fluorobenzyl)carboxylic acid chloride
ureido)thiazol-4-yl)methyl)-
3,5-dimethylisoxazole-4-
carboxamide
874-amino-N-((2-(3-(3-C18H18FN7O2S415.54162Int. 54-Aminopyrimidine-5-
fluorobenzyl)ureido)thiazol-4-carboxylic acid
yl)methyl)-N-
methylpyrimidine-5-
carboxamide
882-amino-N-((2-(3-(3-C19H20FN7O2S429.54302Int. 52-Amino-4-methyl-
fluorobenzyl)ureido)thiazol-4-pyrimidine-5-carboxylic acid
yl)methyl)-N,4-
dimethylpyrimidine-5-
carboxamide
89N-((2-(3-(3-fluorobenzyl)C21H25FN6O5S2524.65265N-(2-Aminoethyl)-N-((2-(3-Methanesulfonyl chloride
ureido)thiazol-4-yl)methyl)-(3-fluorobenzyl)ureido)
3,5-dimethyl-N-(2-thiazol-4-yl)methyl)3,5-
(methylsulfonamido)ethyl)isoxazole-dimethylisoxazole-4-
4-carboxamidecarboxamide (EX# 86)
90N-((2-(3-(3-fluorobenzyl)C21H22FN5O3S443.54442Int. 54,6-Dimethyl-2-oxo-1,2-
ureido)thiazol-4-yl)methyl)-dihydropyridine-3-carboxylic
N,4,6-trimethyl-2-oxo-1,2-acid
dihydropyridine-3-
carboxamide
91N-((2-(3-(3-fluorobenzyl)C21H23FN6O2S442.54432Int. 52,4,6-Trimethylpyrimidine-5-
ureido)thiazol-4-yl)methyl)-carboxylic acid
N,2,4,6-tetramethylpyrimidine-
5-carboxamide
92N-((2-(3-(3-fluorobenzyl)C19H19FN6O2S414.54152Int. 53-Methylpyrazine-2-
ureido)thiazol-4-yl)methyl)-carboxylic acid (Int. 34)
N,3-dimethylpyrazine-2-
carboxamide
93tert-butyl 2-(((2-(3-(3-C23H28FN7O4S517.6Andras2Int. 54-tert-Butoxycrarbonylamino-
fluorobenzyl)ureido)thiazol-4-1-methyl-1H-imidazole-2-
yl)methyl)(methyl)carbamoyl)-carboxylic acid
1-methyl-1H-imidazol-4-
ylcarbamate
944-amino-N-((2-(3-(3-C18H20FN7O2S417.54181tert-butyl 2-(((2-(3-(3-None
fluorobenzyl)ureido)thiazol-4-fluorobenzyl)ureido)thiazol-
yl)methyl)-N,1-dimethyl-1H-4-yl)methyl)(methyl)
imidazole-2-carboxamidecarbamoyl)-1-methyl-1H-
imidazol-4-ylcarbamate
(EX# 93)
954-acetamido-N-((2-(3-(3-C20H22FN7O3S459.546034-amino-N-((2-(3-(3-Acetyl chloride
fluorobenzyl)ureido)thiazol-4-fluorobenzyl)ureido)thiazol-
yl)methyl)-N,1-dimethyl-1H-4-yl)methyl)-N,1-dimethyl-
imidazole-2-carboxamide1H-imidazole-2-
carboxamide (EX# 94)
96N-((2-(3-(3-fluorobenzyl)C20H21FN6O2S428.54292Int. 54,6-Dimethylpyrimidine-5-
ureido)thiazol-4-yl)methyl)-carboxylic acid
N,4,6-trimethylpyrimidine-5-
carboxamide
97N-((2-(3-(3-fluorobenzyl)C19H20FN5O4S433.543412Ethyl 4-(((2-(3-(3-Lithium borohydride
ureido)thiazol-4-yl)methyl)-3-fluorobenzyl)ureido)thiazol-
(hydroxymethyl)-N,5-4-yl)methyl)(methyl)
dimethylisoxazole-4-carbamoyl)-5-
carboxamidemethylisoxazole-3-
carboxylate (EX# 72)
98N-((2-(3-(4-fluorobenzyl)C19H20FN5O3S417.54188Int. 183-Fluorobenzylamine
ureido)thiazol-4-yl)methyl)-
N,3,5-trimethylisoxazole-4-
carboxamide
99N-((2-(3-(3,5-difluorobenzyl)C19H19F2N5O3S435.54368Int. 183,5-Difluorobenzylamine
ureido)thiazol-4-yl)methyl)-
N,3,5-trimethylisoxazole-4-
carboxamide
100N-((2-(3-(3-fluorobenzyl)C20H20FN5O2S413.54142Int. 53-Methyl-isonicotinic acid
ureido)thiazol-4-yl)methyl)-
N,3-dimethylisonicotinamide
101N-((2-(3-(3-chlorobenzyl)C19H20ClN5O3S433.94348Int. 183-Chlorobenzylamine
ureido)thiazol-4-yl)methyl)-
N,3,5-trimethylisoxazole-4-
carboxamide
102N-((2-(3-(benzo[1,3] dioxol-5-C20H21N5O5S443.54448Int. 18Piperonylamine
ylmethyl)ureido) thiazol-4-
yl)methyl)-N,3,5-
trimethylisoxazole-4-
carboxamie
1032-amino-N-((2-(3-(3-C20H22FN7O2S443.54442Int. 52-Amino-4,6-
fluorobenzyl)ureido)thiazol-4-dimethylpyrimidine-5-
yl)methyl)-N,4,6-carboxylic acid
trimethylpyrimidine-5-
carboxamide
104N-((2-(3-((2,2-difluorobenzoC20H19F2N5O5S479.54808; 10Int. 182,4-Dimethoxybenzyl(C-2,2-
[1,3]dioxol-5-yl)methyl)difluoro-benzo[1,3]dioxol-5-
ureido)thiazol-4-yl)methyl)-yl)methyl)amine (per Method
N,3,5-trimethylisoxazole-4-13)
carboxamide
105N-((2-(3-(3-fluorobenzyl)C22H21FN6O2S452.54532Int. 52-Methylimidazo[1,2-
ureido)thiazol-4-yl)methyl)-a]pyridine-3-carboxylic acid
N,2-dimethylimidazo[1,2-
a]pyridine-3-carboxamide
106N,3,5-trimethyl-N-((2-(3-(3-C22H26N6O4S470.64718Int. 183-(N-Acety-methylamino)
(N-methylacetamido)benzylamine
benzyl)ureido)thiazol-4-
yl)methyl)isoxazole-4-
carboxamide
107N-((2-(3-((5-chlorothiophen-C17H18ClN5O3S2439.9440,8; 10Int. 18(5-Chlorothiophen-2-yl-
2-yl)methyl)ureido)thiazol-4-442methyl)(2,4-dimethoxybenzyl)
yl)methyl)-N,3,5-amine (per Method 13)
trimethylisoxazole-4-
carboxamide
108N-((2-(3-(3-fluorobenzyl)C18H21FN4O3S392.53932Int. 5Tetrahydro-2-furoic acid
ureido)thiazol-4-yl)methyl)-N-
methyltetrahydrofuran-2-
carboxamide
1091-(4-((2,4-dioxothiazolidin-3-C15H13FN4O3S2380.438114Int. 7Thiazolidine-2,4-dione
yl)methyl)thiazol-2-yl)-3-(3-
fluorobenzyl)urea
110N-((2-(3-(3-fluorobenzyl)C20H20FN5O3S429.54302Int. 52-Methoxynicotinic acid
ureido)thiazol-4-yl)methyl)-2-
methoxy-N-
methylnicotinamide
111N-((2-(3-(3-fluorobenzyl)C18H21FN4O3S392.53932Int. 5Tetrahydro-3-furoic acid
ureido)thiazol-4-yl)methyl)-N-
methyltetrahydrofuran-3-
carboxamide
112N,3,5-trimethyl-N-((2-(3-C17H19N5O3S2405.54068Int. 18Thiophen-3-yl-methylamine
(thiophen-3-ylmethyl)ureido)
thiazol-4-yl)methyl)isoxazole-
4-carboxamide
113methyl (2-(3-(3-fluorobenzyl)C16H19FN4O4S382.43833Int. 19Methyl chloroformate
ureido)thiazol-4-yl)methyl(2-
hydroxyethyl)carbamate
114N-((2-(3-(3-fluorobenzyl)C21H22FN5O3S443.54442Int. 193-Methyl-isonicotinic acid
ureido)thiazol-4-yl)methyl)-N-
(2-hydroxyethyl)-3-
methylisonicotinamide
1151-(3-fluorobenzyl)-3-(4-((2-C15H15FN4O3S350.435115Int. 21Oxazolidin-2-one
oxooxazolidin-3-
yl)methyl)thiazol-2-yl)urea
1162-chloro-N-((2-(3-(3-C19H17ClFN5O2S433.94342Int. 52-Chloronicotinic acid
fluorobenzyl)ureido)thiazol-4-
yl)methyl)-N-
methylnicotinamide
117N-((2-(3-(3-fluorobenzyl)C20H23FN6O2S430.54312Int. 51,3,5-Trimethyl-1H-pyrazole-
ureido)thiazol-4-yl)methyl)-4-carboxylic acid
N,1,3,5-tetramethyl-1H-
pyrazole-4-carboxamide
118(S)-N-((2-(3-(3-fluorobenzyl)C18H21FN4O3S392.53932Int. 5(S)-Tetrahydro-2-furoic acid
ureido)thiazol-4-yl)methyl)-N-
methyltetrahydrofuran-2-
carboxamide
119(R)-N-((2-(3-(3-fluorobenzyl)C18H21FN4O3S392.53932Int. 5(R)-Tetrahydro-2-furoic acid
ureido)thiazol-4-yl)methyl)-N-
methyltetrahydrofuran-2-
carboxamide
120N-((2-(3-(3-fluorobenzyl)C22H24FN5O3S457.54582Int. 53-n-Propoxylpicolinic acid
ureido)thiazol-4-yl)methyl)-N-
methyl-3-
propoxypicolinamide
121tert-butyl 2-(((2-(3-(3-C23H30FN5O5S507.65082Int. 5N-(tert-Butoxycarbonyl)
fluorobenzyl)ureido)thiazol-4-morpholine-2-carboxylic acid
yl)methyl)(methyl)carbamoyl)
morpholine-4-carboxylate
122N-((2-(3-(3-fluorobenzyl)C18H22FN5O3S407.54081tert-butyl 2-(((2-(3-(3-none
ureido)thiazol-4-yl)methyl)-N-fluorobenzyl)ureido)thiazol-
methylmorpholine-2-4-yl)methyl)(methyl)
carboxamidecarbamoyl)morpholine-4-
carboxylate (EX# 121)
123N-((2-(3-(3,5-difluorobenzyl)C19H18F2N6O2S432.54332Int. 203-Methyl-pyrazine-2-
ureido)thiazol-4-yl)methyl)-carboxylic acid (Int. 34)
N,3-dimethylpyrazine-2-
carboxamide
124N-((2-(3-(3,5-difluorobenzyl)C20H19F2N5O2S431.54322Int. 203-Methyl-isonicotinic acid
ureido)thiazol-4-yl)methyl)-
N,3-dimethylisonicotinamide
125N-((2-(3-(3-C18H17FN6O2S400.44012Int. 5Pyridazine-4-carboxylic acid
fluorobenzyl)ureido)thiazol-4-
yl)methyl)-N-
methylpyridazine-4-
carboxamide
126N-((2-(3-(3-fluorobenzyl)C19H21FN6O2S416.54172Int. 53,5-Dimethyl-1H-pyrazole-4-
ureido)thiazol-4-yl)methyl)-carboxylic acid
N,3,5-trimethyl-1H-pyrazole-
4-carboxamide
127N-((2-(3-(3-fluorobenzyl)C18H17FN6O2S400.44012Int. 5Pyridazine-3-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-
methylpyridazine-3-
carboxamide
128N-((2-(3-(3-fluorobenzyl)C19H23FN4O3S406.54072Int. 5Tetrahydro-2H-pyran-4-
ureido)thiazol-4-yl)methyl)-N-carboxylic acid
methyltetrahydro-2H-pyran-4-
carboxamide
129N-((2-(3-(3-fluorobenzyl)C19H21FN6O2S416.54172Int. 51,5-Dimethylpyrazole-4-
ureido)thiazol-4-yl)methyl)-carboxylic acid
N,1,5-trimethyl-1H-pyrazole-
4-carboxamide
130N-((2-(3-((5-chlorofuran-2-C17H18ClN5O4S423.94258; 10Int. 18(5-Chlorothiophen-2-yl-
yl)methyl)ureido)thiazol-4-methyl)(2,4-dimethoxybenzyl)
yl)methyl)-N,3,5-amine (per Method 13)
trimethylisoxazole-4-
carboxamide
131N-((2-(3-(3-fluorobenzyl)C18H22FN5O3S407.54084Int. 5N-(tert-Butoxycarbonyl)
ureido)thiazol-4-yl)methyl)-N-morpholine-3-carboxylic acid
methylmorpholine-3-
carboxamide
132N-((2-(3-(3-fluorobenzyl)C19H24FN5O2S405.54064Int. 5N-(tert-Butoxycarbonyl)-4-
ureido)thiazol-4-yl)methyl)-methylpyrrolidine-3-
N,4-dimethylpyrrolidine-3-carboxylic acid
carboxamide
133(S)-N-((2-(3-(3-fluorobenzyl)C18H22FN5O2S391.53924Int. 5(S)-N-(tert-Butoxycarbonyl)
ureido)thiazol-4-yl)methyl)-N-pyrrolidine-2-carboxylic acid
methylpyrrolidine-2-
carboxamide
1342-Methyl-5,6-dihydro-4H-C20H23FN4O3S418.54192Int.52-Methyl-5,6-dihydro-4H-
pyran-3-carboxylic acid {2-[3-pyran-3-carboxylic acid
(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
1352-Methyl-5-morpholin-4-C24H28FN5O4S501.65022Int.52-Methyl-5-(morpholin-4-
ylmethyl-furan-3-carboxylicylmethyl)furan-3-carboxylic
acid {2-[3-(3-fluoro-benzyl)-acid
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1362-Methyl-but-2-enoic acid {2-C18H21FN4O2S376.43772Int.52-Methyl-but-2-enoic acid
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
1371,2,3-Thiadiazole-4-C16H15FN6O2S2406.54072Int.51,2,3-Thiadiazole-4-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1383,5-Dimethyl-isoxazole-4-C17H18FN5O3S2423.54248Int. 18C-(5-Fluoro-thiophen-2-
carboxylic acid {2-[3-(5-yl)methylamine (Int. 36)
fluoro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1392-Pyridin-3-yl-thiazole-4-C22H19FN6O2S2482.64832Int.52-Pyridin-3-yl-thiazole-4-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1402,5-Dimethyl-2H-pyrazole-3-C19H21FN6O2S416.54172Int.52,5-Dimethyl-2H-pyrazole-3-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1414-Methyl-furazan-3-C17H17FN6O3S404.44052Int.54-Methyl-furazan-3-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1422-Morpholin-4-ylmethyl-C23H26FN5O4S487.54882Int.52-Morpholin-4-ylmethyl-3-
furan-3-carboxylic acid {2-[3-furoic acid
(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
1431-Methyl-pyrrolidine-2-C19H24FN5O2S405.54062Int.51-Methyl-pyrrolidine-2-
carboxylic acid {2-[3-(3-carboxylc acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1441-Methyl-1H-pyrrole-2-C19H20FN5O2S401.54022Int.51-Methyl-1H-pyrrole-2-
carboxylic acid {2-[3-(3-carboxylc acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1451,5-Dimethyl-1H-C18H20FN7O2S417.54182Int.51,5-Dimethyl-1H-
[1,2,3]triazole-4-carboxylic[1,2,3]triazole-4-carboxylic
acid {2-[3-(3-fluoro-benzyl)-acid
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1465-Fluoro-thiophene-2-C18H16F2N4O2S2422.54232Int.55-Fluoro-thiophene-2-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1474-Methyl-pyrimidine-5-C19H19FN6O2S414.5.4152Int.54-Methyl-pyrimidine-5-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1484-Methyl-2-phenyl-C25H23FN6O2S490.64912Int.54-Methyl-2-phenyl-
pyrimidine-5-carboxylic acidpyrimidine-5-carboxylic acid
{2-[3-(3-fluoro-benzyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
149N-{2-[3-(3-Fluoro-benzyl)-C20H20FN5O2S2445.54463Int.52-Methylthio-nicotinic acid
ureido]-thiazol-4-ylmethyl}-
N-methyl-2-methylsulfanyl-
nicotinamide
1502-Cyano-N-{2-[3-(3-fluoro-C16H16FN5O2S361.43622Int.52-Cyanoacetic acid
benzyl)-ureido]-thiazol-4-
ylmethyl}-N-methyl-
acetamide
1513,5-Dimethyl-isoxazole-4-C19H19BrFN5O3S496.449817N-((2-(3-(3-Fluorobenzyl)Bromine
carboxylic acid {5-bromo-2-ureido)thiazol-4-yl)methyl)-
[3-(3-fluoro-benzyl)-ureido]-N,3,5-trimethylisoxazole-4-
thiazol-4-ylmethyl}-methyl-carboxamide (EX# 54)
amide
152N-{2-[3-(3-Fluoro-benzyl)-C23H25FN6O3S484.54853Int.56-Morpholin-4-yl-nicotinic
ureido]-thiazol-4-ylmethyl}-acid chloride
N-methyl-6-morpholin-4-yl-
nicotinamide
1534-Methyl-thiazole-5-C18H18FN5O2S2419.54202Int.54-Methylthiazole-5-carboxylic
carboxylic acid {2-[3-(3-acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1543-Methyl-1H-pyrazole-4-C18H19FN6O2S402.44032Int.53-Methyl-1H-pyrazole-4-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1552,4-Dimethyl-pyrimidine-5-C20H21FN6O2S428.54292Int.52,4-Dimethyl-pyrimidine-5-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1562-Methyl-[1,6]naphthyridine-C23H21FN6O2S464.54652Int.52-Methyl[1,6]napthyridine-3-
3-carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1576-(4-Methoxy-phenyl)-C25H23FN6O3S506.65072Int.56-(4-Methoxyphenyl)
pyridazine-3-carboxylic acidpyridazine-3-carboxylic acid
{2-[3-(3-fluoro-benzyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1583-Methyl-pyrazine-2-C19H18BrFN6O2S493.449517N-((2-(3-(3-fluorobenzyl)Bromine
carboxylic acid {5-bromo-2-ureido)thiazol-4-yl)methyl)-
[3-(3-fluoro-benzyl)-ureido]-N,3-dimethylpyrazine-2-
thiazol-4-ylmethyl}-methyl-carboxamide (EX# 92)
amide
1593-Methyl-pyrazine-2-C19H18ClFN6O2S448.944918N-((2-(3-(3-fluorobenzyl)N-Chlorosuccinimide
carboxylic acid {5-chloro-2-ureido)thiazol-4-yl)methyl)-
[3-(3-fluoro-benzyl)-ureido]-N,3-dimethylpyrazine-2-
thiazol-4-ylmethyl}-methyl-carboxamide (EX# 92)
amide
1602,6-Bis-dimethylamino-C22H27FN8O2S486.64872Int. 52,6-Bis-dimethylamino-
pyrimidine-4-carboxylic acidpyrimidine-4-carboxylic acid
{2-[3-(3-fluoro-benzyl)
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1612,6-Di-morpholin-4-yl-C26H31FN8O4S570.65712Int. 52,6-Di-morpholin-4-yl-
pyrimidine-4-carboxylic acidpyrimidine-4-carboxylic acid
{2-[3-(3-fluoro-benzyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1622-Cyano-N-{2-[3-(3-fluoro-C22H19FN6O2S450.54512Int. 52-Cyano-3-pyridin-3-yl-
benzyl)-ureido]-thiazol-4-acrylic acid
ylmethyl}-N-methyl-3-
pyridin-3-yl-acrylamide
1632-Methyl-[1,8]naphthyridine-C23H21FN6O2S464.54652Int. 52-Methyl-[1,8]naphthyridine-
3-carboxylic acid {2-[3-(3-3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1642-Dimethylamino-6-methyl-C21H24FN7O2S457.54582Int. 52-Dimethylamino-6-methyl-
pyrimidine-4-carboxylic acidpyrimidine-4-carboxylic acid
{2-[3-(3-fluoro-benzyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
165N-{2-[3-(3-Fluoro-benzyl)-C22H23FN4O3S442.54432Int. 52-Methoxy-2-phenylacetic
ureido]-thiazol-4-ylmethyl}-2-acid
methoxy-N-methyl-2-phenyl-
acetamide
1663-Methyl-pyrazine-2-C17H17FN6O2S2420.54218Int. 22C-(5-Fluoro-thiophen-2-
carboxylic acid {2-[3-(5-yl)methylamine (Int. 36)
fluoro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1673-Methyl-pyrazine-2-C17H18N6O2S2402.54038Int. 22C-(thiophen-3-yl)methylamine
carboxylic acid methyl-[2-(3-
thiophen-3-ylmethyl-ureido)-
thiazol-4-ylmethyl]-amide
1683,5-Dimethyl-isoxazole-4-C20H19FN6O3S442.5443193,5-Dimethyl-isoxazole-4-CuCN
carboxylic acid {5-cyano-2-carboxylic acid {5-bromo-2-
[3-(3-fluoro-benzyl)-ureido]-[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-thiazol-4-ylmethyl}-methyl-
amideamide (EX# 151)
169Acetic acid 1-({2-[3-(3-fluoro-C18H21FN4O4S408.44092Int. 52-Acetoxypropionic acid
benzyl)-ureido]-thiazol-4-
ylmethyl}-methyl-carbamoyl)-
ethyl ester
1701-Ethyl-3-methyl-1H-C20H23FN6O2S430.54312Int. 51-Ethyl-3-methyl-1H-
pyrazole-4-carboxylic acid {2-pyrazole-4-carboxylid acid
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
1712-Methyl-pyrazolo[1,5-C21H20FN7O2S453.54542Int. 52-Methyl-pyrazolo[1,5-
a]pyrimidine-3-carboxylica]pyrimidine-3-carboxylic
acid {2-[3-(3-fluoro-benzyl)-acid
ureido]-thiazol-4-ylmethyl}-
methyl-amide
172N-{2-[3-(3-Fluoro-benzyl)-C16H19FN4O3S366.436720Acetic acid 1-({2-[3-(3-none
ureido]-thiazol-4-ylmethyl}-2-fluoro-benzyl)-ureido]-
hydroxy-N-methyl-thiazol-4-ylmethyl}-methyl-
propionamidecarbamoyl)-ethyl ester (EX#
169)
1733,5-Dimethyl-isoxazole-4-C19H20FN5O3S417.54183Int. 10b3,5-Dimethyl-isoxazole-4-
carboxylic acid (1-{2-[3-(3-carboxylic acid chloride
fluoro-benzyl)-ureido]-thiazol-
4-yl}-ethyl)-amide
1741-Ethyl-5-methyl-1H-C20H23FN6O2S430.54312Int. 51-Ethyl-5-methyl-1H-
pyrazole-4-carboxylic acid {2-pyrazole-4-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
1755,7-Dimethyl-pyrazolo[1,5-C22H22FN7O2S467.54682Int. 55,7-Dimethyl-pyrazolo[1,5-
a]pyrimidine-3-carboxylica]pyrimidine-3-carboxylic
acid {2-[3-(3-fluoro-benzyl)-acid
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1763,5-Dimethyl-isoxazole-4-C19H20FN5O4S433.54343Int. 243,5-Dimethyl-isoxazole-4-
carboxylic acid (1-{2-[3-(3-carboxylic acid chloride
fluoro-benzyl)-ureido]-thiazol-
4-yl}-2-hydroxy-ethyl)-amide
1771-Methyl-1H-indole-3-C23H22FN5O2S451.54522Int. 51-Methyl-1H-indole-3-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1781-Methyl-1H-indazole-3-C22H21FN6O2S452.54532Int. 51-Methyl-1H-indazole-3-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
179Pyrazolo[1,5-a]pyridine-3-C21H19FN6O2S438.44393Int. 5Pyrazolo[1,5-a]pyridine-3-
carboxylic acid {2-[3-(3-carboxylic acid chloride
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
180N-{2-[3-(3-Fluoro-benzyl)-C19H17FN4O4S416.44172Int. 52-Furan-2-yl-2-oxoacetic acid
ureido]-thiazol-4-ylmethyl}-2-
furan-2-yl-N-methyl-2-oxo-
acetamide
1813,5-Dimethyl-isoxazole-4-C19H21N5O3S399.54008Int.18Benzylamine
carboxylic acid [2-(3-benzyl-
ureido)-thiazol-4-ylmethyl]-
methyl-amide
1823-Methyl-pyrazine-2-C17H17ClN6O2S2436.94378; 10Int. 22(5-Chlorothiophen-2-yl-
carboxylic acid {2-[3-(5-methyl)(2,4-
chloro-thiophen-2-ylmethyl)-dimethoxybenzyl)amine (per
ureido]-thiazol-4-ylmethyl}-Method 13)
methyl-amide
1833,5-Dimethyl-isoxazole-4-C22H26FN5O3S459.54603Int. 253,5-Dimethyl-isoxazole-4-
carboxylic acid {2-[3-(3-carboxylic acid chloride
fluoro-benzyl)-ureido]-5-
isopropyl-thiazol-4-ylmethyl}-
methyl-amide
1845-Oxo-pyrrolidine-2-C18H20FN5O3S405.44062Int. 55-Oxo-pyrrolidine-2-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1853-Methyl-pyrazine-2-C17H17ClN6O2S2436.94378Int. 22(5-Chlorothiophen-3-
carboxylic acid {2-[3-(5-yl)methananmine
chloro-thiophen-3-ylmethyl)-hydrochloride (Int. 37)
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1863,5-Dimethyl-isoxazole-4-C20H20F3N5O3S467.54683Int. 263,5-Dimethyl-isoxazole-4-
carboxylic acid (2,2-difluoro-carboxylic acid chloride
ethyl)-{2-[3-(3-fluoro-
benzyl)-ureido]-thiazol-4-
ylmethyl}-amide
1874-Methyl-pyridazine-3-C19H19FN6O2S414.54152Int. 54-Methylpyridazine-3-
carboxylic acid {2-[3-(3-carboxylic acid (Int. 33)
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1885-Methyl-pyridazine-4-C19H19FN6O2S414.54152Int 55-Methylpyridazine-4-
carboxylic acid {2-[3-(3-carboxylc acid (Int. 32)
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1893-Amino-1H-pyrazole-4-C17H18FN7O2S403.44042Int. 53-Amino-1H-pyrazole-4-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
1903,6-Dimethoxy-pyridazine-4-C20H21FN6O4S460.54612Int. 53,6-Dimethoxy-pyridazine-4-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
191(3,5-Dimethyl-isoxazol-4-C20H22FN5O4S447.54483Int. 61Methyl chloroformate
ylmethyl)-{2-[3-(3-fluoro-
benzyl)-ureido]-thiazol-4-
ylmethyl}-carbamic acid
methyl ester
192(R)-Tetrahydro-furan-2-C16H19ClN4O3S2414.94152Int. 29(R)-2-Tetrahydrofuroic acid
carboxylic acid {2-[3-(5-
chloro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1935-Methyl-pyridazine-4-C17H17ClN6O2S2436.94372Int. 295-Methylpyridazine-4-
carboxylic acid {2-[3-(5-carboxylc acid (Int. 32)
chloro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1943,5-Dimethyl-1H-pyrazole-4-C17H19ClN6O2S2439.04392Int. 293,5-Dimethyl-1H-pyrazole-4-
carboxylic acid {2-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1955-Methyl-pyridazine-4-C17H17ClN6O2S2436.94372Int. 305-Methylpyridazine-4-
carboxylic acid {2-[3-(5-carboxylc acid (Int. 32)
chloro-thiophen-3-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
196Tetrahydro-furan-2-carboxylicC16H19ClN4O3S2414.94152Int. 30(R)-2-Tetrahydrofuroic acid
acid {2-[3-(5-chloro-thiophen-
3-ylmethyl)-ureido]-thiazol-4-
ylmethyl}-methyl-amide
1973,5-Dimethyl-1H-pyrazole-4-C17H19ClN6O2S2439.04392Int. 303,5-Dimethyl-1H-pyrazole-4-
carboxylic acid {2-[3-(5-carboxylic acid
chloro-thiophen-3-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1981,3,5-Trimethyl-1H-pyrazole-C18H21ClN6O2S2453.04532Int. 301,3,5-Trimethyl-1H-pyrazole-
4-carboxylic acid {2-[3-(5-4-carboxylic acid
chloro-thiophen-3-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
1993,6-Dichloro-pyridazine-4-C18H15Cl2FN6O2S469.34692Int. 53,6-Dichloro-pyridazine-4-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
2003-Chloro-6-methoxy-C19H18ClFN6O3S465.0465443,6-Dichloropyridazine-4-MeOH
pyridazine-4-carboxylic acidcarboxylic acid {2-[3-(3-
{2-[3-(3-fluoro-benzyl)-fluoro-benzyl)-ureido]-
ureido]-thiazol-4-ylmethyl}-thiazol-4-ylmethyl}-methyl-
methyl-amideamide (EX# 199)
2013,5-Dimethyl-isoxazole-4-C19H19F2N5O3S435.04362Int. 403,5-Dimethyl-isoxazole-4-
carboxylic acid {5-fluoro-2-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
202(R)-Tetrahydro-furan-2-C18H20F2N4O3S410.04112Int. 40(R)-Tetrahydro-furan-2-
carboxylic acid {5-fluoro-2-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
2033,5-Dimethyl-pyridazine-4-C20H21FN6O2S428.04292Int. 53,5-Dimethyl-pyridazine-4-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
204N-{5-Fluoro-2-[3-(3-fluoro-C15H16F2N4O2S354.03552Int. 40acetic acid
benzyl)-ureido]-thiazol-4-
ylmethyl}-N-methyl-
acetamide
2051-Methyl-3-trifluoromethyl-C19H18F4N6O2S470.04712Int. 51-Methyl-3-trifluoromethyl-
1H-pyrazole-4-carboxylic acid1H-pyrazole-4-carboxylic acid
{2-[3-(3-fluoro-benzyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
2061,3,5-Trimethyl-1H-pyrazole-C20H22F2N6O2S448.04492Int. 401,3,5-Trimethyl-1H-pyrazole-
4-carboxylic acid {5-fluoro-2-4-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
2071,3,5-Trimethyl-1H-pyrazole-C18H21ClN6O2S2453.04532Int. 291,3,5-Trimethyl-1H-pyrazole-
4-carboxylic acid {2-[3-(5-4-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
2083-Chloro-6-hydroxy-C18H16ClFN6O3S451.0451453-Chloro-6-methoxy-None
pyridazine-4-carboxylic acidpyridazine-4-carboxylic
{2-[3-(3-fluoro-benzyl)-acid {2-[3-(3-fluoro-
ureido]-thiazol-4-ylmethyl}-benzyl)-ureido]-thiazol-4-
methyl-amideylmethyl}-methyl-amide
(EX# 200)
2092-Methyl-tetrahydro-furan-2-C19H23FN4O3S406.54082Int. 52-Methyl-tetrahydro-furan-2-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
2104-Chloro-1-methyl-1H-C18H18ClFN6O2S437.04372Int. 54-Chloro-1-methyl-1H-
pyrazole-3-carboxylic acid {2-pyrazole-3-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
2115-Chloro-1-methyl-1H-C18H18ClFN6O2S437.04372Int. 55-Chloro-1-methyl-1H-
pyrazole-4-carboxylic acid {2-pyrazole-4-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
2124-Chloro-2-methyl-2H-C18H18ClFN6O2S437.04372Int. 54-Chloro-2-methyl-2H-
pyrazole-3-carboxylic acid {2-pyrazole-3-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
2134-Chloro-1H-pyrazole-3-C17H16ClFN6O2S423.0423/4252Int. 54-Chloro-1H-pyrazole-3-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
2143,5-Dimethyl-isoxazole-4-C20H19FN6O3S442.04432Int. 413,5-Dimethyl-isoxazole-4-
carboxylic acid (cyano-{2-[3-carboxylic
(3-fluoro-benzyl)-ureido]-
thiazol-4-yl}-methyl)-methyl-
amide
2151-Methyl-3-trifluoromethyl-C17H16ClF3N6O2S2493.04932Int. 291-Methyl-3-trifluoromethyl-
1H-pyrazole-4-carboxylic acid1H-pyrazole-4-carboxylic acid
{2-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-thiazol-4-
ylmethyl}-methyl-amide
2161-Methyl-3-trifluoromethyl-C19H22ClN5O3S2468.04682Int. 291-Methyl-3-trifluoromethyl-
1H-pyrazole-4-carboxylic acid1H-pyrazole-4-carboxylic acid
{2-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-thiazol-4-
ylmethyl}-methyl-amide
2171,3,6-Trimethyl-1H-C21H22ClN7O2S2504.05052Int. 291,3,6-Trimethyl-1H-
pyrazolo[3,4-b]pyridine-4-pyrazolo[3,4-b]pyridine-4-
carboxylic acid {2-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
218N-{2-[3-(5-Chloro-thiophen-C19H20ClN5O4S3514.05142Int. 292-Methyl-5-sulfamoyl-benzoic
2-ylmethyl)-ureido]-thiazol-4-acid
ylmethyl}-2,N-dimethyl-5-
sulfamoyl-benzamide
2191-Methyl-6-oxo-1,4,5,6-C17H19ClN6O3S2455.04552Int. 291-Methyl-6-oxo-1,4,5,6-
tetrahydro-pyridazine-3-tetrahydro-pyridazine-3-
carboxylic acid {2-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
2201-Phenyl-C22H23ClN4O2S2475.04752Int. 291-Phenyl-
cyclobutanecarboxylic acidcyclobutanecarboxylic acid
{2-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-thiazol-4-
ylmethyl}-methyl-amide
2213-Methyl-4-oxo-3,4-dihydro-C21H23ClN6O3S2503.05032Int. 293-Methyl-4-oxo-3,4-dihydro-
phthalazine-1-carboxylic acidphthalazine-1-carboxylic acid
{2-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-thiazol-4-
ylmethyl}-methyl-amide
2227-Chloro-benzo[1,3]dioxole-C19H18Cl2N4O4S2499.04992Int. 297-Chloro-benzo[1,3]dioxole-5-
5-carboxylic acid [2-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl]-
methyl-amide
223N-[2-[3-(5-Chloro-thiophen-C19H17ClN3O2S2489.04892Int. 296-[1,2,4]triazol-1-yl-nicotinic
2-ylmethyl)-ureido]-thiazol-4-acid
ylmethyl]-N-methyl-6-
[1,2,4]triazol-1-yl-
nicotinamide
2241-(2-Methoxy-ethyl)-6-oxo-C19H21ClN6O4S2497.04972Int. 291-(2-Methoxy-ethyl)-6-oxo-
1,6-dihydro-pyridazine-3-1,6-dihydro-pyridazine-3-
carboxylic acid {2-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
225N-((2-(3-((5-chlorothiophen-C17H17ClN6O4S2467.04672Int. 292-(2,4-dioxo-3,4-
2-yl)methyl)ureido)thiazol-4-dihydropyrimidin-1(2H)-
yl)methyl)-2-(2,4-dioxo-3,4-yl)acetic acid
dihydropyrimidin-1(2H)-yl)-
N-methylacetamide
2261,1-Dioxo-C16H19ClN4O4S3463.04632Int. 291,1-Dioxo-
tetrahydrothiophene-3-tetrahydrothiophene-3-
carboxylic acid {2-[3-(5-carboxylic acid
chlorothiophen-2-yl)methyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
2276-chloro-N-((2-(3-(3-C18H16ClFN6O3S451.0Structure513-Chloro-6-methoxy-None
fluorobenzyl)ureido)thiazol-4-Confirmedpyridazine-4-carboxylic
yl)methyl)-3-hydroxy-N-byacid {2-[3-(3-fluoro-
methylpyridazine-4-1H-benzyl)-ureido]-thiazol-4-
carboxamideNMRylmethyl}-methyl-amide
(EX# 200)
2285-chloro-N-((2-(3-(3-C19H20ClFN6O2S451.04512Int. 5N,1,3-trimethyl-1H-pyrazole-
fluorobenzyl)ureido)thiazol-4-4-carboxylic acid
yl)methyl)-N,1,3-trimethyl-
1H-pyrazole-4-carboxamide
229N-((2-(3-(3-C21H24FN5O3S446.04462Int. 5N,3-dimethylisoxazole-4-
fluorobenzyl)ureido)thiazol-4-carboxylic acid
yl)methyl)-5-isopropyl-N,3-
dimethylisoxazole-4-
carboxamide
2303-cyano-N-((2-(3-(3-C21H19FN6O3S454.04552Int. 53-cyano-2-hydroxy-6-
fluorobenzyl)ureido)thiazol-4-methylisonicotinic acid
yl)methyl)-2-hydroxy-N,6-
dimethylisonicotinamide
2316-chloro-N-((2-(3-(3-C18H16ClFN6O3S451.04512Int. 56-chloro-3-oxo-2,3-
fluorobenzyl)ureido)thiazol-4-dihydropyridazine-4-
yl)methyl)-N-methyl-3-oxo-carboxylic acid
2,3-dihydropyridazine-4-
carboxamide
232N-((2-(3-(3-fluorobenzyl)C22H22FN7O2S468.04682Int. 51-methyl-5-(1H-pyrrol-1-yl)-
ureido)thiazol-4-yl)methyl)-1H-pyrazole-4-carboxylic acid
N,1-dimethyl-5-(1H-pyrrol-1-
yl)-1H-pyrazole-4-
carboxamide
233N-((2-(3-(3-fluorobenzyl)C21H22FN5O4S2492.04922Int. 5N,2-dimethyl-5-
ureido)thiazol-4-yl)methyl)-sulfamoylbenzoic acid
N,2-dimethyl-5-
sulfamoylbenzamide
234N-((2-(3-(3-fluorobenzyl)C24H25FN4O2S452.04532Int. 51-phenylcyclobutane
ureido)thiazol-4-yl)methyl)-N-carboxylic acid
methyl-1-phenylcyclobutane
carboxamide
235N-((2-(3-(3-fluorobenzyl)C22H19FN6O3S466.04672Int. 54-oxo-3,4-dihydrophthalazine-
ureido)thiazol-4-yl)methyl)-N-1-carboxylic acid
methyl-4-oxo-3,4-
dihydrophthalazine-1-
carboxamide
236N-((2-(3-(3-fluorobenzyl)C21H21FN4O4S444.04452Int. 54,6-dimethyl-2-oxo-2H-pyran-
ureido)thiazol-4-yl)methyl)-5-carboxylic acid
N,4,6-trimethyl-2-oxo-2H-
pyran-5-carboxamide
2377-chloro-N-((2-(3-(3-C21H18ClFN4O4S477.04772Int. 57-chlorobenzo[1,3]dioxole-5-
fluorobenzyl)ureido)thiazol-4-carboxylic acid
yl)methyl)-N-methylbenzo
[1,3]dioxole-5-carboxamide
238N-((2-(3-(3-fluorobenzyl)C19H21FN6O4S2480.04812Int. 51-methyl-4-sulfamoyl-1H-
ureido)thiazol-4-yl)methyl)-pyrrole-2-carboxylic acid
N,1-dimethyl-4-sulfamoyl-
1H-pyrrole-2-carboxamide
2392-(5,7-dimethyl-[1,2,4]C22H23FN8O2S482.04832Int. 52-(5,7-dimethyl-[1,2,4]
triazolo[1,5-a]pyrimidin-6-yl)-triazolo[1,5-a]pyrimidin-6-yl)
N-((2-(3-(3-fluorobenzyl)acetic acid
ureido)thiazol-4-yl)methyl)-N-
methylacetamide
240N-((2-(3-(3-fluorobenzyl)C22H21FN6O4S484.04852Int. 53,6-dimethyl-4-oxo-3,4-
ureido)thiazol-4-yl)methyl)-dihydrofuro[2,3-d]pyrimidine-
N,3,6-trimethyl-4-oxo-3,4-5-carboxylic acid
dihydrofuro[2,3-d]pyrimidine-
5-carboxamide
241N-((2-(3-(3-fluorobenzyl)C21H19FN6O3S2486.04872Int. 55-methyl-4-oxo-3,4-
ureido)thiazol-4-yl)methyl)-dihydrothieno[2,3-
N,5-dimethyl-4-oxo-3,4-d]pyrimidine-6-carboxamide
dihydrothieno[2,3-
d]pyrimidine-6-carboxamide
2422,2-difluoro-N-((2-(3-(3-C21H19F3N4O2S448.04492Int. 52,2-difluoro-N-methyl-2-
fluorobenzyl)ureido)thiazol-4-phenylacetic acid
yl)methyl)-N-methyl-2-
phenylacetamide
243N2-((2-(3-(3-fluorobenzyl)C19H23FN6O4S450.04512Int. 51-carbamoyl-4-
ureido)thiazol-4-yl)methyl)-4-hydroxypyrrolidine-2-
hydroxy-N2-carboxylic acid
methylpyrrolidine-1,2-
dicarboxamide
244N-((2-(3-((5-chlorothiophen-C21H23ClN6O3S2507.05072Int. 292-morpholinonicotinic acid
2-yl)methyl)ureido)thiazol-4-
yl)methyl)-N-methyl-2-
morpholinonicotinamide
245N-((2-(3-((5-chlorothiophen-C20H17ClN6O3S2489.04892Int. 294-oxo-3,4-dihydrophthalazine-
2-yl)methyl)ureido)thiazol-4-1-carboxylic acid
yl)methyl)-N-methyl-4-oxo-
3,4-dihydrophthalazine-1-
carboxamide
246N-((2-(3-((5-chlorothiophen-C19H19ClN4O4S2467.04672Int. 294,6-dimethyl-2-oxo-2H-pyran-
2-yl)methyl)ureido)thiazol-4-5-carboxylic acid
yl)methyl)-N,4,6-trimethyl-2-
oxo-2H-pyran-5-carboxamide
247N-((2-(3-((5-chlorothiophen-C17H19ClN6O4S3503.05032Int. 291-methyl-4-sulfamoyl-1H-
2-yl)methyl)ureido)thiazol-4-pyrrole-2-carboxylic acid
yl)methyl)-N,1-dimethyl-4-
sulfamoyl-1H-pyrrole-2-
carboxamide
248N-((2-(3-((5-chlorothiophen-C20H21ClN8O2S2505.05052Int. 292-(5,7-dimethyl-[1,2,4]
2-yl)methyl)ureido)thiazol-4-triazolo[1,5-a]pyrimidin-6-
yl)methyl)-2-(5,7-dimethyl-yl)acetic acid
[1,2,4]triazolo[1,5-
a]pyrimidin-6-yl)-N-
methylacetamide
249N-((2-(3-((5-chlorothiophen-C19H17ClN6O3S3509.05092Int. 295-methyl-4-oxo-3,4-
2-yl)methyl)ureido)thiazol-4-dihydrothieno[2,3-
yl)methyl)-N,5-dimethyl-4-d]pyrimidine-6-carboxylic
oxo-3,4-dihydrothieno[2,3-acid
d]pyrimidine-6-carboxamide
250N-((2-(3-((5-chlorothiophen-C22H22ClFN4O2S2493.04932Int. 291-(3-fluorophenyl)
2-yl)methyl)ureido)thiazol-4-cyclobutane carboxylic acid
yl)methyl)-1-(3-fluorophenyl)-
N-methylcyclobutane
carboxamide
251N-((2-(3-((5-chlorothiophen-C19H17ClF2N4O2S2471.04712Int. 292,2-difluoro-2-phenylacetic
2-yl)methyl)ureido)thiazol-4-acid
yl)methyl)-2,2-difluoro-N-
methyl-2-phenylacetamide
252N-((2-(3-(3-fluorobenzyl)C18H16F4N6O2S456.04572Int. 55-(trifluoromethyl)-1H-
ureido)thiazol-4-yl)methyl)-N-pyrazole-4-carboxylic acid
methyl-5-(trifluoromethyl)-
1H-pyrazole-4-carboxamide
253N-((2-(3-(3-fluorobenzyl)C19H18F4N6O2S470.04722Int. 51-methyl-5-(trifluoromethyl)-
ureido)thiazol-4-yl)methyl)-1H-pyrazole-4-carboxylic acid
N,1-dimethyl-5-
(trifluoromethyl)-1H-
pyrazole-4-carboxamide
254(S)-N-((2-(3-(3-fluorobenzyl)C17H21FN4O3S380.03812Int. 5(S)-2-methoxypropanoic acid
ureido)thiazol-4-yl)methyl)-2-
methoxy-N-
methylpropanamide
255N-((2-(3-(3-fluorobenzyl)C19H21FN4O4S420.04212Int. 53-methyl-5,6-dihydro-1,4-
ureido)thiazol-4-yl)methyl)-dioxine-2-carboxylic acid
N,3-dimethyl-5,6-dihydro-1,4-
dioxine-2-carboxamide
256(R)-N-((2-(3-(3-fluorobenzyl)C18H19FN4O4S406.04072Int. 55-oxotetrahydrofuran-2-
ureido)thiazol-4-yl)methyl)-N-carboxylic acid
methyl-5-oxotetrahydrofuran-
2-carboxamide
2575-chloro-N-((2-(3-((5-C17H18Cl2N6O2S2473.04752Int. 295-chloro-1,3-dimethyl-1H-
chlorothiophen-2-yl)pyrazole-4-carboxylic acid
methyl)ureido)thiazol-4-yl)
methyl)-N,1,3-trimethyl-1H-
pyrazole-4-carboxamide
258N-((2-(3-(3-fluorobenzyl)C19H21FN6O3S432.04332Int. 51-methyl-6-oxo-1,4,5,6-
ureido)thiazol-4-yl)methyl)-tetrahydropyridazine-3-
N,1-dimethyl-6-oxo-1,4,5,6-carboxylic acid
tetrahydropyridazine-3-
carboxamide
259N-((2-(3-(3-fluorobenzyl)C23H21FN6O3S480.04812Int. 53-methyl-4-oxo-3,4-
ureido)thiazol-4-yl)methyl)-dihydrophthalazine-1-
N,3-dimethyl-4-oxo-3,4-carboxylic acid
dihydrophthalazine-1-
carboxamide
260N-((2-(3-((5-chlorothiophen-C20H20ClN7O2S2490.04902Int. 291-methyl-5-(1H-pyrrol-1-yl)-
2-yl)methyl)ureido)thiazol-4-1H-pyrazole-4-carboxylic acid
yl)methyl)-N,1-dimethyl-5-
(1H-pyrrol-1-yl)-1H-pyrazole-
4-carboxamide
261N-((2-(3-((5-chlorothiophen-C20H19ClN6O4S2507.05072Int. 293,6-dimethyl-4-oxo-3,4-
2-yl)methyl)ureido)thiazol-4-dihydrofuro[2,3-d]pyrimidine-
yl)methyl)-N,3,6-trimethyl-4-5-carboxylic acid
oxo-3,4-dihydrofuro[2,3-
d]pyrimidine-5-carboxamide
262N-((2-(3-(3-fluorobenzyl)C17H21FN4O3S380.03812Int. 53-methoxypropanoic acid
ureido)thiazol-4-yl)methyl)-3-
methoxy-N-
methylpropanamide
263N-((2-(3-(3-fluorobenzyl)C21H25FN6O3S460.04612Int. 51-(2-hydroxyethyl)-3,5-
ureido)thiazol-4-yl)methyl)-1-dimethyl-1H-pyrazole-4-
(2-hydroxyethyl)-N,3,5-carboxylic acid
trimethyl-1H-pyrazole-4-
carboxamide
264(R)-N-((2-(3-(3-fluorobenzyl)C17H21FN4O3S380.03812Int. 5(R)-2-methoxypropanoic acid
ureido)thiazol-4-yl)methyl)-2-
methoxy-N-
methylpropanamide
265N-((2-(3-(3-fluorobenzyl)C22H27FN6O3S474.04752Int. 51-(2-methoxyethyl)-3,5-
ureido)thiazol-4-yl)methyl)-1-dimethyl-1H-pyrazole-4-
(2-methoxyethyl)-N,3,5-carboxylic acid (Int. 42)
trimethyl-1H-pyrazole-4-
carboxamide
266N-((2-(3-(3-fluorobenzyl)C19H23FN4O3S406.04072Int. 5Tetrahydro-2H-pyran-2-
ureido)thiazol-4-yl)methyl)-N-carboxylic acid (Int. 43)
methyltetrahydro-2H-pyran-2-
carboxamide
267N-(cyano(2-(3-(3-C20H18FN7O2S439.04402Int. 413-methylpyrazine-2-
fluorobenzyl)ureido)thiazol-4-carboxylic acid
yl)methyl)-N,3-
dimethylpyrazine-2-
carboxamide
268N-(cyano(2-(3-(3-C19H20FN5O3S417.04182Int. 41tetrahydrofuran-2-carboxylic
fluorobenzyl)ureido)thiazol-4-acid
yl)methyl)-N-
methyltetrahydrofuran-2-
carboxamide
269N-((2-(3-((5-chlorothiophen-C20H19ClN6O3S2491.04922Int. 293,6-dimethylisoxazolo[5,4-
2-yl)methyl)ureido)thiazol-4-b]pyridine-4-carboxylic acid
yl)methyl)-N,3,6-
trimethylisoxazolo[5,4-
b]pyridine-4-carboxamide
270N-((2-(3-(3-fluorobenzyl)C19H23FN4O4S422.04232Int. 55-methoxy-tetrahydrofuran-2-
ureido)thiazol-4-yl)methyl)-5-carboxylic acid (Int. 44)
methoxy-N-
methyltetrahydrofuran-2-
carboxamide
271N-((2-(3-(3-fluorobenzyl)C24H31FN6O3S503.05032Int. 51-(4-methoxybutyl)-3,5-
ureido)thiazol-4-yl)methyl)-1-dimethyl-1H-pyrazole-4-
(4-methoxybutyl)-N,3,5-carboxylic acid (Int. 45)
trimethyl-1H-pyrazole-4-
carboxamide
272N-((2-(3-(3-fluorobenzyl)C23H29FN6O3S488.04892Int. 51-(3-methoxypropyl)-3,5-
ureido)thiazol-4-yl)methyl)-1-dimethyl-1H-pyrazole-4-
(3-methoxypropyl)-N,3,5-carboxylic acid (Int. 46)
trimethyl-1H-pyrazole-4-
carboxamide
273N-((5-fluoro-2-(3-(3-C20H20F2N6O2S446.04472Int. 403,5-dimethylpyridazine-4-
fluorobenzyl)ureido)thiazol-4-carboxylic acid (Int. 50)
yl)methyl)-N,3,5-
trimethylpyridazine-4-
carboxamide
274N-((2-(3-(3-fluorobenzyl)C23H25FN6O3S484.04852Int. 52-morpholinonicotinic acid
ureido)thiazol-4-yl)methyl)-N-
methyl-2-
morpholinonicotinamide
275N-((2-(3-(3-fluorobenzyl)C22H21FN6O3S468.04692Int. 53,6-dimethylisoxazolo[5,4-
ureido)thiazol-4-yl)methyl)-b]pyridine-4-carboxylic acid
N,3,6-trimethylisoxazolo[5,4-
b]pyridine-4-carboxamide
276N-((2-(3-(3-fluorobenzyl)C24H24F2N4O2S470.04712Int. 51-(4-fluorophenyl)
ureido)thiazol-4-yl)methyl)-1-cyclobutanecarboxylic acid
(4-fluorophenyl)-N-
methylcyclobutane
carboxamide
2771,1-Dioxo-C18H21FN4O4S2440.04412Int. 51,1-Dioxo-
tetrahydrothiophene-3-tetrahydrothiophene-3-
carboxylic acid {2-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-thiazol-
4-ylmethyl}-methyl-amide
278N-((2-(3-(3-fluorobenzyl)C19H23FN4O3S406.04072Int. 55-methyltetrahydrofuran-2-
ureido)thiazol-4-yl)methyl)-carboxylic acid (int. 47)
N,5-dimethyltetrahydrofuran-
2-carboxamide
279N-((2-(3-(3-fluorobenzyl)C18H21FN4O3S392.03932Int. 53-methyloxetane-3-carboxylic
ureido)thiazol-4-yl)methyl)-acid (Int. 48)
N,3-dimethyloxetane-3-
carboxamide
2805-chloro-N-((2-(3-(3-C17H16ClFN6O2S423.04232Int. 51H-pyrazole-4-carboxylic acid
fluorobenzyl)ureido)thiazol-4-
yl)methyl)-N-methyl-1H-
pyrazole-4-carboxamide
281(R)-N-((2-(3-(3-C19H23FN4O4S422.04232Int. 5(R)-2,2-dimethyl-1,3-
fluorobenzyl)ureido)thiazol-4-dioxolane-4-carboxylic acid
yl)methyl)-N,2,2-trimethyl-
1,3-dioxolane-4-carboxamide
282(S)-N-((2-(3-(3-fluorobenzyl)C19H23FN4O4S422.04232Int. 5(S)-2,2-dimethyl-1,3-
ureido)thiazol-4-yl)methyl)-dioxolane-4-carboxylic acid
N,2,2-trimethyl-1,3-
dioxolane-4-carboxamide
283N-(2-amino-1-(2-(3-(3-C19H24FN5O3S421.042246N-(Cyano(2-(3-(3-Hydrogen
fluorobenzyl)ureido)thiazol-4-fluorobenzyl)ureido)thiazol-
yl)ethyl)-N-4-yl)methyl)-N-
methyltetrahydrofuran-2-methyltetrahydrofuran-2-
carboxamidecarboxamide (EX# 268)
284(R)-N-((2-(3-((5-C16H19FN4O3S2398.03992Int. 41(R)-tetrahydrofuran-2-
fluorothiophen-2-yl)carboxylic acid
methyl)ureido)thiazol-4-yl)
methyl)-N-
methyltetrahydrofuran-2-
carboxamide
2853,6-dichloro-N-((2-(3-(3-C19H17Cl2FN6O2S483.44833Int. 53,6-dichloro-5-
fluorobenzyl)ureido)thiazol-4-methylpyridazine-4-carboxylic
yl)methyl)-N,5-chloride (Int. 49)
dimethylpyridazine-4-
carboxamide
286N-((2-(3-(3-fluorobenzyl)C20H21FN6O3S444.5Structure473-Chloro-6-methoxy-Trimethylaluminum
ureido)thiazol-4-yl)methyl)-6-confirmedpyridazine-4-carboxylic
methoxy-N,3-byacid {2-[3-(3-fluoro-
dimethylpyridazine-4-1H-benzyl)-ureido]-thiazol-4-
carboxamideNMRylmethyl}-methyl-amide
(EX# 200)
287N-((2-(3-(3-fluorobenzyl)C23H24FN7O2S482.04822Int. 51,3,6-trimethyl-1H-
ureido)thiazol-4-yl)methyl)-pyrazolo[3,4-b]pyridine-4-
N,1,3,6-tetramethyl-1H-carboxylic acid
pyrazolo[3,4-b]pyridine-4-
carboxamide
288N-((2-(3-(3-fluorobenzyl)C18H18FN7O4S447.04482Int. 51-methyl-5-nitro-1H-pyrazole-
ureido)thiazol-4-yl)methyl)-4-carboxylic acid
N,1-dimethyl-5-nitro-1H-
pyrazole-4-carboxamide
289N-((2-(3-(3-fluorobenzyl)C22H21FN4O3S440.04412Int. 52,3-dihydrobenzofuran-2-
ureido)thiazol-4-yl)methyl)-N-carboxylic acid
methyl-2,3-
dihydrobenzofuran-2-
carboxamide
290N-((2-(3-((5-chlorothiophen-C20H19ClN4O3S2463.04632Int. 292,3-dihydrobenzofuran-2-
2-yl)methyl)ureido)thiazol-4-carboxylic acid
yl)methyl)-N-methyl-2,3-
dihydrobenzofuran-2-
carboxamide
291N-((2-(3-(3-fluorobenzyl)C19H19FN6O3S430.043148N-((2-(3-(3-fluorobenzyl)BBr3
ureido)thiazol-4-yl)methyl)-6-ureido)thiazol-4-yl)methyl)-
hydroxy-N,3-6-methoxy-N,3-
dimethylpyridazine-4-dimethylpyridazine-4-
carboxamidecarboxamide (EX# 286)
292N-((2-(3-(3-fluorobenzyl)C23H25FN6O2S468.04692Int. 52-(pyrrolidin-1-yl)nicotinic
ureido)thiazol-4-yl)methyl)-N-acid
methyl-2-(pyrrolidin-1-yl)
nicotinamide
293N-((2-(3-(3-fluorobenzyl)C21H21FN4O3S2460.04612Int. 54-oxo-4-(thiophen-2-yl)
ureido)thiazol-4-yl)methyl)-N-butanoic acid
methyl-4-oxo-4-(thiophen-2-
yl)butanamide
294N-((2-(3-(3-fluorobenzyl)C23H23FN4O3S454.04552Int. 53-benzoylpropionic acid
ureido)thiazol-4-yl)methyl)-N-
methyl-4-oxo-4-
phenylbutanamide
2952-(3-fluoro-4-methoxyphenyl)-C22H22F2N4O3S460.04612Int. 52-(3-fluoro-4-methoxyphenyl)
N-((2-(3-(3-fluorobenzyl)acetic acid
ureido)thiazol-4-yl)methyl)-N-
methylacetamide
2962-(3,4-dimethoxyphenyl)-N-C23H25FN4O4S472.04732Int. 52-(3,4-dimethoxyphenyl)acetic
((2-(3-(3-fluorobenzyl)acid
ureido)thiazol-4-yl)methyl)-N-
methylacetamide
297N-((2-(3-(3-fluorobenzyl)C22H23FN4O4S458.04592Int. 52-(4-(hydroxymethyl)
ureido)thiazol-4-yl)methyl)-2-phenoxy)acetic acid
(4-(hydroxymethyl)phenoxy)-
N-methylacetamide
298N-((2-(3-(3-fluorobenzyl)C22H23FN4O4S2490.04912Int. 52-(3-(methylsulfonyl)
ureido)thiazol-4-yl)methyl)-N-phenyl)acetic acid
methyl-2-(3-(methylsulfonyl)
phenyl)acetamide
299N-((2-(3-(3-fluorobenzyl)C19H20FN5O2S3466.04662Int. 52-(2-mercapto-4-methylthiazol-
ureido)thiazol-4-yl)methyl)-2-5-yl)acetic acid
(2-mercapto-4-methylthiazol-
5-yl)-N-methylacetamide
300N-((2-(3-(3-fluorobenzyl)C19H16F4N4O3S456.04572Int. 55-(trifluoromethyl)furan-2-
ureido)thiazol-4-yl)methyl)-N-carboxylic acid
methyl-5-(trifluoromethyl)
furan-2-carboxamide
301(R)-N-((5-fluoro-2-(3-(3-C17H20F2N4O3S398.03992Int. 40(R)-2-methoxypropanoic acid
fluorobenzyl)ureido)thiazol-4-
yl)methyl)-2-methoxy-N-
methylpropanamide
302N-((2-(3-(3-fluorobenzyl)C19H20FN7O3S445.0446503-(dimethylamino)-N-((2-BBr3
ureido)thiazol-4-yl)methyl)-6-(3-(3-fluorobenzyl)ureido)
hydroxy-N-methyl-3-thiazol-4-yl)methyl)-6-
(methylamino)pyridazine-4-methoxy-N-
carboxamidemethylpyridazine-4-
carboxamide (EX# 303)
3033-(dimethylamino)-N-((2-(3-C21H24FN7O3S474.0474493-Chloro-6-methoxy-dimethylamine
(3-fluorobenzyl) ureido)pyridazine-4-carboxylic
thiazol-4-yl)methyl)-6-acid {2-[3-(3-fluoro-
methoxy-N-methylpyridazine-benzyl)-ureido]-thiazol-4-
4-carboxamideylmethyl}-methyl-amide
(EX# 200)
304N-((2-(3-(3-fluorobenzyl)C21H23FN6O4S474.04752Int. 51-(2-methoxyethyl)-6-oxo-1,6-
ureido)thiazol-4-yl)methyl)-1-dihydropyridazine-3-
(2-methoxyethyl)-N-methyl-6-carboxylic acid
oxo-1,6-dihydropyridazine-3-
carboxamide
305N-((2-(3-((5-chlorothiophen-C21H23ClN6O2S2491.04912Int. 292-(pyrrolidin-1-yl)nicotinic
2-yl)methyl)ureido)thiazol-4-acid
yl)methyl)-N-methyl-2-
(pyrrolidin-1-yl)nicotinamide
306N-((2-(3-(3-fluorobenzyl)C21H27FN4O3S434.04352Int. 52,2-dimethyltetrahydro-2H-
ureido)thiazol-4-yl)methyl)-pyran-4-carboxylic acid
N,2,2-trimethyltetrahydro-2H-
pyran-4-carboxamide
307N-((2-(3-((5-chlorothiophen-C19H25ClN4O3S2457.04572Int. 292,2-dimethyltetrahydro-2H-
2-yl)methyl)ureido)thiazol-4-pyran-4-carboxamide
yl)methyl)-N,2,2-
trimethyltetrahydro-2H-pyran-
4-carboxamide
308N-((2-(3-((1H-indol-5-C21H22N6O3S438.54378Int. 18C-(1H-Indol-5-yl)-
yl)methyl)ureido)thiazol-4-methylamine
yl)methyl)-N,3,5-
trimethylisoxazole-4-
carboxamide
309N-((2-(3-(benzo[1,2,5]C19H19N7O4S441.54408Int. 18C-Benzo[1,2,5]oxadiazol-5-yl-
oxadiazol-5-ylmethyl)ureido)methylamine
thiazol-4-yl)methyl)-N,3,5-
trimethylisoxazole-4-
carboxamide
310N-((2-(3-(benzo[1,2,5]C19H19N7O3S2457.54568Int. 18C-Benzo[1,2,5]thiadiazol-5-
thiadiazol-5-ylmethyl)ureido)yl-methylamine
thiazol-4-yl)methyl)-N,3,5-
trimethylisoxazole-4-
carboxamide
3112-(4-(dimethylamino)phenyl)-C23H26FN5O2S456.04562Int. 52-(4-(dimethylamino)phenyl)
N-((2-(3-(3-fluorobenzyl)acetic acid
ureido)thiazol-4-yl)methyl)-N-
methylacetamide
312N-((2-(3-(3-fluorobenzyl)C23H24FN5O3S470.04702Int. 57-hydroxy-1,2,3,4-
ureido)thiazol-4-yl)methyl)-7-tetrahydroisoquinoline-3-
hydroxy-N-methyl-1,2,3,4-carboxylic acid
tetrahydroisoquinoline-3-
carboxamide
3133-(1H-benzoimidazol-2-yl)-N-C23H23FN6O2S466.04672Int 5.3-(1H-benzoimidazol-2-
((2-(3-(3-fluorobenzyl)yl)propanoic acid
ureido)thiazol-4-yl)methyl)-N-
methylpropanamide
314N-((2-(3-(3-fluorobenzyl)C25H23FN4O2S462.04632Int. 52-(naphthalen-2-yl)acetic acid
ureido)thiazol-4-yl)methyl)-N-
methyl-2-(naphthalen-2-yl)
acetamide
315N-((2-(3-(3-fluorobenzyl)C23H25FN4O3S456.04572Int. 52-(4-methoxy-3-
ureido)thiazol-4-yl)methyl)-2-methylphenyl)acetic acid
(4-methoxy-3-methylphenyl)-
N-methylacetamide
3162-amino-3-(benzyloxy)-N-((2-C23H26FN5O3S472.04722Int. 52-amino-3-(benzyloxy)
(3-(3-fluorobenzyl)ureido)propanoic acid
thiazol-4-yl)methyl)-N-
methylpropanamide
317N-((2-(3-(3-fluorobenzyl)C22H19FN6O4S482.04832Int. 51,4-dioxo-1,2,3,4-
ureido)thiazol-4-yl)methyl)-N-tetrahydrophthalazine-6-
methyl-1,4-dioxo-1,2,3,4-carboxylic acid
tetrahydrophthalazine-6-
carboxamide
318N-((2-(3-(3-fluorobenzyl)C21H19FN8O2S466.04672Int. 56-(1H-1,2,4-triazol-1-yl)
ureido)thiazol-4-yl)methyl)-N-nicotinic acid
methyl-6-(1H-1,2,4-triazol-1-
yl)nicotinamide
3192-(2,4-dioxo-3,4-C19H19FN6O4S446.04472Int. 52-(2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)-dihydropyrimidin-1(2H)-yl)
N-((2-(3-(3-fluorobenzyl)acetic acid
ureido)thiazol-4-yl)methyl)-N-
methylacetamide
320N-((2-(3-((5-chlorothiophen-C20H17ClN6O4S2505.05052Int. 291,4-dioxo-1,2,3,4-
2-yl)methyl)ureido)thiazol-4-tetrahydrophthalazine-6-
yl)methyl)-N-methyl-1,4-carboxylic acid
dioxo-1,2,3,4-
tetrahydrophthalazine-6-
carboxamide
321N2-((2-(3-((5-chlorothiophen-C17H21ClN6O4S2473.04732Int. 291-carbamoyl-4-
2-yl)methyl)ureido)thiazol-4-hydroxypyrrolidine-2-
yl)methyl)-4-hydroxy-N2-carboxylic acid
methylpyrrolidine-1,2-
dicarboxamide
322N-((2-(3-((5-chlorothiophen-C16H16ClN7O4S2470.04702Int. 291-methyl-5-nitro-1H-pyrazole-
2-yl)methyl)ureido)thiazol-4-4-carboxylic acid
yl)methyl)-N,1-dimethyl-5-
nitro-1H-pyrazole-4-
carboxamide
323(S)-3,3-difluoro-N-((2-(3-(3-C18H19F3N4O3S428.04292Int. 5(S)-3,3-
fluorobenzyl)ureido)thiazol-4-difluorotetrahydrofuran-2-
yl)methyl)-N-carboxylic acid
methyltetrahydrofuran-2-
carboxamide
324N-((2-(3-(3-fluorobenzylC23H23FN4O3S454.04552Int. 5Chroman-2-carboxylic acid
ureido)thiazol-4-yl)methyl)-N-
methylchroman-2-
carboxamide
3254-(3,5-dimethyl-1H-pyrazol-4-C25H25FN6O2S492.04932Int. 54-(3,5-dimethyl-1H-pyrazol-4-
yl)-N-((2-(3-(3-fluorobenzyl)yl)benzoic acid
ureido)thiazol-4-yl)methyl)-N-
methylbenzamide
326N-((2-(3-(3-fluorobenzyl)C18H19FN4O2S374.03752Int. 5Pent-4-ynoic acid
ureido)thiazol-4-yl)methyl)-N-
methylpent-4-ynamide
327N-((2-(3-(3-fluorobenzyl)C24H26FN5O2S468.04682Int. 52-methyl-1,2,3,4-
ureido)thiazol-4-yl)methyl)-tetrahydroisoquinoline-3-
N,2-dimethyl-1,2,3,4-carboxylic acid
tetrahydroisoquinoline-3-
carboxamide
328(S)-2-amino-N-((2-(3-(3-C21H23FN6O2S442.04432; 6 Int. 5N-Fmoc-(S)-2-amino-3-
fluorobenzyl)ureido)thiazol-4-(pyridin-4-yl)propanoic acid
yl)methyl)-N-methyl-3-
(pyridin-4-yl)propanamide
329cis-N-((2-(3-(3-fluorobenzyl)C19H23FN4O4S422.04232Int. 5cis-3-methoxytetrahydrofuran-
ureido)thiazol-4-yl)methyl)-3-2-carboxylic acid (Int. 56)
methoxy-N-
methyltetrahydrofuran-2-
carboxamide
3301-cyano-N-((2-(3-(3-C18H18FN5O2S387.03882Int. 51-cyanocyclopropane
fluorobenzyl)ureido)thiazol-4-carboxylic acid
yl)methyl)-N-
methylcyclopropane
carboxamide
331N-((2-(3-(3-fluorobenzyl)C16H15FN4O2S346.03472Int. 5propiolic acid
ureido)thiazol-4-yl)methyl)-N-
methylpropiolamide
332N-((2-(3-(1H-indol-2-C21H22N6O3S438.54398Int. 18C-(1H-Indol-2-yl)-
yl)methyl)ureido)thiazol-4-methylamine
yl)methyl)-N,3,5-
trimethylisoxazole-4-
carboxamide
333N-((2-(3-(benzoxazol-6-C20H20N6O4S440.54398Int. 18C-Benzooxazol-6-yl-
ylmethyl)ureido)thiazol-4-methylamine [Int. 57]
yl)methyl)-N,3,5-
trimethylisoxazole-4-
carboxamide
3342-ethoxy-N-((2-(3-(3-C18H23FN4O3S394.03952Int. 52-ethoxypropanoic acid
fluorobenzyl)ureido)thiazol-4-
yl)methyl)-N-
methylpropanamide
335N-((2-(3-(3-fluorobenzyl)C23H25FN4O4S472.04732Int. 52-(4-methoxyphenoxy)
ureido)thiazol-4-yl)methyl)-2-propanoic acid
(4-methoxyphenoxy)-N-
methylpropanamide
3362-(cyclopropylmethoxy)-N-C20H25FN4O3S420.04212Int. 52-(cyclopropylmethoxy)
((2-(3-(3-fluorobenzyl)propanoic acid
ureido)thiazol-4-yl)methyl)-N-
methylpropanamide
3372,5-diamino-N-((2-(3-(3-C18H25FN6O2S408.04092; 1 Int. 5N,N′-di-(tert-butoxylcarbony)-
fluorobenzyl)ureido)thiazol-4-2,5-diaminopentanoic acid
yl)methyl)-N-
methylpentanamide
338N-((2-(3-(3-fluorobenzyl)C24H27FN4O4S486.04872Int. 52-(2-phenoxyethoxy)
ureido)thiazol-4-yl)methyl)-N-propanoic acid
methyl-2-(2-phenoxyethoxy)
propanamide
3392-cyclopropyl-N-((2-(3-(3-C18H21FN4O2S376.03772Int. 52-cyclopropylacetic acid
fluorobenzyl)ureido)thiazol-4-
yl)methyl)-N-
methylacetamide
340N,3,5-trimethyl-N-((2-(3-(4-C19H20N6O5S444.04458Int. 184-nitrobenzyl amine
nitrobenzyl)ureido)thiazol-4-
yl)methyl)isoxazole-4-
carboxamide
341N,3,5-trimethyl-N-((2-(3-(3-C19H20N6O5S444.04458Int. 183-nitrobenzyl amine
nitrobenzyl)ureido)thiazol-4-
yl)methyl)isoxazole-4-
carboxamide
3423-ethyl-N-((2-(3-(3-C19H23FN4O3S406.04072Int. 53-Ethyloxetane-3-carboxylic
fluorobenzyl)ureido)thiazol-4-acid (Int. 55)
yl)methyl)-N-methyloxetane-
3-carboxamide
3432-(2,2-difluoroethoxy)-N-((2-C18H21F3N4O3S430.04312Int. 52-(2,2-difluoroethoxy)
(3-(3-fluorobenzyl)ureido)propanoic acid
thiazol-4-yl)methyl)-N-
methylpropanamide
344N-((2-(3-(3-fluorobenzyl)C23H24F2N4O3S474.04752Int. 52-(4-fluorobenzyloxy)
ureido)thiazol-4-yl)methyl)-2-propanoic acid
(4-fluorobenzyloxy)
propanamide
3452-(2,2,2-trifluoroethoxy)-N-C18H20F4N4O3S448.04492Int. 52-(2,2,2-trifluoroethoxy)
((2-(3-(3-fluorobenzyl)ureido)propanoic acid
thiazol-4-yl)methyl)-N-
methylpropanamide
346N-((2-(3-(3-fluorobenzyl)C19H21FN4O3S404.04052Int. 52-(prop-2-ynyloxy)propanoic
ureido)thiazol-4-yl)methyl)-2-acid
(prop-2-ynyloxy)propanamide
347N-((2-(3-(3-fluorobenzyl)C21H24FN5O4S462.04622Int. 52-((5-methylisoxazol-3-
ureido)thiazol-4-yl)methyl)-N-yl)methoxy)propanamide
methyl-2-((5-methylisoxazol-
3-yl)methoxy)propanamide
348N-((2-(3-(3-fluorobenzyl)C21H28FN5O3S450.04502Int. 52-(1-methylpyrrolidin-3-
ureido)thiazol-4-yl)methyl)-N-yloxy)propanoic acid
methyl-2-(1-methylpyrrolidin-
3-yloxy)propanamide
349N-((2-(3-(3-fluorobenzyl)C18H23FN4O4S410.04112Int. 52-(2-hydroxyethoxy)
ureido)thiazol-4-yl)methyl)-2-propanamide
(2-hydroxyethoxy)
propanamide
350N-((2-(3-((5-chlorothiophen-C17H21ClN4O2S2413.04132Int. 29Cyclopentane carboxylic acid
2-yl)methyl)ureido)thiazol-4-
yl)methyl)-N-
methylcyclopentane
carboxamide
351N-((2-(3-((5-chlorothiophen-C15H17ClN4O3S2401.04012Int. 291-hydroxycyclopropane
2-yl)methyl)ureido)thiazol-4-carboxylic acid
yl)methyl)-1-hydroxy-N-
methylcyclopropane
carboxamide
352N-((2-(3-((5-chlorothiophen-C18H23ClN4O2S2427.04272Int. 29Cyclohexane carboxylic acid
2-yl)methyl)ureido)thiazol-4-
yl)methyl)-N-
methylcyclohexane
carboxamide
3531-cyano-N-((5-fluoro-2-(3-(3-C18H17F2N5O2S405.04062Int. 51-cyanocyclopropane
fluorobenzyl)ureido)thiazol-4-carboxylic acid
yl)methyl)-N-
methylcyclopropane
carboxamide
354N-((2-(3-(3-fluorobenzyl)C19H23FN4O2S390.03912Int. 5Cyclopentane carboxylic acid
ureido)thiazol-4-yl)methyl)-N-
methylcyclopentane
carboxamide
355N-((2-(3-(3-fluorobenzyl)C21H27FN4O2S418.04192Int. 52-methylcyclohexane
ureido)thiazol-4-yl)methyl)-carboxylic acid
N,2-dimethylcyclohexane
carboxamide
356N-((2-(3-(3-fluorobenzyl)C20H25FN4O2S404.04052Int. 5Cyclohexane carboxylic acid
ureido)thiazol-4-yl)methyl)-N-
methylcyclohexane
carboxamide
357N-((2-(3-(3-fluorobenzyl)C21H18FN5O4S455.04562Int. 52-oxo-2,3-dihydrobenzoxazole-
ureido)thiazol-4-yl)methyl)-N-6-carboxamide
methyl-2-oxo-2,3-
dihydrobenzoxazole-6-
carboxamide
3583,3,3-trifluoro-N-((2-(3-(3-C16H16F4N4O2S404.04052Int. 53,3,3-trifluoropropanoic acid
fluorobenzyl)ureido)thiazol-4-
yl)methyl)-N-
methylpropanamide
359N-((2-(3-(3-fluorobenzyl)C17H21FN4O3S380.03812Int. 52-hydroxy-2-methylpropanoic
ureido)thiazol-4-yl)methyl)-2-acid
hydroxy-N,2-
dimethylpropanamide
3602,3-cis-N-((2-(3-(3-C19H23FN4O3S406.04072Int. 5cis-3-methyl-tetrahydrofuran-
fluorobenzyl)ureido)thiazol-4-2-carboxylic acid (Int. 54)
yl)methyl)-N,3-
dimethyltetrahydrofuran-2-
carboxamide
361(5R)-N-((2-(3-(3-C19H23FN4O4S422.04232; 11Int. 5(R)-5-(tert-Butyl-diphenyl-
fluorobenzyl)ureido)thiazol-4-silanyloxymethyl)-tetrahydro-
yl)methyl)-5-(hydroxymethyl)-furan-2-carboxylic acid (Int.
N-methyltetrahydrofuran-2-53)
carboxamide
362N-((2-(3-((5-chlorothiophen-C15H19ClN4O3S2403.04032Int. 52-hydroxy-2-methylpropanoic
2-yl)methyl)ureido)thiazol-4-acid
yl)methyl)-2-hydroxy-N,2-
dimethylpropanamide
363N-((2-(3-(5-chlorothiophen-2-C19H16ClN5O4S2478.04782Int. 52-oxo-2,3-dihydrobenzoxazole-
yl)methyl)ureido)thiazol-4-6-carboxamide
yl)methyl)-N-methyl-2-oxo-
2,3-dihydrobenzoxazole-6-
carboxamide
364(S)-N-((2-(3-((5-C17H20ClN5O4S2458.04582Int. 5(S)-2-(4-hydroxy-2-
chlorothiophen-2-oxopyrrolidin-1-yl)acetic acid
yl)methyl)ureido)thiazol-4-
yl)methyl)-2-(4-hydroxy-2-
oxopyrrolidin-1-yl)-N-
methylacetamide
365(R)-N-((2-(3-(benzo[1,2,5]C18H20N6O4S416.04177Int. 522,1,3-Benzoxadiazole-5-
oxadiazol-5-ylmethyl)ureido)methanamine hydrochloride
thiazol-4-yl)methyl)-N-[RN 321330-19-2]
methyltetrahydrofuran-2-
carboxamide
366(R)-N-((2-(3-((7-chlorobenzoC19H21ClN4O5S453.04537Int. 525-Chloropiperonylamine (Int.
[1,3]dioxol-5-yl)methyl)66)
ureido)thiazol-4-yl)methyl)-N-
methyltetrahydrofuran-2-
carboxamide
3672,3,3,3-tetrafluoro-N-((2-(3-C16H15F5N4O2S422.04232Int. 52,3,3,3-tetrafluoropropanoic
(3-fluorobenzyl)ureido)acid
thiazol-4-yl)methyl)-N-
methylpropanamide
368N-((2-(3-(3-fluorobenzyl)C17H19FN4O2S362.03632Int. 5Cyclopropane carboxylic acid
ureido)thiazol-4-yl)methyl)-N-
methylcyclopropane
carboxamide
369N-((2-(3-(3-fluorobenzyl)C18H20FN5O3S405.04062Int. 51-carbamoylcyclopropane
ureido)thiazol-4-yl)methyl)-N-carboxylic acid
methylcyclopropane-1,1-
dicarboxamide
370N-((2-(3-(3-fluorobenzyl)C18H21FN4O2S376.03772Int. 52-methylcyclopropane
ureido)thiazol-4-yl)methyl)-carboxylic acid
N,2-dimethylcyclopropane
carboxamide
371(S)-N-((2-(3-(3-fluorobenzyl)C19H22FN5O4S435.04362Int. 5(S)-2-(4-hydroxy-2-
ureido)thiazol-4-yl)methyl)-2-oxopyrrolidin-1-yl)acetic acid
(4-hydroxy-2-oxopyrrolidin-1-
yl)-N-methylacetamide

[0577]

Preparation of Thiadiazolyl Amides
MOLMOLStarting
EX#NAMEFORMULAWEIGHTMASSMETHODMaterial 1 (SM1)Starting Material 2 (SM2)
372N-((5-(3-(3-fluorobenzyl)C18H19FN6O3S418.54192Int. 683,5-Dimethylisoxazole-4-
ureido)-1,2,4-thiadiazol-3-carboxylic acid
yl)methyl)-N,3,5-
trimethylisoxazole-4-
carboxamide
373N-((5-(3-(3-fluorobenzyl)C21H22FN5O2S427.54282Int. 682,6-Dimethylbenzoic acid
ureido)-1,2,4-thiadiazol-3-
yl)methyl)-N,2,6-
trimethylbenzamide
374N-((5-(3-(3-fluorobenzyl)C19H19FN6O2S414.54152Int. 683-Methyl-nicotinic acid
ureido)-1,2,4-thiadiazol-3-
yl)methyl)-N,3-
dimethylisonicotinamide
375N-((5-(3-(3-fluorobenzyl)C18H18FN7O2S415.54162Int. 683-Methylpyrazine-2-
ureido)-1,2,4-thiadiazol-3-carboxylic acid
yl)methyl)-N,3-
dimethylpyrazine-2-
carboxamide
3761,3,5-Trimethyl-1H-C19H22FN7O2S431.54322Int. 681,3,5-Trimethyl-1H-pyrazole-
pyrazole-4-carboxylic acid4-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3775-Chloro-1,3-dimethyl-1H-C18H19ClFN7O2S451.94522Int. 685-Chloro-1,3-dimethyl-1H-
pyrazole-4-carboxylic acidpyrazole-4-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3785-Isopropyl-3-methyl-C20H23FN6O3S446.54472Int. 685-Isopropyl-3-methyl-
isoxazole-4-carboxylic acidisoxazole-4-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3791,3,5-Trimethyl-1H-pyrazoloC20H21ClN8O2S2505.05052Int. 691,3,5-Trimethyl-1H-
[4,3-b]pyridine-7-carboxylicpyrazolo[4,3-b]pyridine-7-
acid {5-[3-(5-chloro-carboxylic acid
thiophen-2-ylmethyl)-ureido]-
[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3801-Methyl-5-pyrrol-1-yl-1H-C21H21FN8O2S468.54692Int. 681-Methyl-5-pyrrol-1-yl-1H-
pyrazole-4-carboxylic acidpyrazole-4-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3813-Methyl-4-oxo-3,4-dihydro-C22H20FN7O3S481.54822Int. 683-Methyl-4-oxo-3,4-dihydro-
phthalazine-1-carboxylic acidphthalazine-1-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3822,4-Dimethyl-6-oxo-6H-C20H20FN5O4S445.54462Int. 682,4-Dimethyl-6-oxo-6H-
pyran-3-carboxylic acid {5-pyran-3-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3833,6-Dimethyl-isoxazolo[5,4-C21H20FN7O3S469.54702Int. 683,6-Dimethyl-isoxazolo[5,4-
b]pyridine-4-carboxylic acidb]pyridine-4-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3842-(5,7-Dimethyl-[1,2,4]C21H22FN9O2S483.54842Int. 682-(5,7-Dimethyl-[1,2,4]
triazolo[1,5-a]pyrimidin-6-triazolo[1,5-a]pyrimidin-6-yl)-
yl)-N-{5-[3-(3-fluoro-acetic acid
benzyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-N-
methyl-acetamide
3853,6-Dimethyl-4-oxo-3,4-C21H20FN7O4S485.54862Int. 683,6-Dimethyl-4-oxo-3,4-
dihydro-furo[2,3-dihydro-furo[2,3-
d]pyrimidine-5-carboxylicd]pyrimidine-5-carboxylic
acid {5-[3-(3-fluoro-benzyl)-acid
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
386N-{5-[3-(3-Fluoro-benzyl)-C20H18FN9O2S467.54682Int. 68[1,2,4]triazol-1-yl-nicotinic
ureido]-[1,2,4]thiadiazol-3-acid
ylmethyl}-N-methyl-6-
[1,2,4]triazol-1-yl-
nicotinamide
3871-(2-Methoxy-ethyl)-6-oxo-C20H22FN7O4S475.54762Int. 681-(2-Methoxy-ethyl)-6-oxo-
1,6-dihydro-pyridazine-3-1,6-dihydro-pyridazine-3-
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3881-Methyl-4-sulfamoyl-1H-C16H18ClN7O4S3504.05042Int. 691-Methyl-4-sulfamoyl-1H-
pyrrole-2-carboxylic acid {5-pyrrole-2-carboxylic acid
[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
389N-{5-[3-(5-Chloro-thiophen-C19H20ClN9O2S2506.05062Int. 69(5,7-Dimethyl-[1,2,4]triazolo
2-ylmethyl)-ureido]-[1,2,4][1,5-a]pyrimidin-6-yl)-acetic
thiadiazol-3-ylmethyl}-2-acid
(5,7-dimethyl-[1,2,4]triazolo
[1,5-a]pyrimidin-6-yl)-N-
methyl-acetamide
3903,6-Dimethyl-4-oxo-3,4-C19H18ClN7O4S2508.05082Int. 693,6-Dimethyl-4-oxo-3,4-
dihydro-furo[2,3-dihydro-furo[2,3-d]pyrimidine-
d]pyrimidine-5-carboxylic5-carboxylic acid
acid{5-[3-(5-chloro-thiophen-
2-ylmethyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
391(R)-Tetrahydro-furan-2-C17H20FN5O3S393.43942; 10Int. 70(R)-Tetrahydro-furan-2-
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3921,3,5-Trimethyl-1H-pyrazoloC22H23FN8O2S482.54832Int. 681,3,5-Trimethyl-1H-
[4,3-b]pyridine-7-carboxylicpyrazolo[4,3-b]pyridine-7-
acid {5-[3-(3-fluoro-benzyl)-carboxylic acid
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3931-Methyl-3-trifluoromethyl-C16H15ClF3N7O2S2493.94942Int. 691-Methyl-3-trifluoromethyl-
1H-pyrazole-4-carboxylic1H-pyrazole-4-carboxylic acid
acid {5-[3-(5-chloro-thiophen-
2-ylmethyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
394N-{5-[3-(5-Chloro-thiophen-C18H16ClN7O3S2478.04782Int. 693-cyano-2-hydroxy-6,N-
2-ylmethyl)-ureido]-[1,2,4]dimethyl-isonicotinic acid
thiadiazol-3-ylmethyl}-3-
cyano-2-hydroxy-6,N-
dimethyl-isonicotinamide
3956-Chloro-3-oxo-2,3-dihydro-C17H15ClFN7O3S451.94522Int. 686-Chloro-3-oxo-2,3-dihydro-
pyridazine-4-carboxylic acidpyridazine-4-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
3961-Methyl-6-oxo-1,4,5,6-C18H20FN7O3S433.54342Int. 681-Methyl-6-oxo-1,4,5,6-
tetrahydro-pyridazine-3-tetrahydro-pyridazine-3-
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
3977-Chloro-benzo[1,3]dioxole-C20H17ClFN5O4S477.94782Int. 687-Chloro-benzo[1,3]dioxole-5-
5-carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
3985-Methyl-4-oxo-3,4-dihydro-C20H18FN7O3S2487.54882Int. 685-Methyl-4-oxo-3,4-dihydro-
thieno[2,3-d]pyrimidine-6-thieno[2,3-d]pyrimidine-6-
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
3991-Methyl-5-pyrrol-1-yl-1H-C19H19ClN8O2S2491.04912Int. 691-Methyl-5-pyrrol-1-yl-1H-
pyrazole-4-carboxylic acidpyrazole-4-carboxylic acid
{5-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
4001-Methyl-6-oxo-1,4,5,6-C16H18ClN7O3S2455.94562Int. 691-Methyl-6-oxo-1,4,5,6-
tetrahydro-pyridazine-3-tetrahydro-pyridazine-3-
carboxylic acid {5-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4013-Methyl-4-oxo-3,4-dihydro-C20H18ClN7O3S2504.05042Int. 693-Methyl-4-oxo-3,4-dihydro-
phthalazine-1-carboxylic acidphthalazine-1-carboxylic acid
{5-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
4022,4-Dimethyl-6-oxo-6H-C18H18ClN5O4S2468.04682Int. 692,4-Dimethyl-6-oxo-6H-
pyran-3-carboxylic acid {5-pyran-3-carboxylic acid
[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
4035-Methyl-4-oxo-3,4-dihydro-C18H16ClN7O3S3510.05102Int. 695-Methyl-4-oxo-3,4-dihydro-
thieno[2,3-d]pyrimidine-6-thieno[2,3-d]pyrimidine-6-
carboxylic acid {5-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
404N-{5-[3-(5-Chloro-thiophen-C18H16ClN9O2S2490.04902Int. 696-[1,2,4]triazol-1-yl-nicotinic
2-ylmethyl)-ureido]-[1,2,4]acid
thiadiazol-3-ylmethyl}-N-
methyl-6-[1,2,4]triazol-1-yl-
nicotinamide
4051-(2-Methoxy-ethyl)-6-oxo-C18H20ClN7O4S2498.04982Int. 691-(2-Methoxy-ethyl)-6-oxo-
1,6-dihydro-pyridazine-3-1,6-dihydro-pyridazine-3-
carboxylic acid {5-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
406N-{5-[3-(5-Chloro-thiophen-C18H16ClF2N5O2S2471.94722Int. 69Difluoro-phenyl-acetic acid
2-ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-2,2-
difluoro-N-methyl-2-phenyl-
acetamide
407(R)-Tetrahydro-furan-2-C17H19N7O4S417.54182Int. 32,1,3-Benzoxadiazole-5-
carboxylic acid [5-(3-methanamine hydrochloride
benzo[1,2,5]oxadiazol-5-[RN 321330-19-2]
ylmethyl-ureido)-
[1,2,4]thiadiazol-3-
ylmethyl]-methyl-amide
4083,5-Dimethyl-1H-pyrazole-4-C18H20FN7O2S417.54182; 10Int. 703,5-Dimethyl-1H-pyrazole-4-
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
4093,5-Dimethyl-pyridazine-4-C19H20FN7O2S429.54302; 10Int. 703,5-Dimethyl-pyridazine-4-
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4105-Isopropyl-3-methyl-C18H21ClN6O3S2469.04692Int. 695-Isopropyl-3-methyl-
isoxazole-4-carboxylic acidisoxazole-4-carboxylic acid
{5-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
411N-{5-[3-(3-Fluoro-benzyl)-C20H21FN6O4S2492.64932Int. 682-Methyl-5-sulfamoyl-benzoic
ureido]-[1,2,4]thiadiazol-3-acid
ylmethyl}-2,N-dimethyl-5-
sulfamoyl-benzamide
4121,1-Dioxo-C17H20FN5O4S2441.54422Int. 681,1-Dioxo-
tetrahydrothiophene-3-tetrahydrothiophene-3-
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
413N-{5-[3-(5-Chloro-thiophen-C20H22ClN7O3S2508.05082Int. 692-Morpholin-4-yl-nicotinic
2-ylmethyl)-ureido]-[1,2,4]acid
thiadiazol-3-ylmethyl}-N-
methyl-2-morpholin-4-yl-
nicotinamide
4141-Phenyl-cyclobutaneC21H22ClN5O2S2476.04762Int. 691-Phenyl-cyclobutane
carboxylic acid {5-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4154-Oxo-3,4-dihydro-C19H16ClN7O3S2490.04902Int. 694-Oxo-3,4-dihydro-
phthalazine-1-carboxylic acidphthalazine-1-carboxylic acid
{5-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
4167-Chloro-benzo[1,3]dioxole-C18H15Cl2N5O4S2500.45002Int. 697-Chloro-benzo[1,3]dioxole-5-
5-carboxylic acid {5-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4171-(4-Fluoro-phenyl)-C21H21ClFN5O2S2494.04942Int. 691-(4-Fluoro-phenyl)-
cyclobutane carboxylic acidcyclobutanecarboxylic acid
{5-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
4181-Methyl-3-trifluoromethyl-C18H17F4N7O2S471.44722Int. 681-Methyl-3-trifluoromethyl-
1H-pyrazole-4-carboxylic1H-pyrazole-4-carboxylic acid
acid {5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4195-Chloro-1,3-dimethyl-1H-C16H17Cl2N7O2S2474.44742Int. 695-Chloro-1,3-dimethyl-1H-
pyrazole-4-carboxylic acidpyrazole-4-carboxylic acid
{5-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
4201-Phenyl-cyclobutaneC23H24FN5O2S453.54542Int. 681-Phenyl-cyclobutane
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
4214-Oxo-3,4-dihydro-C21H18FN7O3S467.54682Int. 684-Oxo-3,4-dihydro-
phthalazine-1-carboxylic acidphthalazine-1-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4221-(4-Fluoro-phenyl)-C23H23F2N5O2S471.54722Int. 681-(4-Fluoro-phenyl)-
cyclobutane carboxylic acidcyclobutanecarboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4232,2-Difluoro-N-{5-[3-(3-C20H18F3N5O2S449.54502Int. 68Difluoro-phenyl-acetic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-
ylmethyl}-N-methyl-2-
phenyl-acetamide
4241,1-Dioxo-tetrahydro-C15H18ClN5O4S3464.04642Int. 691,1-Dioxo-tetrahydro-
thiophene-3-carboxylic acidthiophene-3-carboxylic acid
{5-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
4252,2-Dimethyl-tetrahydro-C18H24ClN5O3S2458.04582Int. 692,2-Dimethyl-tetrahydro-
pyran-4-carboxylic acid {5-pyran-4-carboxylic acid
[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
4262,3-Dihydro-benzofuran-2-C21H20FN5O3S441.54422Int. 682,3-Dihydro-benzofuran-2-
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
427(R)-Tetrahydro-furan-2-C15H18ClN5O3S2415.94162Int. 69(R)-Tetrahydro-furan-2-
carboxylic acid {5-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4282,2-Dimethyl-tetrahydro-C20H26FN5O3S435.54362Int. 682,2-Dimethyl-tetrahydro-
pyran-4-carboxylic acid {5-pyran-4-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
4291-Methyl-5-nitro-1H-C17H17FN8O4S448.44492Int. 681-Methyl-5-nitro-1H-
pyrazole-4-carboxylic acidpyrazole-4-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4301-Methyl-5-nitro-1H-C15H15ClN8O4S2470.94712Int. 691-Methyl-5-nitro-1H-pyrazole-
pyrazole-4-carboxylic acid4-carboxylic acid
{5-[3-(5-chloro-thiophen-2-
ylmethyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-
methyl-amide
4312,3-Dihydro-benzofuran-2-C19H18ClN5O3S2464.04642Int. 692,3-Dihydro-benzofuran-2-
carboxylic acid {5-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
432(R)—N-{5-[3-(3-Fluoro-C16H20FN5O3S381.43822; 10Int. 70(R)-2-Methoxy-propionic acid
benzyl)-ureido]-[1,2,4]
thiadiazol-3-ylmethyl}-2-
methoxy-N-methyl-
propionamide
433(R)—N-{5-[3-(5-chloro-C14H18ClN5O3S2403.94042Int. 69(R)-2-Methoxy-propionic acid
thiophen-2-ylmethyl)-ureido]-
[1,2,4]thiadiazol-3-
ylmethyl}-2-methoxy-N-
methyl-propionamide
434N-{5-[3-(3-Fluoro-benzyl)-C22H24FN7O3S485.54862Int. 682-Morpholin-4-yl-nicotinic
ureido]-[1,2,4]thiadiazol-3-acid
ylmethyl}-N-methyl-2-
morpholin-4-yl-nicotinamide
435N-{5-[3-(3-Fluoro-benzyl)-C22H24FN7O2S469.54702Int. 682-pyrrolidin-1-yl-nicotinic
ureido]-[1,2,4]thiadiazol-3-acid
ylmethyl}-N-methyl-2-
pyrrolidin-1-yl-nicotinamide
436N-{5-[3-(5-Chloro-thiophen-C18H19ClN6O4S3515.05152Int. 692-Methyl-5-sulfamoyl-benzoic
2-ylmethyl)-ureido]-[1,2,4]acid
thiadiazol-3-ylmethyl}-2,N-
dimethyl-5-sulfamoyl-
benzamide
437N-{5-[3-(5-chloro-thiophen-C20H22ClN7O2S2492.04922Int. 692-pyrrolidin-1-yl-nicotinic
2-ylmethyl)-ureido]-[1,2,4]acid
thiadiazol-3-ylmethyl}-N-
methyl-2-pyrrolidin-1-yl-
nicotinamide
4382,2-Difluoro-N-{5-[3-(3-C19H17F3N6O2S450.44512; 10Int. 70Difluoro-pyridin-2-yl-acetic
fluoro-benzyl)-ureido]-acid
[1,2,4]thiadiazol-3-ylmethyl}-
N-methyl-2-pyridin-2-yl-
acetamide
4391-Methyl-4-sulfamoyl-1H-C18H20FN7O4S2481.54822Int. 681-Methyl-4-sulfamoyl-1H-
pyrrole-2-carboxylic acid {5-pyrrole-2-carboxylic acid
[3-(3-fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
4404-Hydroxy-pyrrolidine-1,2-C18H22FN7O4S451.54522Int. 684-Hydroxy-pyrrolidine-1-
dicarboxylic acid 1-amide 2-carboxamide-2-carboxylic
({5-[3-(3-fluoro-benzyl)-acid
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide)
441Cyclopentanecarboxylic acidC18H22FN5O2S391.53922Int. 68Cyclopentane carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4422-Methyl-cyclohexanecarboxylicC20H26FN5O2S419.54202Int. 682-Methyl-
acid {5-[3-(3-cyclohexanecarboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
443Cyclohexanecarboxylic acidC19H24FN5O2S405.54062Int. 68Cyclohexanecarboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4442,6-Dioxo-hexahydro-C17H18FN7O4S435.44362Int. 682,6-Dioxo-hexahydro-
pyrimidine-4-carboxylic acidpyrimidine-4-carboxylic acid
{5-[3-(3-fluoro-benzyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4451-Cyano-cyclopropaneC15H15ClN6O2S2410.94112Int. 691-Cyano-cyclopropane
carboxylic acid {5-[3-(5-carboxylic acid
chloro-thiophen-2-ylmethyl)-
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
4461-Hydroxy-cyclopropaneC16H18FN5O3S379.43802Int. 681-Hydroxy-cyclopropane
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
4472-Oxo-2,3-dihydro-C20H17FN6O4S456.54572Int. 682-Oxo-2,3-dihydro-
benzooxazole-6-carboxylicbenzooxazole-6-carboxylic
acid {5-[3-(3-fluoro-benzyl)-acid
ureido]-[1,2,4]thiadiazol-3-
ylmethyl}-methyl-amide
448N-{5-[3-(3-Fluoro-benzyl)-C16H20FN5O3S381.43822Int. 682-Hydroxy-2-methyl-
ureido]-[1,2,4]thiadiazol-3-propionic acid
ylmethyl}-2-hydroxy-2,N-
dimethyl-propionamide
4491-Cyano-cyclopropaneC17H17FN6O2S388.43892; 10Int. 701-Cyano-cyclopropane
carboxylic acid {5-[3-(3-carboxylic acid
fluoro-benzyl)-ureido]-
[1,2,4]thiadiazol-3-ylmethyl}-
methyl-amide
450N-{5-[3-(3-Fluoro-benzyl)-C18H21FN6O4S436.54372Int. 68((S)-4-Hydroxy-2-oxo-
ureido]-[1,2,4]thiadiazol-3-pyrrolidin-1-yl)-acetic acid
ylmethyl}-2-((S)-4-hydroxy-
2-oxo-pyrrolidin-1-yl)-N-
methyl-acetamide

[0578]

Preparation of Thiazolyl Sulfonamides
MOLMOLStarting
EX#NAMEFORMULAWEIGHTMASSMETHODMaterial 1 (SM1)Starting Material 2 (SM2)
4511,1-Dioxo-tetrahydro-1l6-C17H20C12N4O5S3527.5527,5Int. 31,1-Dioxo-
thiophene-3-sulfonic acid529tetrahydrothiophene-3-
{2-[3-(3,4-dichloro-benzyl)-sulfonyl chloride
ureido]-thiazol-4-ylmethyl}-
methyl-amide
452N-((2-(3-(3,4-C20H20C12N4O3S2499.4499,5Int. 34-Toluenesulfonyl chloride
dichlorobenzyl)ureido)501
thiazol-4-yl)methyl)-N,4-
dimethyl benzene
sulfonamide
453N-((2-(3-(3,4-C18H19C12N5O4S2504.4504,5Int. 33,5-Dimethylisoxazole-4-
dichlorobenzyl)ureido)506sulfonyl chloride
thiazol-4-yl)methyl)-N,3,5-
trimethylisoxazole-4-
sulfonamide
454N-((2-(3-(3,4-C14H16C12N4O3S2423.34235Int. 3Methanesulfonyl chloride
dichlorobenzyl)ureido)
thiazol-4-yl)methyl)-N-
methyl methane
sulfonamide
455N-((2-(3-(3-fluorobenzyl)C14H17FN4O3S2372.43735Int. 5Methanesulfonyl chloride
ureido)thiazol-4-yl)methyl)-
N-methylmethane
sulfonamide
456N-((2-(3-(3-fluorobenzyl)C16H21FN4O3S2400.54015Int. 51-Propanesulfonyl chloride
ureido)thiazol-4-yl)methyl)-
N-methylpropane-1-
sulfonamide
4575-(2-(3-(3,4-dichlorobenzyl)C18H20C12N4O5S2507.4507,5Int. 58Methanesulfonyl chloride
ureido) thiazol-4-yl)-1-509
(methylsulfonyl)pyrrolidin-
3-yl acetate
4581-(3,4-dichlorobenzyl)-3-(4-C16H18C12N4O4S2465.4465,205-(2-(3-(3,4-none
(4-hydroxy-1-467dichlorobenzyl)
(methylsulfonyl)pyrrolidin-ureido)thiazol-4-
2-yl)thiazol-2-yl)ureayl)-1-(methylsulfonyl)-
pyrrolidin-
3-yl acetate
(EX# 457)
459N-((2-(3-(3-fluorobenzyl)C17H23FN4O3S2414.54155Int. 51-Butanesulfonyl chloride
ureido)thiazol-4-yl)methyl)-
N-methylbutane-1-
sulfonamide
460N-((2-(3-(3-fluorobenzyl)C15H19FN4O3S2386.53875Int. 5Ethanesulfonyl chloride
ureido)thiazol-4-yl)methyl)-
N-methylethane
sulfonamide
461N-((2-(3-(3-fluorobenzyl)C18H20FN5O4 S2453.54545Int. 53,5-Dimethylisoxazole-4-
ureido)thiazol-4-yl)methyl)-sulfonyl chloride
N,3,5-trimethylisoxazole-4-
sulfonamide
462N-((2-(3-(3-fluorobenzyl)C16H19FN4O3S2398.53995Int. 5Cyclopropanesulfonyl chloride
ureido)thiazol-4-yl)methyl)-
N-methylcyclopropane
sulfonamide
463N-((2-(3-(3-fluorobenzyl)C16H22FN5O5 S3479.64815Int. 59Methanesulfonyl chloride
ureido)thiazol-4-yl)methyl)-
N-(2-(methylsulfonamido)
ethyl)methane sulfonamide
4641-[4-(1,1-Dioxo-1l6-C15H17FN4O3S2384.538516Int. 21Isothiazolidine 1,1-dioxide
isothiazolidin-2-ylmethyl)-
thiazol-2-yl]-3-(3-fluoro-
benzyl)-urea
4651-(3-Fluoro-benzyl)-3-{4-C18H23FN4O3S2426.54275Int. 60Propanesulfonyl chloride
[1-(propane-1-sulfonyl)-
pyrrolidin-2-yl]-thiazol-2-
yl}-urea
466Ethanesulfonic acid {5-C15H18BrFN4O3S2465.446517N-((2-(3-(3-Bromine
bromo-2-[3-(3-fluoro-fluorobenzyl)
benzyl)-ureido]-thiazol-4-ureido)thiazol-
ylmethyl}-methyl-amide4-yl)methyl)-N-
methylethane-
sulfonamide
(EX# 460)
467N-{2-[3-(3-Fluoro-benzyl)-C23H26FN5O4S2519.65215Int. 54-Morpholin-4-yl-
ureido]-thiazol-4-ylmethyl}-benzenesulfonyl chloride
N-methyl-4-morpholin-4-yl-
benzenesulfonamide
468Furan-2-sulfonic acid {2-[3-C17H17FN4O4S2424.54255Int. 5Furan-2-sulfonyl chloride
(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
469Thiophene-2-sulfonic acidC17H17FN4O3S3440.54415Int. 5Thiophene-2-sulfonyl chloride
{2-[3-(3-fluoro-benzyl)-
ureido]-thiazol-4-ylmethyl}-
methyl-amide
470Pyridine-3-sulfonic acid {2-C18H18FN5O3S2435.54365Int. 5Pyridine-3-sulfonyl chloride
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
471Pyridine-2-sulfonic acid {2-C18H18FN5O3S2435.54365Int. 5Pyridine-2-sulfonyl chloride
[3-(3-fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
4721-Methyl-1H-imidazole-4-C17H19FN6O3S2438.54395Int. 51-Methyl-1H-imidazole-4-
sulfonic acid {2-[3-(3-sulfonyl chloride
fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
4731,2-Dimethyl-1H-imidazole-C18H21FN6O3S2452.54535Int. 51,2-Dimethyl-1H-imidazole-4-
4-sulfonic acid {2-[3-(3-sulfonyl chloride
fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-methyl-
amide
474N-{2-[3-(3-Fluoro-benzyl)-C19H20FN5O3S2449.54505Int. 5Pyridin-3-yl-methanesulfonyl
ureido]-thiazol-4-ylmethyl}-chloride
N-methyl-C-pyridin-3-yl-
methanesulfonamide
475N-(3,5-Dimethyl-isoxazol-C19H22FN5O4S2467.54685Int. 61Methanesulfonyl chloride
4-ylmethyl)-N-{2-[3-(3-
fluoro-benzyl)-ureido]-
thiazol-4-ylmethyl}-
methane sulfonamide

Example 476

Intermediates

Intermediate 1: 4-(Chloromethyl)thiazol-2-amine hydrochloride

[0579]

[0580]

To a solution of 1,3-dichloroacetone (150 g, 1.18 mol) in acetone (600 mL) was added a solution of thiourea (91.7 g, 1.23 mol) in acetone (3000 mL). The mixture was stirred overnight at room temperature. The resulting suspension was concentrated to dryness in vacuo. Ethanol (1.2 L) was added and the mixture was stirred for 3 h. The insolubles were removed by filtration and the filtrate was concentrated to 500 mL. Heptanes (1.5 L) were slowly added resulting in the formation of a white precipitate. This was isolated by filtration, washed with heptane and dried in vacuo to afford 4-(chloromethyl)thiazol-2-amine hydrochloride as a white solid (141.3 g, 0.76 mol, 64%).1H NMR (DMSO-d6): δ 9.50 (bs, 2H); 7.00 (s, 1H); 4.68 (s, 2H).

[0581]

Alternative Process for Intermediate 1: A mixture of 1,3-dichloroacetone (380.9 g, 3 mol), thiourea (228.3 g, 3 mol), and isopropanol (3.6 L) was stirred at 40° C. under an inert atmosphere, affording a clear solution. The product crystallized after stirring overnight at room temperature. After cooling to −20° C., the product was isolated by filtration, washed with cold isopropanol (0.4 L), and dried in vacuo to afford the title compound as white crystals (408 g, 73.5% yield).

Intermediate 2: 1-(3,4-Dichlorobenzyl)-3-(4-(chloromethyl)thiazol-2-yl) urea

[0582]

[0583]

To a suspension of 4-(chloromethyl)thiazol-2-amine hydrochloride (7.55 g, 41 mmol) in DCM (150 mL) at 0° C. was added 3,4-dichlorobenzyl isocyanate (8.27 g, 41 mmol). A solution of DIPEA in DCM (30 mL) was added over a period of 30 minutes and the mixture was stirred overnight at room temperature. Evaporation of the volatiles followed by purification by column chromatography (EtOAc/heptanes 1/1) afforded 1-(3,4-dichlorobenzyl)-3-(4-(chloromethyl)thiazol-2-yl)urea as an off-white solid (10.5 g, 30 mmol) in 73% yield.1H NMR (DMSO-d6): δ 10.80 (bs, 1H); 7.60 (d, 1H); 7.55 (s, 1H); 7.11 (t, 1H); 7.05 (s, 1H); 4.63 (s, 2H); 4.30 (d, 2H).

Intermediate 3: 1-(3,4-Dichlorobenzyl)-3-(4-((methylamino)methyl)thiazol-2-yl)urea

[0584]

[0585]

A solution of 1-(3,4-dichlorobenzyl)-3-(4-(chloromethyl)thiazol-2-yl)urea and excess methylamine (2.0 M solution in tetrahydrofuran) was heated for 15 minutes at 60° C. under microwave irradiation. The volatiles were removed in vacuo and the product was purified by column chromatography (DCM/0-15% NH3saturated MeOH) to afford the title compound.

Intermediate 4: 1-(4-(Chloromethyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea

[0586]

[0587]

Prepared by same procedure described for Intermediate 2 with 4-(chloromethyl)thiazol-2-amine hydrochloride and 3-fluorobenzyl isocyanate.1H-NMR (ppm, DMSO-d6): 10.70 (bs, 1H), 7.36 (dd, 1H), 7.07 (m, 4H), 4.63 (s, 2H), 4.34 (d, 2H).

[0588]

Alternative process for Intermediate 4 Using Carbonyl Diimidazole:

[0589]

A stirred mixture of Intermediate 1: 2-amino-4-chloromethyl-thiazole hydrochloride (27.8 g, 0.15 mol), carbonyl diimidazole (25.5 g, 0.157 mol), and anhydrous THF (0.2 L) was treated dropwise with a solution of DIPEA (26.2 mL, 0.15 mol) in THF (20 mL) at 20-30 C. After 2-3 hours stirring, a solution of 3-fluorobenzylamine (18.5 mL, 0.164 mol) in THF (40 mL) was added. The reaction was diluted with water (200 mL) and THF was evaporated under reduced pressure. The residue was extracted with DCM (2×200 mL). The combined extracts were dried over sodium sulfate and concentrated to leave an orange resin that was purified by silica gel chromatography (acetone/hexane) to afford Intermediate 4 as a pale yellow solid (26 g, 58% yield).

Intermediate 5: 1-(3-Fluorobenzyl)-3-(4-((methylamino)methyl)thiazol-2-yl) urea

[0590]

[0591]

Prepared by reaction of Intermediate 4 with methylamine, following the procedure described for Intermediate 3.

[0592]

Alternative Process for Intermediate 5 Using N,O-Dimethylhydroxylamine:

[0593]

[0594]

Step 1: 2-(3-(3-Fluorobenzyl)ureido)-4-(N-methoxy-N-methyl-aminomethyl)-thiazole. A mixture of Intermediate 4: 2-(3-(3-fluorobenzyl)ureido)-4-chloromethyl-thiazole (40 g, 0.133 mol), N,O-dimethylhydroxylamine (80 g, 0.820 mol), sodium carbonate (40 g, 0.754 mol), and abs. EtOH (0.2 L) was stirred and heated at 60-70 C for 8-12 hours. The mixture was diluted with water (0.8 L) and cooled to 20 C with continued stirring. The solids were collected by filtration, washed with water, and dried in vacuo to afford the title compound (37 g, 86% yield).

[0595]

[0596]

Step 2: Zinc Reduction of methoxyamine to amine (J. Natural Products 53(4), 995-999 (1990)). A solution of 2-(3-(3-fluorobenzyl)ureido)-4-(N-methoxy-N-methyl-aminomethyl)-thiazole (10.1 g, 31.1 mmol) in glacial HOAc (140 mL) was treated with micronized zinc dust (50 g) and the mixture was heated to 60-65 C with vigorous agitation. The reduction was complete in 2-16 hours and water (140 mL) was added. The mixture was filtered on Celite, the filter cake was reslurried in 1:1 HOAC:water (150 mL) and refiltered. The combine filtrate was made alkaline to pH 10 with NH4OH and cooled in ice. The solids were collected by filtration, washed with water, and dried in vacuo to afford Intermediate 5 as an off-white solid (8.2 g, 89% yield). This product could be used directly or further purified by crystallization as the hydrochloride salt (1:1 MeOH:EtOH).

Intermediate 6: 1-(3,4-Dichlorobenzyl)-3-(4-(iodomethyl)thiazol-2-yl)urea

[0597]

[0598]

To a solution of 1-(3,4-dichlorobenzyl)-3-(4-(chloromethyl)thiazol-2-yl)urea (Intermediate 2, 1 eq) in acetone was added sodium iodide (10 eq) at once. The mixture was stirred at room temperature for 2 h. The volatiles were removed in vacuo and the mixture was taken up in water and EtOAc. The layers were separated and the organic phase was washed with water and brine, dried over Na2SO4, and concentrated in vacuo to afford 1-(3,4-dichlorobenzyl)-3-(4-(iodomethyl)thiazol-2-yl)urea as a tan-colored solid.

Intermediate 7: 1-(3-Fluorobenzyl)-3-(4-(iodomethyl)thiazol-2-yl) urea

[0599]

[0600]

Prepared in a similar manner as 1-(3,4-dichlorobenzyl)-3-(4-(iodomethyl)thiazol-2-yl)urea.1H-NMR (ppm, CDCl3): 7.27 (m, 1H), 7.10 (m, 2H), 6.95 (t, 1H), 6.75 (s, 1H), 4.50 (d, 2H), 4.35 (s, 2H).

Intermediate 8: 1-(3,4-Dichlorobenzyl)-3-(4-((ethylamino)methyl)thiazol-2-yl)urea

[0601]

[0602]

The 1-(3,4-dichloro-benzyl)-3-(4-iodomethyl-thiazol-2-yl)-urea (Intermediate 6, 0.3 mmol) was taken up in a 2.0 M solution of ethylamine in tetrahydrofuran (5 ml). Reaction was stirred at room temperature for 1 hour. The volatiles were removed in vacuo and the crude title compound was taken on as is, ˜75% pure.

Intermediate 9: 1-(3,4-Dichlorobenzyl)-3-(4-((isopropylamino)methyl)thiazol-2-yl)urea

[0603]

[0604]

The 1-(3,4-Dichloro-benzyl)-3-(4-iodomethyl-thiazol-2-yl)-urea intermediate (0.3 mmol) was taken up in tetrahydrofuran (5 ml) and isopropyl amine (20 eq.) was added. The reaction was stirred overnight at room temperature. Added a saturated solution of NaSO3(40 ml). Extracted this with EtOAc twice. The combined organic extracts were dried over Na2SO4, filtered and solvent removed in vacuo. The crude 1-(3,4-dichlorobenzyl)-3-(4-((isopropylamino)methyl)thiazol-2-yl)urea was used as is.

Intermediate 10a: 1-(3,4-Dichlorobenzyl)-3-(4-(1-(methylamino)ethyl)thiazol-2-yl)urea

[0605]

[0606]

Step 1: The commercial starting material ethyl 2-aminothiazole-4-carboxylate (2 mmol) was dissolved in NMP and DIEA (1 equivalent) was added followed by addition of the 3,4-dichloro-benzyl isocyanate (1 equivalent). Add 5% DMAP. Heat at 160° C. under microwave irradiation for 30 min Added additional isocyanate reagent (1.0 eq) and microwave for another 30 minutes at 160° C. to obtain ethyl 2-(3-(3,4-dichlorobenzyl)ureido)thiazole-4-carboxylate in >90% conversion.

[0607]

Step 2: Hydrolysis with NaOH to give 2-(3-(3,4-dichlorobenzyl)ureido)thiazole-4-carboxylic acid.

[0608]

Step 3: Method 2 is followed to couple the above acid with N,O-dimethylhydroxylamine HCl salt to give 2-(3-(3,4-dichlorobenzyl)ureido)-N-methoxy-N-methylthiazole-4-carboxamide.

[0609]

Step 4: 1 mmol of 2-(3-(3,4-dichlorobenzyl)ureido)-N-methoxy-N-methylthiazole-4-carboxamide was suspended in 10 ml dry tetrahydrofuran and cooled to 0 C. 1.5 ml of 3 M methylmagnesium chloride in tetrahydrofuran was added and stirred for 2 hours. The solution was poured in to 20 ml of 5% concentrate HCl in ethanol. The solution was diluted with brine and the precipitate was filtered, washed with water and dried.

[0610]

Step 5: 156 mg of 1-(4-acetylthiazol-2-yl)-3-(3,4-dichlorobenzyl)urea was dissolved in 5 ml of 2 M methylamine solution in tetrahydrofuran. To the solution, 2.0 eq. of sodium triacetoxyborohydride was added and stirred overnight at room temp. The volatile was removed by evaporation and the residue was purified by column chromatography using 0-10% gradient of 7 N ammonia/MeOH and DCM to give the title compound.

Intermediate 10b: 1-(3-Fluorobenzyl)-3-(4-(1-(methylamino)ethyl)thiazol-2-yl)urea

[0611]

[0612]

The 1-(3-fluorobenzyl)-3-(4-(1-(methylamino)ethyl)thiazol-2-yl)urea was prepared following the same procedure described for Intermediate 10a using 3-fluoro-benzyl isocyanate in step one.

Intermediate 11: 1-(3,4-Dichlorobenzyl)-3-(4-((2,4-dimethoxybenzylamino) methyl)thiazol-2-yl) urea

[0613]

[0614]

1-(3,4-dichlorobenzyl)-3-(4-(iodomethyl)thiazol-2-yl)urea (Intermediate 6) was taken up in tetrahydrofuran and an excess of the 2,4-dimethoxy-benzylamine (20 eq.) was added. The reaction was allowed to stir overnight at room temperature. The volatiles were removed in vacuo. Resulting oil triturated with water to give a gooey solid. Water was decanted off and resulting residue was purified by column chromatography using 0-8% gradient of 7 N ammonia/MeOH and DCM to give 1-(3,4-Dichloro-benzyl)-3-{4-[(2,4-dimethoxy-benzylamino)-methyl]-thiazol-2-yl}-urea.

Intermediate 12: 1-(3,4-Dichlorobenzyl)-3-(4-((2-methoxyethylamino)methyl)thiazol-2-yl)urea

[0615]

[0616]

1-(4-Chloromethyl-thiazol-2-yl)-3-(3,4-dichloro-benzyl)-urea (Intermediate 2, 1 eq.) was taken up in NMP (0.3 M) and methoxyethylamine (2.2 eq.) was added. The reaction was heated overnight at 80° C. An aqueous workup was performed. The crude title compound was purified by column chromatography using 0-8% gradient of 7 N ammonia/MeOH and DCM.

Intermediate 13: 2-(2-(3-(3,4-Dichlorobenzyl)ureido)thiazol-4-yl)-N-methyl-2-(methylamino)acetamide

[0617]

[0618]

Step 1: Ethyl 2-(2-aminothiazol-4-yl)-2-oxoacetate (2.0 mmol) was dissolved in NMP (5 ml) and 3,4-dichlorobenzylisocyanate (2.0 eq.) was added and heated at 130 C under microwave irradiation for 30 minutes. The reaction solution was poured into water. The Ethyl 2-(2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)-2-oxoacetate precipitate was filtered, washed with water and tetrahydrofuran and dried.

[0619]

Step 2: Ethyl 2-(2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)-2-oxoacetate (800 mg) was dissolved in 2 M methylamine in tetrahydrofuran (20 ml) and NaCNBH3(2.2 eq.) was added and stirred at room temperature overnight. The title compound was purified by column using 0-10% gradient of 7 N ammonia/MeOH and DCM.

Intermediate 14: 1-(3,4-dichlorobenzyl)-3-(4-((2-hydroxyethylamino)methyl)thiazol-2-yl)urea

[0620]

[0621]

1-(3,4-Dichloro-benzyl)-3-(4-iodomethyl-thiazol-2-yl)-urea (Intermediate 6, 0.3 mmol) was taken up in tetrahydrofuran (5 ml) and 2-Amino-ethanol (20 eq.) was added. The reaction was stirred overnight at room temperature. Added a saturated solution of NaSO3(40 ml). Extracted this with EtOAc twice. The combined organic extracts were dried over Na2SO4, filtered and solvent removed in vacuo to give the title compound a solid.

Intermediate 15: tert-Butyl 2-(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methylamino)ethylcarbamate

[0622]

[0623]

Step 1: Preparation of 2-(3-(3-fluorobenzyl)ureido)thiazole-4-carboxylate according to the procedure described for Intermediate 10b, step 1 and step 2.

[0624]

Step 2: 2-(3-(3-fluorobenzyl)ureido)thiazole-4-carboxylate (4.08 mmol) is taken up in THF and solution is cooled to −78° C. Added LiAlH4(2.6 equivalents, 1M solution in THF). Stir at ambient temperature for 3 hours. Add slowly Na2SO4.10H2O (6.4 g), then NaHSO4(1.8 g). Stir for 30 hours. Aqueous workup with EtOAc. Crystallized from DCM/hexanes to give 1-(3-fluorobenzyl)-3-(4-(hydroxymethyl)thiazol-2-yl)urea in 79% yield.

[0625]

Step 3: The 1-(3-fluorobenzyl)-3-(4-(hydroxymethyl)thiazol-2-yl) urea is taken up in DCM and cooled to 0° C. and Dess-Martin oxidant (1.1 equiv) was added. Stirred at ambient temperature for 1 hour. Washed with dilute Na2SO3. Removed solvent in vacuo to give 1-(3-fluorobenzyl)-3-(4-formylthiazol-2-yl)urea (used directly in next step).

[0626]

Step 4: Reductive amination with tert-butyl 2-aminoethylcarbamate (1.5 equiv) and the aldehyde (1.0 equiv) described in the previous step. The two are combined in DCM and cooled to 0° C., and NaBH(OAc)3(2.0 equiv) is added. Stirred at 0° C. for 1 hour. Quenched with dilute NaHCO3. Purified by column chromatography with a gradient of 2-5% MeOH in DCM to give the title compound.

Intermediate 16: tert-Butyl 4-(chloromethyl)thiazol-2-ylcarbamate

[0627]

[0628]

To a solution of N-Boc-thiourea (3.0 g, 17 mmol) in acetone (75 mL) was added 1,3-dichloroacetone (2.4 g, 18.7 mmol) at once. The mixture was stirred at room temperature for 72 h. The reaction mixture was treated with 3 g of NaHCO3and stirred for 15 min. The solids were removed by filtration and the filtrate was concentrated in vacuo. Column chromatography (EtOAc/Heptanes 4/1) afforded N-Boc-4-(chloromethyl)thiazol-2-amine (2.9 g, 11.6 mmol, 68%) as a white solid.

Intermediate 17: tert-Butyl 4-((methylamino)methyl)thiazol-2-ylcarbamate

[0629]

[0630]

tert-Butyl 4-(chloromethyl)thiazol-2-ylcarbamate (8.0 g, 24.16 mmol) was dissolved in 2.0 M methylamine in tetrahydrofuran (640 mL, ˜40 eq.) and heated in the microwave for 60 minutes at 60° C. The precipitate (impurity) was filtered off and the filtrate was concentrated under reduced pressure to furnish 1.97 g product as orange foam.1H NMR (DMSO-d6): δ 11.79 (s, br, 1H), 7.50 (s, 1H), 7.36 (d, 1H), 7.10 (m, 2H), 5.14 (s, br, 1H), 4.63 (s, 2H), 4.36 (s, 2H), 3.83 (t, 2H), 3.43 (t, 2H).

Intermediate 18: (4-{[Methyl(3,5-dimethylisoxazole-4-carbonyl)-amino]-methyl}-thiazol-2-yl) carbamic acid phenyl ester

[0631]

[0632]

Step 1: The crude tert-butyl 4-((methylamino)methyl)thiazol-2-ylcarbamate (Intermediate 17, 7.78 g, 32 mmol) was dissolved in DCM (100 mL) and DIPEA (6.34 mL, 38 mmol, 1.2 eq.) was added. This mixture was stirred for 5 minutes and 3,5-dimethylisoxazole-4-carbonylchloride (5.45 mL, 0.035 mmol, 1.1 eq.) was added and the reaction mixture was stirred at ambient temperature overnight. After work-up and purification by column chromatography (silica gel, 3% MeOH/DCM) the tert-butyl 4-((N,3,5-trimethylisoxazole-4-carboxamido)methyl) thiazol-2-ylcarbamate was furnished (6.7 g, ca. 80% purity).1H NMR (DMSO-d6): 11.79 (s, br, 1H), 7.50 (s, 1H), 7.36 (d, 1H), 7.10 (m, 2H), 5.14 (s, br, 1H), 4.63 (s, 2H), 4.36 (s, 2H), 3.83 (t, 2H), 3.43 (t, 2H).

[0633]

Step 2: The crude tert-butyl 4-((N,3,5-trimethylisoxazole-4-carboxamido)methyl) thiazol-2-ylcarbamate (6.7 g) was dissolved in an excess of 4M HCl in dioxane (300 mL). The reaction was stirred at 40 C for 2 hours. Volatiles were removed under reduced pressure and 6.16 g of N-((2-aminothiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide hydrochloride was obtained.1H-NMR (DMSO-d6): δ 11.79 (s, br, 1H), 7.50 (s, 1H), 7.36 (d, 1H), 7.10 (m, 2H), 5.14 (s, br, 1H), 4.63 (s, 2H), 4.36 (s, 2H), 3.83 (t, 2H), 3.43 (t, 2H).

[0634]

Step 3: N-((2-aminothiazol-4-yl)methyl)-N,3,5-trimethylisoxazole-4-carboxamide hydrochloride (6.16 g, 20.34 mmol) was dissolved in pyridine (35 mL) and DMAP (150 mg, 5 mol %) was added. The solution was cooled to 0° C. and a solution of phenylchloroformate (2.55 mL, 3.18 g, 20.34 mmol) in tetrahydrofuran (35 mL) was added dropwise. The mixture was stirred overnight at room temperature and the volatiles were evaporated in vacuo. The residue was taken up in water/EtOAc. The organic phase was dried over MgSO4and the volatiles were evaporated under reduced pressure. The material was crystallized from EtOAc/i-Pr2O to afford (4-{[methyl(3,5-dimethylisoxazole-4-carbonyl)-amino]-methyl}-thiazol-2-yl) carbamic acid phenyl ester (1.80 g) as a tan-colored solid (purity ˜85%).1H NMR (CDCl3): δ 9.85 (bs, 1H), 7.45 (m, 2H), 7.25 (m, 2H), 7.20 (m, 2H), 6.80 (b, 1H), 4.75 (bs, 1H), 4.45 (bs, 1H), 3.00 (bs, 3H), 2.36 (s, 3H), 2.24 (s, 3H).

Intermediate 19: 1-(3-Fluorobenzyl)-3-(4-((2-hydroxyethylamino)methyl)thiazol-2-yl)urea

[0635]

[0636]

1-(3-Fluorobenzyl)-3-(4-(iodomethyl)thiazol-2-yl)urea (Intermediate 7) was taken up in tetrahydrofuran and an excess of the 2-amino-ethanol (20 equiv.) was added. The reaction was allowed to stir overnight at room temperature. The reaction was poured into water and extracted with EtOAc, partitioned with brine, dried over Na2SO4, filtered, and volatiles were removed in vacuo. The resulting solid was triturated with EtOAc, followed by diethyl ether to give the title compound.

Intermediate 20: 1-(3,5-Difluorobenzyl)-3-(4-((methylamino)methyl)thiazol-2-yl)urea

[0637]

[0638]

Step 1: A 3-neck 500 ml round bottle flask was charged with 4-Chloromethyl-thiazol-2-ylamine hydrochloride (Intermediate 1, 1 eq.) and CDI (1.05 eq.) and purged with nitrogen. Anhydrous THF was added via cannula. To the resulting stirring granular suspension was added DIPEA (1.05 eq.) dropwise via an addition funnel. After the addition of DIPEA was complete, the 3,5-difluoro-benzyl amine (1.0 eq.) was added dropwise in the same manner. The reaction was quenched with DI water and the THF was removed in vacuo. The resulting orange residue was partitioned with water and DCM. The organic layer was dried with Na2SO4, filtered and solvent was removed in vacuo. The crude was purified by column chromatography (acetone/hexanes) followed by recrystallization from iPrOAc and hexanes. The solid was isolated via filtration and dried under vacuum to give 1-(4-Chloromethyl-thiazol-2-yl)-3-(3,5-difluoro-benzyl)-urea.

[0639]

Step 2: The title compound was prepared from the above 1-(4-Chloromethyl-thiazol-2-yl)-3-(3,5-difluoro-benzyl)-urea following the procedure described for Intermediate 3.

Intermediate 21: 1-(4-(Chloromethyl)thiazol-2-yl)-1-(2,4-dimethoxybenzyl)-3-(3-fluorobenzyl)urea

[0640]

[0641]

Step 1: The HCl salt of 4-(chloromethyl)thiazol-2-amine (10 mmol) was suspended in DCM (50 ml), and 2,4-dimethoxybenzaldehyde (1.0 eq. of) and DIEA (1.0 eq.) were added. To the mixture, acetic acid (1 ml) was added followed by addition of sodium triacetoxyborohydride (2.5 eq.) and the reaction was stirred at room temperature overnight. The reaction mixture was filtered through Celite and washed with DCM. The filtrate was concentrated and purified by column chromatography using 0-10% gradient of 7 N ammonia/MeOH and DCM to give 4-(chloromethyl)-N-(2,4-dimethoxybenzyl)thiazol-2-amine.

[0642]

Step 2: The 4-(chloromethyl)-N-(2,4-dimethoxybenzyl)thiazol-2-amine was dissolved in DCM (50 ml) and 3-fluorobenzylisocyanate (1.2 eq.) was added and stirred overnight. The mixture was concentrated and the residue was purified on a column using 0-100% gradient of EtOAc and hexanes to give the title compound.

Intermediate 22: (4-{[Methyl-(3-methyl-pyrazine-2-carbonyl)-amino]-methyl}-thiazol-2-yl)-carbamic acid phenyl ester

[0643]

[0644]

Step 1: To a solution of tert-butyl 4-((methylamino)methyl)thiazol-2-ylcarbamate (Intermediate 17, 1.30 g, 5.3 mmol) and 3-methylpyrazine-2-carboxylic acid (1.1 g, 8 mmol) in CH2Cl2 (25 mL) was added DCC (1.64 g, 8 mmol). The mixture was stirred for 2 hours and the solids were removed by filtration. The filtrate was concentrated in vacuo and purified by column chromatography (2% MeOH in CH2Cl2, Rf=0.15) to afford tert-butyl 4-((N,2-dimethylpyrazine-3-carboxamido)methyl)thiazol-2-ylcarbamate (1.30 g, 3.6 mmol) as an off-white solid in 68% yield.

[0645]

Step 2: A solution of tert-butyl 4-((N,2-dimethylpyrazine-3-carboxamido)methyl)thiazol-2-ylcarbamate (1.30 g, 3.6 mmol) in dioxane (10 mL) was treated with 4N HCl in dioxane (10 mL) for 2 hours. The resulting suspension was concentrated in vacuo to afford N-((2-aminothiazol-4-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide (1.10 g).

[0646]

Step 3: A mixture of N-((2-aminothiazol-4-yl)methyl)-N,3-dimethylpyrazine-2-carboxamide (555 mg, 1.84 mmol) and DMAP (20 mg) in pyridine (10 mL) was cooled to 0° C. and a solution of phenyl chloroformate (433 mg, 2.8 mmol) in THF was added drop wise. The mixture was stirred overnight and all volatiles were removed in vacuo at 30° C. The residue was triturated with TBME to afford (4-{[Methyl-(3-methyl-pyrazine-2-carbonyl)-amino]-methyl}-thiazol-2-yl)-carbamic acid phenyl ester (125 mg) as a tan colored solid (purity 96%).

Intermediate 23: 3-((2-(3-(3,4-Dichlorobenzyl)ureido)thiazol-4-yl)methylamino) propylphosphonic acid

[0647]

[0648]

Step 1: 0.58 g of 2-(3-(3,4-dichlorobenzyl)ureido)thiazole-4-carboxylic acid was dissolved in 15 ml of DMF and 3.0 eq. of DIEA and 1.05 eq. of TBTU was added. To the mixture, 1.2 eq. of N,O-dimethylhydroxylamine HCl salt was added and the reaction was stirred at room temp. overnight. The product was precipitated from water, filtered, washed with water and dried to give 2-(3-(3,4-dichlorobenzyl)ureido)-N-methoxy-N-methylthiazole-4-carboxamide.

[0649]

Step 2: 1.0 g of 2-(3-(3,4-dichlorobenzyl)ureido)-N-methoxy-N-methylthiazole-4-carboxamide was dissolved in 20 ml dry tetrahydrofuran and cooled to −78 C. 1.10 eq. of 1 N lithium aluminum hydride in tetrahydrofuran was added slowly. The reaction was stirred at 0 C for 2 hours. The reaction was cooled to −78 C again and quenched with 1 N HCl and extracted with EtOAc three times. The organic was combined, dried over sodium sulfate and concentrated. The residue was purified by column chromatography using 0-100% gradient of EtOAc and hexanes to give 1-(3,4-dichlorobenzyl)-3-(4-formylthiazol-2-yl)urea.

[0650]

Step 3: 300 mg of 1-(3,4-dichlorobenzyl)-3-(4-formylthiazol-2-yl) urea was dissolved in 5 ml MeOH. 1.0 eq. of tetrabutylammonium bromide and 1.0 eq. of sodium hydroxide were added followed by addition of 1.0 eq. of 3-aminopropylphosphonic acid. To the mixture, 3.0 eq. of sodium cyanoborohydride was added and the reaction was stirred at room temp. overnight. The reaction mixture was loaded to reverse phase column and purified by HPLC to give 3-((2-(3-(3,4-dichlorobenzyl)ureido)thiazol-4-yl)methylamino)propylphosphonic acid.

Intermediate 24: 1-(4-(1-Amino-2-hydroxyethyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea

[0651]

[0652]

Step 1: An N-methylpyrrolidinone (5 mL) solution of ethyl 2-(2-aminothiazol-4-yl)-2-oxoacetate (commercial, 1.00 g, 5.0 mmol) and 1-fluoro-3-(isocyanatomethyl)benzene (831 mg, 5.5 mmol) was heated in a microwave reactor at 120 C for 30 minutes. Upon cooling, water (50 mL) was added with vigorous stiffing. Filtration of the precipitate afforded ethyl 2-(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)-2-oxoacetate. M/Z 352 (M+H)+. The filtrate was dissolved in EtOH (100 mL) then hydroxylamine hydrochloride (700 mg, 10 mmol) and sodium acetate (1.07 g, 13 mmol) were added to the mix. The solution was stirred at 75 C for 4 hours and filtered while hot. Evaporation of the mixture and Flash chromatography afforded ethyl 2-(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)-2-(hydroxyimino)acetate as a mixture of isomers. M/Z 367 (M+H)+.

[0653]

Step 2: LiAlH4(10 mL, 10 mmol, 1 M in THF) was added to a THF (20 mL) solution of ethyl 2-(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)-2-(hydroxyimino)acetate (1.05 g, 2.86 mmol). The mixture was stirred for a day at 50 C. Upon cooling the mixture to 0 C, Na2SO4x10H2O (9.2 g, 28.6 mmol) was added carefully. The suspension was stirred for two days at ambient temperature which was followed by the addition of NaHSO4(1.2 g, 28.6 mmol) and MeOH (20 mL). The mixture is further stirred for an hour then HCl (5 mL, 2 M in ether) was added. Stirring was continued for another hour. Filtration, evaporation of the filtrate and Flash chromatography afforded 1-(4-(1-amino-2-hydroxyethyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea.1H NMR (400 MHz, MeOH): δ 7.28 (m, 1H), 7.09 (d, 1H), 7.01 (d, 1H), 6.92 (td, 1H), 6.81 (s, 1H), 4.42 (s, 2H), 4.10 (m, 1H), 3.84 (dd, 1H), 3.72 (dd, 1H). MS (ES+): M/Z 311 (M+H)+.

Intermediate 25: 1-(3-Fluorobenzyl)-3-(5-isopropyl-4-((methylamino)methyl)thiazol-2-yl)urea

[0654]

[0655]

Step 1: A THF (5 mL) solution of methy; 2-amino-5-isopropylthiazole-4-carboxylate (commercially available, 200 mg, 1 mmol) and 1-fluoro-3-(isocyanatomethyl)benzene (140 μL, 1.1 mmol) was microwave irradiated at 160 C for 35 minutes. Usual work-up concluded with recrystallization from MeOH afforded methyl 2-(3-(3-fluorobenzyl)ureido)-5-isopropylthiazole-4-carboxylate.1H NMR (400 MHz, DMSO-d6): δ7.35 (m, 1H), 7.08 (m, 3H), 4.34 (d, 2H), 3.94 (m, 1H), 3.76 (s, 3H), 1.24 (d, 6H). MS (ES+): M/Z 452 (M+H)+.

[0656]

Step 2: LiAlH4(5.5 mL, 5.5 mmol, 1 M in THF) was added to a THF (30 mL) solution of methyl 2-(3-(3-fluorobenzyl)ureido)-5-isopropylthiazole-4-carboxylate (780 mg, 2.22 mmol) at 0 C. Upon completion of the reaction Na2SO4x10H2O (1.5 g, 4.5 mmol) was added carefully. The suspension was stirred for a day at ambient temperature which was followed by the addition of NaHSO4(0.5 g, 4.5 mmol) and MeOH (5 mL). The mixture extracted with CH2Cl2, washed with dilute HCl, dried and evaporated to afford 1-(3-fluorobenzyl)-3-(4-(hydroxymethyl)-5-isopropylthiazol-2-yl)urea.1H NMR (400 MHz, CDCl3): δ 7.70 (s, 1H, br), 7.24 (m, 1H), 7.05 (d, 1H), 6.99 (d, 1H), 6.92 (td, 1H), 4.55 (s, 2H), 4.41 (d, 2H), 3.20 (m, 1H), 1.27 (d, 6H). MS (ES+): M/Z 324 (M+H)+.

[0657]

Step 3: 1-(3-Fluorobenzyl)-3-(4-(hydroxymethyl)-5-isopropylthiazol-2-yl)urea (32 mg, 0.1 mmol) was oxidized with MnO2(87 mg, 1.0 mmol) in CH2Cl2(5 mL). Filtration and evaporation afforded 1-(3-fluorobenzyl)-3-(4-formyl-5-isopropylthiazol-2-yl)urea.1H NMR (400 MHz, CDCl3): δ 9.83 (s, 1H), 7.60 (s, 1H, br), 7.27 (m, 1H), 7.12 (d, 1H), 7.06 (d, 1H), 6.93 (td, 1H), 4.48 (d, 2H), 3.80 (m, 1H), 1.42 (d, 6H). MS (ES+): M/Z 322 (M+H)+.

[0658]

Step 4: NaBH4(100 mg, 3 mmol) was added in portions to a mixture of MeNH2(5 mL, 30% in EtOH) and 1-(3-fluorobenzyl)-3-(4-formyl-5-isopropylthiazol-2-yl)urea (322 mg, 1 mmol) at 0 C. The mixture was stirred for 6 hours then quenched with dilute HCl solution. Basic aqueous work-up with CH2Cl2followed by flash chromatography afforded 1-(3-fluorobenzyl)-3-(5-isopropyl-4-((methylamino)methyl)thiazol-2-yl)urea. MS (ES+): M/Z 337 (M+H)+.

Intermediate 26: 1-(4-((2,2-Difluoroethylamino)methyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea

[0659]

[0660]

1-(4-Iodomethyl-thiazol-2-yl)-3-(3-fluorobenzyl)-urea (Intermediate 7, 1 eq.) was taken up in THF (0.3 M) and 2,2-difluoroethanamine (20 eq.) was added. The reaction was stirred overnight at ambient temperature. Some of the starting material, Intermediate 7 remained. Added additional 2,2-difluoroethanamine (10 equivalents). The reaction was complete after 2-4 hours. Removed solvent; coevaporated twice with MeOH. Crude is a 1:1 mixture of title compound and bis addition impurity. (used as is in subsequent step).

Intermediate 27: Not used

Intermediate 28: N-(4-((methoxy(methyl)amino)methyl)thiazol-2-yl)-1H-imidazole-1-carboxamide

[0661]

[0662]

Step 1: 2-Amino-4-(N-methoxy-N-methyl-aminomethyl)thiazole. A mixture of 2-amino-4-chloromethyl-thiazole hydrochloride (27.8 g, 0.15 mol), N,O-dimethylhydroxylamine hydrochloride (87.8 g, 0.90 mol), and anhydrous THF (300 mL) was rapidly stirred and DIPEA (157 mL, 0.90 mol) was added. The resulting mixture was heated at 60 C for 10-15 hours. The mixture was cooled in an ice/salt bath and the solid byproduct (DIPEA hydrochloride) was removed by filtration and washed with cold THF (300 mL). The combined filtrate was concentrated to afford the title compound as a dark oil (31 g, >100% theory), which partially crystallized on standing. This product was used in the next step without further purification.

[0663]

Step 2: 2-(N-Imidazocarbonylamino)-4-(N-methoxy-N-methyl-aminomethyl)thiazole. A flask was purged with dry nitrogen and charged with carbonyl diimidazole (37.2 g, 0.222 mol) and anhydrous THF (0.4 L). The mixture was stirred and heated to 27-32 C, affording a clear solution. A solution of crude 2-amino-4-(N-methoxy-N-methyl-aminomethyl)thiazole (31 g (as is), ˜0.15 mol) in anhydrous THF (0.1 L) was added dropwise. The resulting cloudy reaction mixture was cooled to room temperature and stirred overnight affording a thick slurry. The solids were isolated by filtration, washed with diethyl ether (80 mL), and dried in vacuo (no heat) to afford the title compound as an off-white solid (20.0 g, 0.075 mol, 50% yield for 2-steps).

Intermediate 29: 1-[(5-Chlorothiophen-2-yl)methyl)-3-(4-((methylamino)methyl) thiazol-2-yl]urea

[0664]

[0665]

Step 1: Intermediate 28 (imidazolide) was reacted with C-(5-chlorothiophen-2-yl)methylamine using Method 7.

[0666]

Step 2: The methoxyamine-urea product obtained in Step 1 was reduced with micronized zinc dust in acetic acid, following the procedure for Intermediate 5/Alternative Process/Step 2, to afford Intermediate 29.

Intermediate 30: 1-((5-Chlorothiophen-3-yl)methyl)-3-(4-((methylamino)methyl) thiazol-2-yl) urea

[0667]

[0668]

Step 1: Intermediate 28 (imidazolide) was reacted with Intermediate 37 (amine) using Method 7.

[0669]

Step 2: The methoxyamine-urea product obtained in Step 1 was reduced with micronized zinc dust in acetic acid, following the procedure for Intermediate 5/Alternative Process/Step 2, to afford intermediate 30.

Intermediate 31: 5-(Methoxymethyl)-3-methylisoxazole-4-carboxylic acid

[0670]

[0671]

Step 1: A mixture of methyl 4-methoxyacetoacetate (34.2 mmol, 5 g) and pyrrolidine (1.1 eq, 37.6 mmol, 2.6 g) in toluene (50 ml) was refluxed under Dean-Stark-conditions for 14 h. The solvent was then removed under reduced pressure. The remaining oil was dissolved in chloroform (50 ml) and nitroethane (3 eq, 102.6 mmol, 7.69 g) and triethylamine (1.1 eq, 37.6 mmol, 3.79 g) were added. The mixture was cooled to 0° C. before dropwise addition of a solution of phosphorus oxychloride (1.1 eq, 37.6 mmol, 5.75 g) in chloroform (20 ml). The mixture was stirred over night at room temperature and then poured into water (20 ml). The organic layer was washed successively with hydrochloric acid (20 ml), aqueous sodium hydroxide (5% w/v, 50 mL) and brine (50 mL), dried (Na2SO4) and concentrated. After column chromatography, 1.47 g of methyl 5-(methoxymethyl)-3-methylisoxazole-4-carboxylyate was isolated.1H NMR (300 MHz, CDCl3), δ 4.80 (s, 2H), 3.87 (s, 3H), 3.45 (s, 3H), 2.45 (s, 3H).

[0672]

Step 2: The methyl ester obtained in Step 1 (7.8 mmol, 1.4 g) was dissolved in tetrahydrofuran/water (20 ml, 10:1). Lithium hydroxide (1.1 eq, 8.68 mmol, 0.21 g) was added and the mixture was stirred at room temperature over night. The solvent was removed under reduced pressure to give the title compound as a white solid (0.85 g, 60% yield).1H NMR (300 MHz, CD3OD): δ 4.83 (s, 2H), 3.41 (s, 3H), 2.42 (s, 3H).

Intermediate 32: 5-Methylpyridazine-4-carboxylic acid

[0673]

Intermediate 33: 4-Methylpyridazine-3-carboxylic acid

[0674]

[0675]

Step: 1: Ethyl pyruvate (4.5 eq, 66.9 g) was cooled to −10° C. and H2O2(3.0 eq, 37.3 g) was added drop wise keeping the temperature below 0° C. Subsequently, the mixture was stirred for 15 minutes. A solution of 4-methylpyridazine (12.05 g, 128 mmol), FeSO47H2O (3.0 eq, 106.8 g), H2SO4(36 g) in H2O (35 mL)/CH2Cl2(270 mL) was cooled to −5° C. The mixture of H2O2and ethyl pyruvate was added drop wise keeping the temperature below 0° C. and stirred for 15 minutes. The reaction mixture was poured into H2O/EtOAc mixture and stirred for 3 hours. The H2O-layer was removed and the organic layer was stirred overnight with aq. Na2SO3. Subsequently, the layers were separated and the organic layer was washed twice with H2O and dried over MgSO4. Removal of the volatiles afforded a mixture of ethyl 5-methylpyridazine-4-carboxylate and ethyl 4-methylpyridazine-3-carboxylate and 3 other compounds (29.0 g) as a yellow/orange oil.

[0676]

The crude material was purified by silica chromatography, affording a mixture of ethyl 5-methylpyridazine-4-carboxylate and ethyl 4-methylpyridazine-3-carboxylate and another compound (3.7 g) as a yellow oil. The mixture was again purified by column chromatography (SiO2; CH2Cl2/EtOAc 9:1-8:2) affording Ethyl 5-methylpyridazine-4-carboxylate (614 mg, 29% yield) as a yellow oil and Ethyl 4-methylpyridazine-3-carboxylate (447 mg, 23% yield) as a yellow oil/solid.

[0677]

Intermediate 32: To a solution of ethyl 5-methylpyridazine-4-carboxylate (240 mg, 1.4 mmol) in H2O/THF was added 7.5 N aq. NaOH (1.25 eq, 0.25 mL) and the mixture was stirred for 1 hour at 60° C. Concentrated HCl was added to pH 2 and subsequently the volatiles were removed in vacuo. The residue was first stirred with EtOAc and the solids were collected by filtration. Then stirred with THF and the solids were again collected by filtration. The solids were extracted with MeOH and removal of the volatiles afforded 5-methylpyridazine-4-carboxylic acid (358 mg) as a brown solid.

[0678]

Intermediate 33: To a solution of ethyl 4-methylpyridazine-3-carboxylate (240 mg, 1.4 mmol) in H2O/THF was added 7.5 N aq. NaOH (1.25 eq, 0.25 mL) and the mixture was stirred for 1 hour at 60° C. Concentrated HCl was added to pH 2 and subsequently the volatiles were removed in vacuo. The residue was first stirred with EtOAc and the solids were collected by filtration then stirred with THF and the solids were again collected by filtration. The solids were extracted with MeOH and removal of the volatiles afforded 4-methylpyridazine-3-carboxylic acid (328 mg) as a brown solid.

Intermediate 34: 3-Methyl-pyrazine-2-carboxylic acid

[0679]

[0680]

A solution of dimethylpyrazine (25 g, 231 mmol) in water (250 mL) was heated at 70° C. and a solution of KMnO4(82.2 g, 520 mmol) in water was added at such a rate to maintain the temperature between 70 and 75° C. The mixture was stirred until the purple color vanished and was filtered over Celite. The aqueous solution was extracted with EtOAc (6×800 mL), dried over Na2SO4and concentrated in vacuo. The residue was titrated with TBME to afford 3-methylpyrazine-2-carboxylic acid (9.3 g, 67 mmol) as a white solid in 30% yield.

Intermediate 35: 3-(Ethoxycarbonyl)-5-methylisoxazole-4-carboxylic acid

[0681]

[0682]

Step 1: To a solution of tert-butyl acetoacetate (42.1 mmol, 6.6 g) and ethyl cyanoformate (1.2 eq, 50.5 mmol, 5.0 g) in dry DCM (20 ml) [Zn(acac)2] (2.1 mmol, 0.55 g) was added. After stirring at room temperature for 2 hours, TLC indicated complete conversion. The solvent was evaporated under reduced pressure, the residue was dissolved in ethyl ether and the suspension was filtered through Celite. After concentration, 2-acetyl-3-oxo-succinic acid 1-tert-butyl ester 4-ethyl ester (8.93 g, 82% yield) was obtained as a yellow oil.

[0683]

Step 2: The 1,3-diketone obtained in Step 1 (34.7 mmol, 8.9 g) was dissolved in chloroform (50 ml). 4.91 g of triethylamine (1.4 eq, 48.6 mmol) and hydroxylamine-HCl salt (1.3 eq, 45.1 mmol, 3.13 g) were added and the mixture was refluxed for 3 h. The reaction was cooled to room temperature and 1N aq. HCl (100 ml) was added followed by extraction with DCM (3×100 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated. Column purification by silica gel yielded (6.89 g, 77% yield) of tert-butyl 3-(ethoxycarbonyl)-5-methylisoxazole-4-carboxylate.1H NMR (300 MHz, CDCl3), δ 4.42 (q, 2H), 2.66 (s, 3H), 1.53 (s, 15H), 1.39 (t, 3H).

[0684]

Step 3: The tert-butyl ester obtained in Step 2 (0.8 g, 3.13 mmol) was dissolved in formic acid (20 mL) and stirred at room temperature overnight. 6N aq. HCl (50 ml) was added. The mixture was extracted with DCM (3×50 mL). The combined organic layers were dried over sodium sulfate and concentrated to give the title compound, Intermediate 35: 3-(ethoxycarbonyl)-5-methylisoxazole-4-carboxylic acid, as a brownish oil (0.4 g, 64%).1H NMR (300 MHz, MeOH-d4): δ 4.40 (q, 2H), 2.68 (s, 3H), 1.35 (t, 3H).

Intermediate 36: C-(5-Fluoro-thiophen-2-yl)-methylamine

[0685]

[0686]

Step 1: Synthesis of 5-fluoro-thiophene-2-carbonitrile starting from 5-nitro-thiophene-2-carbonitrile following a literature procedure: Syn Comm 30 (19) 3629-3632 (2000).

[0687]

Step 2: A 500 ml 3 neck flask was fitted with septum, N2inlet, and an addition funnel. Under N2, the flask was charged with LAH (130 ml of a 1M solution of LAH in diethyl ether), and cooled in an ice bath with stirring. Added the 5-Fluoro-thiophene-2-carbonitrile (9.43 g) as a solution in dry diethyl ether (15 mL) over 30 minutes via addition funnel. After addition, the reaction was allowed to warm to room temperature over an hour. The resulting thin mixture was diluted with diethyl ether (200 ml) and then slowly, 2N NaOH (25 ml) was added dropwise. Stirred overnight; a tan mass was present. Filtered the diethyl ether layer. The tan mass was broken up and titrated with diethyl ether (50 ml) and then filtered. The diethyl ether portions were combined and the solvent removed in vacuo. Dried overnight under reduced pressure to give a clear orange oil. Distilled at 68-70° C. (10 mm) to give C-(5-fluoro-thiophen-2-yl)-methylamine as a clear colorless liquid.

Intermediate 37: (5-Chlorothiophen-3-yl)methanamine hydrochloride

[0688]

Step 1: To a solution of N-chlorosuccinimide (1.0 eq, 12.2 g) in hexane (100 mL) were added thiophene-3-carbonitrile (10 g, 91.6 mmol) and 70% HClO4(1 mol %, 0.1 mL). The reaction mixture was stirred overnight at room temperature and subsequently K2CO3was added. Removal of the solids and the volatiles afforded the crude product as a yellow oil. (This was a mixture of starting material: desired product: wrong isomer: dichlorinated 48%:26%:19%:6%.) Purification twice by column chromatography afforded 5-chlorothiophene-3-carbonitrile (1.71 g, 13%) as a yellow oil.

[0689]

Step 2: To a pre-cooled (ice-water bath) solution of BH3.THF (3.4 eq, 11.8 mL) was added a solution of 5-chlorothiophene-3-carbonitrile (0.5 g, 3.48 mmol) in THF (11.5 ml). The reaction mixture was stirred for 4 hours at room temperature and subsequently 6 N HCl (17 ml) was added slowly followed by H2O/MeOH (17/114 mL). The reaction mixture was stirred overnight. Removal of the volatiles afforded the title product (1.0 g) as an off-white solid.

Intermediate 38: 3-Chloromethyl-[1,2,4]thiadiazol-5-ylamine

[0690]

[0691]

2-Chloroacetamidine hydrochloride (10.3 g, 80 mmol) was dissolved in anhydrous MeOH (300 mL) and then cooled to 0 C. TEA (20.2 g, 200 mol) was added followed by bromine (11.5 g, 72 mmol, dropwise over 5 minutes at 0 C). Potassium thiocyanate (8.15 g, 84 mmol) in MeOH (100 mL) was added dropwise over 1 hour and the resultant mixture was stirred at 0 C for 2 hours. Reaction was maintained at ambient temperature for 1 h. Solid was removed by filtration and filtrate concentrated in vacuo. This syrupy residue was treated with EtOAc (300 mL) followed by filtration and purification by silica gel chromatography (PE:EA=4:1 to 3:1) to afford Intermediate 67: 3-chloromethyl-[1,2,4]thiadiazol-5-ylamine as white solid (5 g, 42%).1H-NMR (400 MHz, DMSO-d6) δ: 8.03 (s, 2H, —NH2), 4.51 (s, 2H, —CH2Cl); LC-MS (m/z): 150.1 μM+Hr.

Intermediate 39: (3-{[Methyl-((R)-tetrahydro-furan-2-carbonyl)-amino]-methyl}-[1,2,4]thiadiazol-5-yl)-carbamic acid phenyl ester

[0692]

[0693]

Step 1: 3-Chloromethyl-[1,2,4]thiadiazol-5-ylamine (Intermediate 38) (1.5 g, 10 mmol) was dissolved in 27% methylamine alcohol solution (20 mL, 174 mmol) to give a yellowish solution. The solution was heated in microwave reactor at 60 C for 15 min After cooling to room temperature, the reaction mixtures were combined and concentrated at room temperature (20-25 C; attention: the product is sensitive to heat). A solution of potassium carbonate (9.7 g, 70 mmol) in water (15 mL) was added into the residue and the resultant mixture was concentrated to dryness. The crude product was purified by silica gel column chromatography (DCM:MeOH=5:1) to afford 3-(N-methylaminomethyl)[1,2,4]thiadiazol-5-ylamine (14.0 g, yield: 69%) as a yellow solid. LC-MS (m/z): 145.1 [M+H]+.

[0694]

Step 2: To a solution of (R)-tetrahydrofuran-2-carboxylic acid (5.0 g, 43 mmol) in DMF (100 mL) was added carbonyl diimidazole (7.68 g, 47 mmol) at 0 C under N2. After 2 hours agitation at 0 C, the product obtained from Step 1 (7.0 g, 49 mmol) in DMF (20 mL) was added and the mixture was stirred at room temperature overnight. The reaction mixture was then diluted with water (800 mL), extracted with EA (10×200 mL). The combined organic layers were washed twice with brine (100 mL) and concentrated. The residue was purified by silica gel column chromatography (PE:EA=1:3) to afford (R)-tetrahydro-furan-2-carboxylic acid (5-amino-[1,2,4]thiadiazol-3-ylmethyl)-methyl-amide (5.9 g, yield: 59%) as a red syrup. LC-MS (m/z): 243.1 [M+H]+.

[0695]

Step 3: To a solution of the product from Step 2, (R)-tetrahydro-furan-2-carboxylic acid (5-amino-[1,2,4]thiadiazol-3-ylmethyl)-methyl-amide (3.0 g, 12.4 mmol), and pyridine (1.08 g, 13.6 mmol) in DCM (120 mL) was added phenyl chloroformate (1.95 g, 12.4 mmol) by syringe at 0 C under N2. The reaction mixture was stirred at room temperature overnight, concentrated and purified by silica gel column chromatography (PE:EA=1:1) to afford Intermediate 39: (3-{[methyl-((R)-tetrahydro-furan-2-carbonyl)-amino]-methyl}-[1,2,4]thiadiazol-5-yl)-carbamic acid phenyl ester (3.0 g, yield: 67%) as a pale solid. LC-MS (m/z): 363.1 [M+H]+.

Intermediate 40: 2-(3-(3-Fluorobenzyl)ureido)-4-(N-methyl-aminomethyl)-5-fluorothiazole

[0696]

[0697]

Step 1: 2-(tert-Butoxycarbonylamino)-4-(N-methoxy-N-methyl-aminomethyl)thiazole. A mixture of Intermediate 28: 2-(N-imidazocarbonylamino)-4-(N-methoxy-N-methyl-aminomethyl)thiazole (23.3 g, 87.2 mmol) and anhydrous tert-butanol (140 mL) was stirred under an inert atmosphere and heated to 80 C. After 20 minutes, a clear solution was obtained. tert-Butanol was evaporated at reduced pressure and the oily residue was dissolved in hexane (200 mL) and washed with water (2×100 mL). The organic layer was dried over sodium sulfate, filtered and evaporated to afford the title compound as a colorless oil which crystallized on standing (21.4 g, 90% yield).

[0698]

[0699]

Step 2: Fluorination of Thiazole 5-Position (Organic Process R & D (10), 346-348 (2006)). 2-(tert-Butoxycarbonylamino)-4-(N-methoxy-N-methyl-aminomethyl)-5-fluorothiazole. A solution of 2-(tert-butoxycarbonylamino)-4-(N-methoxy-N-methyl-aminomethyl)thiazole (34.4 g, 0.126 mol) and anhydrous THF (0.71 L) was cooled to −78 C under an inert atmosphere. A solution of 1.6 M n-BuLi in hexane (165 mL, 0.264 mol) was added dropwise over 45 minutes. The resulting mixture was stirred at −78 C for 2-3 hours, then treated dropwise with a solution of N-fluorobenzenesulfonimide (51.6 g, 0.164 mol) in THF (0.3 L). The reaction was warmed to −10 C and quenched with 1 N HCl (0.28 L). The mixture was made alkaline with saturated sodium bicarbonate solution (˜200 mL) and extracted with diethyl ether (0.5 L). The organic layer was dried with magnesium sulfate and concentrated to leave a red oil (51 g) which was purified by silica gel chromatography (40% EtOAc/hexane) to afford the title compound as a yellow resin (15.1 g, 41% yield).

[0700]

[0701]

Step 3: 2-(3-(3-fluorobenzyl)ureido)-4-(N-methoxy-N-methyl-aminomethyl)-5-fluorothiazole. A solution of 2-(tert-butoxycarbonylamino)-4-(N-methoxy-N-methyl-aminomethyl)-5-fluorothiazole (3.6 g, 12.4 mmol) in 1,4-dioxane (60 mL) was saturated with dry HCl gas and held overnight. The mixture was evaporated to dryness to leave the 2-amino-5-fluorothiazole dihydrochloride salt (3.3 g, 100% yield).

[0702]

Step 4: The salt was suspended in anhydrous THF (50 mL) and DIPEA (4.3 mL, 25 mmol) was added. The resulting mixture was added to a solution of carbonyl diimidazole (2.07 g, 12.8 mmol) in THF (30 mL) at 30-35 C. After stirring overnight at room temperature, the solids were collected and washed with diethyl ether (5 mL) to give a 2-(N-imidazocarbonylamino)-5-fluorothiazole intermediate (2.1 g, 55% yield).

[0703]

Step 5: The imidazolide intermediate (2.0 g, 6 mmol) was suspended in THF (40 mL) and 3-fluorobenzylamine (0.71 mL, 6 mmol) was added slowly. After 1 hour, water (40 mL) was added and THF was evaporated at reduced pressure. Extraction with DCM (60 mL), drying over sodium sulfate, and concentration afforded the title compound as a pale yellow foam (2.05 g, 100% yield).

[0704]

[0705]

Step 6: 2-(3-(3-Fluorobenzyl)ureido)-4-(N-methyl-aminomethyl)-5-fluorothiazole (Intermediate 40). A solution of 2-(3-(3-fluorobenzyl)ureido)-4-(N-methoxy-N-methyl-aminomethyl)-5-fluorothiazole (2.05 g, 6 mmol) in glacial acetic acid (30 mL) was treated with micronized zinc dust (12 g) and stirred at 60 C for 1-2 hours. The mixture was diluted with water (30 mL) and filtered on Celite. The filter cake was washed with 1:1 HOAc:water (3×20 mL) and the combined filtrate were brought to pH 10 with ammonium hydroxide (−82 mL). The resulting mixture was stirred in ice and the crude product was collected by filtration and washed with water (4 mL). The crude product was further purified by silica gel chromatography (5:94:1 MeOH:DCM:NH4OH) to afford Intermediate 40 as a white solid (1.25 g, 67% yield).

Intermediate 41: 1-[4-(Cyano-methylamino-methyl)-thiazol-2-yl]-3-(3-fluoro-benzyl)-urea

[0706]

[0707]

Step 1: Preparation of acetic acid 2-amino-thiazol-4-ylmethyl ester. 1-Chloro-3-hydroxy-propan-2-one (15.06 g) and thiourea (8.36 g) were dissolved in EtOH (55 mL) and heated at reflux over 30 min. The reaction mixture was concentrated under reduced pressure to afford the desired product.

[0708]

Step 2: Preparation of -(3-fluoro-benzyl)-3-(4-hydroxymethyl-thiazol-2-yl)-urea. To a solution of acetic acid 2-amino-thiazol-4-ylmethyl ester (6.89 g) in THF (50 mL) were 3-fluorobenzylisocyanate (5.50 g) and TEA (5.03 mL) added. The resultant solution was heated at 70° C. over 2 h. Then, MeOH (30 mL) and NaOH (6N, 15 mL) were added to the above solution. The reaction mixture was heated at 60° C. for 30 min After cooling down, the reaction mixture was diluted with EtOAc (150 mL) and was washed with water. The organic solvents were concentrated and the residue was purified by silica-gel column chromatography to afford 8.29 g of the desired product-1-(3-fluoro-benzyl)-3-(4-hydroxymethyl-thiazol-2-yl)-urea.

[0709]

[0710]

Step 3: Preparation of 1-(3-fluoro-benzyl)-3-(4-formyl-thiazol-2-yl)-urea. (3-Fluoro-benzyl)-3-(4-hydroxymethyl-thiazol-2-yl)-urea (909.52 mg) was added in a solution of Dess-Martin periodinane (0.3 M, 10.8 mL) in DCM (100 mL) at 0° C. The reaction mixture was stirred at room temperature over a couple of hours until all starting materials were consumed. After concentration, the residue was recrystallized from DCM/Hexane to afford the desired product (580 mg).

[0711]

Step 4: Preparation of 1-[4-(cyano-methylamino-methyl)-thiazol-2-yl]-3-(3-fluoro-benzyl)-urea. Trimethylsilyl cyanide (161 μL) was added to a solution of 1-(3-fluoro-benzyl)-3-(4-formyl-thiazol-2-yl)-urea (409 mg) and MeNH2(8 M, 0.4 mL) in (EtOH 10 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The additional of 170 μL of trimethylsilyl cyanide was added to convert all starting material into the product. The product was purified by aqueous work-up and chromatography.

Intermediate 42: 1-(2-Methoxyethyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid

[0712]

[0713]

Sodium hydride (60%, 120 mg, 3.0 mmol) was suspended in THF (2 ml) at 0 C. Ethyl 3,5-dimethyl-1H-pyrazole-4-carboxylate (168 mg, 1.0 mmol) dissolved in THF (2 mL) was added drop-wise. Stirring was maintained until the evolution of hydrogen stopped. 1-Bromo-2-methoxyethane (208 mg, 1.5 mmol) was added and the reaction was heated at reflux at 70 C for 48 hours. Reaction was quenched with water at 0 C, acidified to pH=1-2 with HCl (2M) and was extracted with EtOAc. The organic layer was washed with water, NH4Cl aq., and brine, and dried with Na2SO4, and concentrated. The residue was subjected to HPLC purification. White solid (67 mg, 0.34 mmol, 34%) was obtained after stripping of solvents and drying. ESI-MS m/z 199.4 (M+H).

Intermediate 43: Tetrahydro-2H-pyran-2-carboxylic acid

[0714]

[0715]

(Tetrahydro-2H-pyran-2-yl)methanol (0.51 g, 4.30 mmol) was dissolved in 10 mL of 1:1 ACN/water mixture, and bis-acetoxyiodobenzene [BAIB] (3.04 g, 9.46 mmol) was added to the mixture. It was then cooled to 0 C in an ice bath, and TEMPO (0.134 g, 0.86 mmol) was added under argon flow. The mixture was stirred at room temperature for 3 hours, and the reaction was quenched by addition of 2×20 mL of 1 M NaOH. Basic solution was washed 3×30 mL of EtOAc, and re-acidified with 1 M HCl to ca. pH 2. Aqueous layer was then extracted 6×30 mL of EtOAc, organic layers were combined, dried over sodium sulfate and evaporated. The title compound was isolated as an oil (0.34 g, 61%) was used in the next step without further purification.1H NMR (300 MHz, CDCl3) δ4.11 (d, 1H, J=10.5 Hz), 3.98 (d, 1H, J=9.9 Hz), 3.53 (m, 1H), 2.10-1.92 (m, 3H), 1.60-1.54 (m, 3H).

Intermediate 44: (R)-5-Methoxytetrahydrofuran-2-carboxylic acid

[0716]

[0717]

Step 1: ((R)-5-methoxy-tetrahydro-furan-2-yl)-methanol. ((R)-5-Methoxy-tetrahydro-furan-2-ylmethoxy)-methyl-diphenylsilane (Pilli, R. A.; Riatto, V. B. Tet. Asymm. (2000)), 11, 3675) (0.80 g, 2.25 mmol) was dissolved in 35 mL of anhydrous MeOH and 5 mL of formic acid was added to the mixture. The mixture was stirred at room temperature for 30 minutes at which point TLC (9:1 hexanes:EtOAc) indicated complete conversion to the product. Volatiles were removed in vacuo and 0.83 g, 100% of the title compound was obtained as clear oil.

[0718]

Step 2: (R)-5-methoxytetrahydrofuran-2-carboxylic acid. Material from Step 1 was oxidized via the same method in Step 2 of the synthesis of Intermediate 47, it was prepared as oil.1H NMR (300 MHz, CDCl3) δ 5.19 (d, 0.6H, J=4.2 Hz), 5.10 (d, 0.4H, J=4.5 Hz), 4.63-4.58 (m, 1H), 3.42 (s, 1.2H), 3.34 (s, 1.8 Hz), 2.28-1.88 (m, 4H).

Intermediate 45: 1-(4-methoxybutanyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid

[0719]

[0720]

Prepared by following the same method as the preparation of Intermediate 42, ethyl 3,5-dimethyl-1H-pyrazole-4-carboxylate (280 mg) was reacted with 1-bromo-2-methoxybutane (367 mg) to afford white solid (185 mg, 41%). ESI-MS m/z 227.4 (M+H).

Intermediate 46: 1-(3-methoxypropyl)-3,5-dimethyl-1H-pyrazole-4-carboxylic acid

[0721]

[0722]

Prepared by following the same method as the preparation of intermediate 42: ethyl 3,5-dimethyl-1H-pyrazole-4-carboxylate (280 mg) was reacted with 1-bromo-2-methoxybutane (337 mg) to afford white solid (42 mg, 0.20 mmol, 10%). ESI-MS m/z 213.2 (M+H).

Intermediate 47: (R)-5-methyltetrahydrofuran-2-carboxylic acid

[0723]

[0724]

Step 1: (R)-tert-butyl((5-methyltetrahydrofuran-2-yl)methoxy)diphenylsilane (Tet. Asym. (2000), 11, 3675) (0.523 g, 1.48 mmol) was dissolved in 5 mL of anhydrous THF, TBAF (1 M solution in THF, 1.48 mL) was added to the solution and it was stirred at room temperature under argon flow overnight. Volatiles were then removed in vacuo and resulting oil was used in the next step with no purification

[0725]

Step 2: Crude (R)-(5-methyltetrahydrofuran-2-yl)methanol was dissolved in 6 mL of 1:1 ACN/water mixture, and bis-acetoxyiodobenzene [BAIB] (0.71 g, 2.20 mmol) was added to the mixture. It was then cooled to 0 C in an ice bath, and TEMPO (0.031 g, 0.2 mmol) was added under argon flow. The mixture was stirred at room temperature for 3 h, and the reaction was quenched by addition of 20 mL of 1 M NaOH. Basic solution was washed 3×15 mL of EtOAc, and re-acidified with 1 M HCl to ca. pH 2. Aqueous layer was then extracted 6×15 mL of EtOAc, organic layers combined, dried over sodium sulfate and evaporated. Resulting oil (0.05 g, 26%) was used in the next step with no purification.1H NMR (300 MHz, CDCl3) δ 4.48-4.43 (m, 1H), 4.20-4.17 (m, 1H), 2.33-2.21 (m, 3H), 2.08-2.02 (m, 1H), 1.35 (dd, 3H, J1=6.3 Hz, J2=1.8 Hz).

Intermediate 48: 3-Methyloxetane-3-carboxylic acid

[0726]

[0727]

The title compound was prepared following the same method described in step 2 of the preparation of intermediate 47 from (3-methyloxetan-3-yl)methanol (0.51 g, 5 mmol).1H NMR (300 MHz, CDCl3) δ 4.98 (d, 2H, J=6.0 Hz), 4.44 (d, 2H, J=6.0 Hz), 1.65 (s, 3H).

Intermediate 49: 3,6-Dichloropyridazine-4-carbonyl chloride

[0728]

[0729]

To a suspension of 3,6-dichloropyridazine-4-carboxylic acid (1.16 g, 6 mmol) in toluene (20 mL) were added DMF (2 drops) and SOCl2(4 mL) and the mixture was heated at reflux temperature for 3 h. The volatiles were removed and the residue was stripped with toluene. The resulting brown oil (3,6-dichloropyridazine-4-carbonyl chloride) was used without purification.

Intermediate 50: 3,5-Dimethylpyridazine-4-carboxylic acid

[0730]

[0731]

Step 1: Ethyl 2,3-dimethylcycloprop-2-enecarboxylate. Under a nitrogen atmosphere 2-butyn (9.50 g, 176 mmol) was cooled to 0° C. and Rh2(OAc)4(195 mg) was added. To the resulting suspension was added slowly over a period of 4.5 hours ethyl diazoacetate (8.02 g, 70 mmol). The mixture was stirred for 30 minutes and pentane (30 mL) was added. The solids were removed by filtration over Celite and the filtrate was concentrated in vacuo to afford ethyl 2,3-dimethylcycloprop-2-enecarboxylate (below) as a mixture with ethyl diazoacetate.

[0732]

[0733]

Step 2: Ethyl 1,5-dimethyl-2,3-diaza-bicyclo[3.1.0]hex-2-ene-6-carboxylate. Diazomethane was prepared from Diazald (21.5 g), KOH (6.6 g) in 2-(2-ethoxyethoxy)ethanol (35 mL). To the diazomethane solution in Et2O was added ethyl 2,3-dimethylcycloprop-2-enecarboxylate as obtained above. The mixture was stirred at 0° C. for 14 days in the dark. A solution of acetic acid in Et2O was added to quench off remaining diazomethane and the volatiles were removed in vacuo. Remaining starting material was removed by Kugelrohr distillation to afford ethyl 1,5-dimethyl-2,3-diaza-bicyclo[3.1.0]hex-2-ene-6-carboxylate (1.25 g, 6.9 mmol) as a yellowish oil in 10% yield over 2 steps.

[0734]

Step 3: Ethyl 3,5-dimethyl-1,4-dihydropyridazine-4-carboxylate. To a solution of ethyl 1,5-dimethyl-2,3-diaza-bicyclo[3.1.0]hex-2-ene-6-carboxylate (1.25 g, 6.9 mmol) in ethanol (20 mL) was added a solution of NaOEt in ethanol (7 mL 0.2N) and the mixture was stirred for 10 min The resulting solution was partitioned between diethyl ether and water. The organic phase was isolated and the aqueous phase was extracted with diethyl ether. The combined organic phases were dried over MgSO4and the volatiles were removed in vacuo to afford ethyl 3,5-dimethyl-1,4-dihydropyridazine-4-carboxylate (1.0 g, 5.5 mmol, 80%) which was partially (circa 50%) oxidized to the pyridazine analog.

[0735]

Step 4: Ethyl 3,5-dimethylpyridazine-4-carboxylate. To a solution of ethyl 3,5-dimethyl-1,4-dihydropyridazine-4-carboxylate (1.0 g, 5.5 mmol) as obtained above in acetone (30 mL) was added a solution of KMnO4(0.48 g, 3.0 mmol) in water (6 mL). The mixture was stirred for 30 minutes at room temperature and the solids were removed by filtration. The filtrate was concentrated and purified by column chromatography (SiO2, EtOAc/Heptane 1/1) to afford ethyl 3,5-dimethylpyridazine-4-carboxylate (600 mg, 3.3 mmol) as a colorless oil in 60% yield.

[0736]

Step 5: 3,5-Dimethylpyridazine-4-carboxylic acid (Intermediate 50). To a solution of ethyl 3,5-dimethylpyridazine-4-carboxylate (600 mg, 3.3 mmol) in ethanol (1 mL) was added a solution of NaOH (166 mg, 4.16 mmol) in water (5 mL). The mixture was heated at 50° C. for 1 hour and a clear solution was obtained. The solution was acidified by addition of aq. HCl until pH 5 and all volatiles were removed in vacuo. The residue was extracted with DCM/MeOH 4/1. The extract was concentrated to dryness to afford Intermediate 50: 3,5-dimethylpyridazine-4-carboxylic acid (550 mg) as an off-white solid.

Intermediate 51: 1-(5-Fluoro-thiophen-2-ylmethyl)-3-(4-methylaminomethyl-thiazol-2-yl)-urea

[0737]

[0738]

It was prepared following the same method of the preparation of Intermediate 29, starting from (5-fluoro-thiophen-2-yl)-methylamine.

Intermediate 52: Imidazole-1-carboxylic acid (4-{[methyl-((R)-tetrahydro-furan-2-carbonyl)-amino]-methyl}-thiazol-2-yl)-amide

[0739]

[0740]

Step 1: tert-Butyl 4-((methylamino)methyl)thiazol-2-ylcarbamate (Intermediate 17) was coupled with (R)-2-tetrahydrofuroic acid using TBTU (Method 2) to afford (4-{[methyl-((R)-tetrahydro-furan-2-carbonyl)-amino]-methyl}-thiazol-2-yl)-carbamic acid tert-butyl ester.

[0741]

Step 2: The product from Step 1 was treated with TFA to cleave the BOC group (Method 1) to afford (R)-tetrahydro-furan-2-carboxylic acid (2-amino-thiazol-4-ylmethyl)-methyl-amide.

[0742]

Step 3: (R)-Tetrahydro-furan-2-carboxylic acid (2-amino-thiazol-4-ylmethyl)-methyl-amide (1.65 g, 6.5 mmol) was dissolved in THF (5 mL) and added dropwise to a solution of carbonyl diimidazole (1.1. eq) in THF (10 mL) at 35° C. After stirring overnight at 20° C., the mixture was cooled in ice. The solids were collected by filtration and washed with Et2O to afford Intermediate 52: Imidazole-1-carboxylic acid (4-{[methyl-((R)-tetrahydro-furan-2-carbonyl)-amino]-methyl}-thiazol-2-yl)-amide (1.2 g, 55% yield) as felty white crystals.

Intermediate 53: (R)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-2-carboxylic acid

[0743]

[0744]

Prepared from the corresponding 2-nitrile via a 3 step procedure:

[0745]

Step 1: (R)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-2-carbonitrile was treated with sodium methoxide in MeOH to afford (R)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-2-carboxylic acid methyl ester.

[0746]

Step 2: The methyl ester obtained in Step 1 was reduced with LAH in THF to afford the alcohol: (R)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-2-methanol.

[0747]

Step 3: The alcohol obtained in Step 2 was oxidized with BAIB/TEMPO (using the procedure for Intermediate 55) to afford Intermediate 53: (R)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-2-carboxylic acid.

Intermediate 54: cis-3-Methyl-tetrahydrofuran-2-carboxylic acid

[0748]

[0749]

Prepared by catalytic hydrogenation (Rh/C, 50 psi, MeOH) of 3-methyl-2-furoic acid.

Intermediate 55: 3-Ethyloxetane-3-carboxylic acid

[0750]

[0751]

(3-Ethyloxetan-3-yl)methanol (0.58 g, 5.00 mmol) was dissolved in 10 mL of a 1:1 ACN-water mixture, and bis-acetoxyiodobenzene (BAIB, 3.54 g, 11.0 mmol) was added. The mixture was cooled in an ice bath, and TEMPO (0.156 g, 1.00 mmol) was added under argon flow. The mixture was stirred at room temperature for 1 hr, and then treated with 1 M aqueous sodium hydroxide (20 mL). The solution was washed twice with EtOAc and then acidified to pH 2. The aqueous solution was extract six times with EtOAc and these combined extracts were dried over sodium sulfate and concentrated to afford 0.37 g (57%) of Intermediate 55 as oil, which was used without further purification.

Intermediate 56: cis-3-methoxy-tetrahydrofuran-2-carboxylic acid

[0752]

[0753]

Step 1: cis-2-Benzyloxymethyl-tetrahydro-furan-3-ol was O-methylated using methyliodide and sodium hydride in DMF.

[0754]

Step 2: The 3-methoxy-compound obtained in Step 1 was hydrogenated over palladium on carbon in acetic acid to cleave the O-benzyl protecting group.

[0755]

Step 3: The 2-hydroxymethyl group in the product form Step 2 was oxidized to the carboxylic acid using BAIB/TEMPO to afford Intermediate 56, which was purified by chromatography.

Intermediate 57: Benzooxazol-6-yl-methylamine [RN 872047-63-7]

[0756]

[0757]

Step 1: 6-Methyl-benzooxazole. A 50 ml flask was charged with 6-amino-m-cresol (2 g, 16.24 mmole), 20 ml toluene and 5.4 ml triethyl orthoformate. The reaction mixture was refluxed for 2 hours. The mixture was concentrated down to about 2.3 g crude. Purification by silicagel column chromatography using 20% EtOAc/hexane provided 1.45 g brown oil (69% yield) that solidified in the freezer.

[0758]

Step 2: 6-Bromo-methyl-benzooxazole. To a 100 ml flask equipped with magnetic stirre and condenser were added: 6-methyl-benzooxazole (1.4 g, 10.52 mmole), 50 ml carbon tertrachloride, NBS (1.7 g, 9.5 mmole) and AIBN (200 mg, 1.21 mmole). The reaction mixture was refluxed for 4 hours. The mixture was cooled down, concentrated and purified by silicagel column chromatography using 10 to 15% EtOAc/hexane. 1.81 g (75% yield) yellow solid was obtained.

[0759]

Step 3: 6-Azidomethyl-benzooxazole. A 100 ml flask was loaded with 6-bromo-methyl-benzooxazole (1.8 g, 8.5 mmole), 40 ml DMF and sodium azide (1.1 g, 16.98 mmole). The reaction mixture was stirred at room temperature, overnight. The reaction mixture was diluted with 40 ml water and extracted 2×50 ml EtOAc. Combined organic layers were washed with water, brine, dried over sodium sulfate, filtered and concentrated to afford 2 g oily crude. HNMR shows 90% pure product. This was used for next step.

[0760]

Step 4: Benzooxazol-6-yl-methylamine (Int. 57). To a solution of 6-azidomethyl-benzooxazole (500 mg, 2.87 mmole) in 25 ml MeOH, 10% Pd/C (300 mg, 10% eq.) was added. The reaction mixture was stirred at ambient temperature under hydrogen atmosphere for 24 hours. The reaction mixture was filtered trough a pad of celite and washed with MeOH. The filtrate was concentrated to give Intermediate 57 as a brown oil (400 mg).

Intermediate 58: Acetic acid (R)-5-{2-[3-(3,4-dichloro-benzyl)-ureido]-thiazol-4-yl}-pyrrolidin-3-yl ester Hydrochloride

[0761]

[0762]

Step 1: (R)-4-Acetoxy-pyrrolidin-2-yl chloromethyl ketone was condensed with thiourea in ethanol in the manner described for Intermediate 1, to afford (R)-4-Acetoxy-2-(2-amino-thiazol-4-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester.

[0763]

Step 2: (R)-4-Acetoxy-2-(2-amino-thiazol-4-yl)-pyrrolidine-1-carboxylic acid tert-butyl ester (327 mg, 1 mmol) was combined with 3,4-dichlorobenzyl isocyanate (303 mg, 1.5 mmol) in DCM (10 mL) and stirred overnight. The reaction mixture was concentrated and purified by chromatography (silica gel, DCM/MeOH/NH4OH) to afford (R)-4-acetoxy-2-{2-[3-(3,4-dichloro-benzyl)-ureido]-thiazol-4-yl}-pyrrolidine-1-carboxylic acid tert-butyl ester.

[0764]

Step 3: The product obtained in Step 2 was dissolved in 4M HCl in 1,4-dioxane (7 mL). After stirring overnight the reaction mixture was concentrated and the residue was crystallized from THF/Et2O to afford Intermediate 58: acetic acid (R)-5-{2-[3-(3,4-dichloro-benzyl)-ureido]-thiazol-4-yl}-pyrrolidin-3-yl ester hydrochloride, as a white solid (224 mg, 52% yield).

Intermediate 59: 1-{4-[(2-Amino-ethylamino)-methyl]-thiazol-2-yl}-3-(3-fluoro-benzyl)-urea bis-Trifluoroacetate

[0765]

[0766]

Step 1: Sodium triacetoxyborohydride (937 mg, 4.42 mmol) was added to a CH2Cl2(50 mL) solution of 1-(3-fluorobenzyl)-3-(4-formylthiazol-2-yl)urea (620 mg, 2.21 mmol) and tert-butyl 2-aminoethylcarbamate (532 mg, 3.32 mmol) at 0 C. Upon completion of the reaction, it was quenched with dilute NaHCO3. The organics were dried and evaporated. Flash chromatography afforded tert-butyl 2-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methylamino)ethylcarbamate.1H NMR (400 MHz, CDCl3): δ 8.05 (1H, br), 7.28 (m, 1H), 7.00 (m, 3H), 6.61 (s, 1H), 4.80 (s, 1H), 4.49 (d, 2H), 3.73 (s, 2H), 3.17 (m, 2H), 2.63 (t, 2H), 1.41 (s, 9H). MS (ES+): M/Z 424 (M+H)+.

[0767]

Step 2: [Method 1]: Trifluoroacetic acid (1 mL) was added to a CH2Cl2(5 mL) solution of tert-butyl 2-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methylamino)ethylcarbamate (70 mg, 0.16 mmol). Upon completion of the reaction, the mixture was evaporated to dryness to afford Intermediate 59: 1-{4-[(2-amino-ethylamino)-methyl]-thiazol-2-yl}-3-(3-fluoro-benzyl)-urea bis-trifluoroacetate as a white solid.

Intermediate 60: 1-(3-Fluorobenzyl)-3-(4-(pyrrolidin-2-yl)thiazol-2-yl)urea Hydrochloride

[0768]

[0769]

Step 1: An ethanol (20 mL) solution of tert-butyl 2-(2-chloroacetyl)pyrrolidine-1-carboxylate (1.08 g, 4.4 mol) and thiourea (334 mg, 4.4 mmol) was stirred at 55 C for 70 hours. Upon completion of the condensation, the solution was evaporated. The solid was dissolved in CH2Cl2(100 mL). It was washed with dilute NaHCO3solution, dried and evaporated. Recrystallization from CH2Cl2/hexane afforded tert-butyl 2-(2-aminothiazol-4-yl)pyrrolidine-1-carboxylate.1H NMR (400 MHz, CDCl3): mixture of rotamers: δ 8.81 (s, 2H, br), 6.22 and 6.15 (2s, 1H), 4.84 and 4.78 (2s, 1H), 3.62 and 3.44 (2m, 2H), 2.4-1.8 (m, 4H), 1.46 and 1.36 (2s, 9H). MS (ES+): M/Z 270 (M+H)+, 170 (M−C5H8O2)+.

[0770]

Step 2: A THF (5 mL) solution of tert-butyl 2-(2-aminothiazol-4-yl)pyrrolidine-1-carboxylate (270 mg, 1 mmol) and 3-fluororbenzyl isocyanate (140 μL, 1.1 mmol) was microwave irradiated at 120 C for 60 minutes. Aqueous work-up, followed by flash chromatography afforded tert-butyl 2-(2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)pyrrolidine-1-carboxylate. MS (ES+): M/Z 421 (M+H)+, 321 (M−C5H8O2)+.

[0771]

Step 3: tert-Butyl 2-(2-aminothiazol-4-yl)pyrrolidine-1-carboxylate (870 mg, 2.1 mmol) was deprotected with trifluoroacetic acid (5 mL) in CH2Cl2(20 mL). Evaporation of the reaction mixture and treatment with HCl (5 mL, 10 mmol, 2M in ether) afforded Intermediate 60: 1-(3-fluorobenzyl)-3-(4-(pyrrolidin-2-yl)thiazol-2-yl)urea hydrochloride as a white solid.1H NMR (400 MHz, DMSO): δ 11.93 (s, 1H, 9.96 (s, 1H), 8.85 (s, 1H), 7.76 (t, 1H), 7.38 (m, 1H), 7.1 (m, 4H), 4.56 (t, 1H), 4.37 (d, 2H), 2.30 (m, 1H), 2.08 (m, 3H). MS (ES+): M/Z 321 (M+H)+.

Intermediate 61: 1-(4-(((3,5-Dimethylisoxazol-4-yl)methylamino)methyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea

[0772]

[0773]

Step 1: Sodium azide (390 mg, 6.0 mmol) was added to a DMSO (5 mL) solution of Intermediate 4: 1-(4-(chloro-methyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea (600 mg, 2 mmol). The mixture was stirred for 4 hours at 40 C. Upon completion of the reaction, water was added at 10 C and the mixture was extracted with EtOAc. Organics were washed with brine, dried and evaporated. Recrystallization from CH2Cl2/hexane afforded 1-(4-(azidomethyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea.1H NMR (400 MHz, CDCl3): δ 10.3 (1H, br), 7.27 (m, 1H), 7.1-6.9 (m, 3H), 6.74 (s, 1H), 4.50 (d, 2H), 4.27 (s, 2H). MS (ES+): M/Z 307 (M+H)+.

[0774]

Step 2: Trimethylphosphine (107 μL, 1.2 mmol) was added dropwise to a THF (5 mL) solution of 1-(4-(azidomethyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea (307 mg, 1.0 mmol) at 0 C under a nitrogen atmosphere. The mixture was stirred for 22 hours then HCl (0.5 mL, 4M in water) was added and the stirring was continued for 22 hours. Upon evaporation of the mixture, the product was recrystallized from acetonitrile to afford 1-(4-(aminomethyl) thiazol-2-yl)-3-(3-fluorobenzyl)urea hydrochloride.1H NMR (400 MHz, CD3OD): δ 10.3 (1H, br), 7.34 (m, 1H), 7.17-6.95 (m, 4H), 4.45 (s, 2H), 4.08 (s, 2H). MS (ES+): M/Z 281 (M+H)+.

[0775]

Step 3: NaBH4(35 mg, 1 mmol) was added in portions to a MeOH (5 mL) solution of 3,5-dimethylisoxazole-4-carbaldehyde (65 mg, 0.5 mmol) and 1-(4-(aminomethyl) thiazol-2-yl)-3-(3-fluorobenzyl)urea hydrochloride (157 mg, 0.5 mmol) at 0 C. The mixture was stirred for 6 hours then quenched with dilute HCl solution. Basic aqueous work-up with CH2Cl2followed by flash chromatography afforded Intermediate 61: 1-(4-(((3,5-dimethylisoxazol-4-yl)methylamino)methyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea.1H NMR (400 MHz, CDCl3): δ 8.2 (1H, br), 7.27 (m, 1H), 6.92 (m, 3H), 6.60 (s, 1H), 4.37 (d, 2H), 3.66 (s, 2H), 3.33 (s, 2H), 2.22 (s, 3H), 2.11 (s, 3H). MS (ES+): M/Z 390 (M+H)+.

Intermediates 62-65: Not used

Intermediate 66: Chlorobenzo[1,3]dioxol-5-ylmethylamine (alt. name: 5-Chloro-piperonyl amine)

[0776]

Step 1: 5-Chloropiperonal was prepared by the literature method (Berichte der Deutschen Chemischen Gesellschaft, 43, 2605-2606 (1911)).

[0777]

Step 2: Reductive amination of 5-chloropiperonal was performed by borane reduction of the O-methyloxime derivative by literature method (J. Org. Chem. 34(6), 1817-1821, (1969)).

Intermediate 67: Not used

Intermediate 68: 1-(3-Fluorobenzyl)-3-(3-methylaminomethyl-[1,2,4]thiadiazol-5-yl)-urea

[0778]

[0779]

Step 1: To a solution of triphosgene (2.37 g, 8 mmol) in CH2Cl2(48 mL) was added dropwise a mixture of 3-fluorobenzylamine (2.0 g, 16 mmol) and DIPEA (4.14 g, 32 mmol) in CH2Cl2(32 mL) over 2 hours at 0 C under N2atmosphere. After addition was complete, the mixture was refluxed for 1 hour and then cooled to ambient temperature. The mixture was washed with aq. KHSO4, brine, dried over Na2SO4, and concentrated to give 3-fluorobenzyl isocyanate as a yellow liquid (1.34 g, yield 100%), which was used in the next step without further purification.

[0780]

Step 2: 3-Fluorobenzyl isocyanate (1.3 g, 8 mmol) was added into a mixture of Intermediate 38: 3-chloromethyl-[1,2,4]thiadiazol-5-ylamine (0.83 g, 5.5 mmol), and DMAP (22 mg, 0.14 mmol) in NMP (11 mL). The reaction mixture was heated in a microwave reactor for 1 hour at 100 C and then cooled to ambient temperature. The reaction mixture was diluted with EtOAc (75 mL) and washed with water (30 mL×2). The aqueous phase was extracted with EtOAc (40 mL×2). The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to give the crude product, which was purified by silica gel column chromatography to afford 1-(3-chloromethyl-[1,2,4]thiadiazol-5-yl)-3-(3-fluoro-benzyl)-urea as an off-white solid (1.2 g, 72%). LC-MS (m/z): 303.0 (M+H)

[0781]

Step 3: A solution of the urea obtained above (8.5 g, 28.3 mmol) and excess methylamine (27% alcohol solution, 54 mL) was heated in a microwave reactor for 15 minutes at 60 C. After cooling to room temperature, a solution of K2CO3(1.8 g) in water (5 mL) was added, and the volatiles were removed in vacuo. The crude product was purified by column chromatography DCM:MeOH:Et3N=20:1:0.151 to give Intermediate 68: 1-(3-fluorobenzyl)-3-(3-methyl aminomethyl-[1,2,4]thiadiazol-5-yl)-urea as a yellowish solid (4.4 g, yield: 52.7%, purity detected by LC-MS: >97%).1H NMR (400 MHz, DMSO-d6) δ: 7.95 (s, 1H), 7.90 (s, 1H), 7.37 (m, 1H), 7.10 (m, 3H), 4.37 (d, J=5.6 Hz, 2H), 3.71 (s, 2H), 2.31 (s, 3H).

Intermediate 69: 1-(5-Chloro-thiophen-2-ylmethyl)-3-(3-methylaminomethyl-[1,2,4]thiadiazol-5-yl)-urea

[0782]

[0783]

Step 1: To a solution of triphosgene (1.15 g, 3.9 mmol) in CH2Cl2(30 mL) was added dropwise a mixture of (5-chlorothiophen-2-yl)methanamine (1.14 g, 7.8 mmol) and DIPEA (2.0 g, 15.6 mmol) in CH2Cl2(32 mL) over 2 hours at 0 C under N2atmosphere. After addition was complete, the mixture was refluxed for 1 hour and then cooled to ambient temperature. The mixture was washed with aq. KHSO4, brine, dried over Na2SO4, and concentrated to give 5-chlorothiophen-2-yl-methyl isocynate a yellow liquid (1.34 g, yield 100%), which was used in the next step without further purification.

[0784]

Step 2: The isocyanate obtained above was added into a mixture of Intermediate 38: 3-chloromethyl-[1,2,4]thiadiazol-5-ylamine (0.96 g, 6.4 mmol), and DMAP (26 mg, 0.17 mmol) in NMP (7 mL). The reaction mixture was heated in a microwave reactor for 1 hour at 100 C and then cooled to ambient temperature. The reaction mixture was diluted with EtOAc (50 mL) and washed with water (20 mL×2). The aqueous phase was extracted with EtOAc (25 mL×2). The combined organic layers were washed with brine, dried over Na2SO4, filtered and evaporated to give the crude product, which was purified by silica gel column chromatography [petroleum ether:EtOAc (PE:EA)=3:1] to give 1-(3-chloromethyl-[1,2,4]thiadiazol-5-yl)-3-(5-chloro-thiophen-2-ylmethyl)-urea as a brown oil (1.74 g, 70%).

[0785]

Step 3: A solution of the urea obtained above (7.33 g, 22.7 mmol) and excess methylamine (27% alcohol solution, 36 mL) was heated in a microwave oven for 15 minutes at 60 C. After having been cooled to room temperature, a solution of K2CO3(1.7 g) in water (3 mL) was added and the volatiles were removed in vacuo. The crude product was purified by column chromatography [EtOAc, then DCM:MeOH:Et3N=20:1:0.15] to give Intermediate 69: 1-(5-chloro-thiophen-2-ylmethyl)-3-(3-methylaminomethyl-[1,2,4]thiadiazol-5-yl)-urea as a yellowish solid (2.22 g, yield: 31%).1H NMR (400 MHz, DMSO-d6) δ: 7.74 (s, 1H), 6.94 (d, J=4.0 Hz, 1H), 6.85 (d, J=3.2 Hz, 1H), 4.42 (d, J=6.0 Hz, 2H), 3.70 (s, 2H), 2.31 (s, 3H).

Intermediate 70: 1-(2,4-Dimethoxy-benzyl)-3-(3-fluoro-benzyl)-1-(3-methylamino-methyl-[1,2,4]thiadiazol-5-yl)-urea

[0786]

[0787]

Step 1: A solution of 5-chloro-3-chloromethyl-[1,2,4]thiadiazole (3 g, 18 mmol, [74461-64-6]) in DCM (20 mL) was treated with DIPEA (1 eq), followed by 2,4-dimethoxybenzylamine (1 eq). After stirring overnight, the mixture was concentrated and purified by silica gel chromatography (10% MeOH/EtOAc) to afford (3-chloromethyl-[1,2,4]thiadiazol-5-yl)-(2,4-dimethoxy-benzyl)-amine, which was used directly in the next step.

[0788]

Step 2: The amine obtained above was dissolved in THF (45 mL) and treated with 3-fluorobenzylisocyanate (1 eq). The resulting solution was heated at 140 C for 20 minutes in a sealed tube. The reaction mixture was concentrated and purified by silica gel chromatography (50% EtOAc/hexanes to afford 1-(3-chloromethyl-[1,2,4]thiadiazol-5-yl)-1-(2,4-dimethoxy-benzyl)-3-(3-fluoro-benzyl)-urea (3.8 g, 47% yield for two steps).

[0789]

Step 3: The urea product obtained above (1.0 g, 2.2 mmol) was dissolved in a solution of 33% methylamine in ethanol. The solution was heated in a sealed tube at 60 C for 15 minutes, then concentrated and purified by silica gel chromatography (4% 7N ammonia/MeOH: 96% DCM) to afford Intermediate 70: 1-(2,4-dimethoxy-benzyl)-3-(3-fluoro-benzyl)-1-(3-methylamino-methyl-[1,2,4]thiadiazol-5-yl)-urea, as a white solid (825 mg, 83% yield).

[0000]

End of Intermediates.

Example 477

Synthesis Methods For Compounds of Tables 1-3

Method 1: BOC Deprotection Method using TFA

[0790]

The BOC-protected thiazole urea analog (0.2-0.5 mmol) was dissolved in trifluoroacetic acid (2 ml) and the solution is stirred overnight. The volatiles were removed by evaporation and the residue was triturated with ether to afford the TFA salt of the final product; or purified by column chromatography using 0-10% gradient of 7 N ammonia/MeOH and DCM. In cases where the HCl salt was desired, this was treated with HCl (4.0M in dioxane) to give the HCl salt.

Method 2: Amide Formation by TBTU Coupling of Carboxylic Acid and Amine

[0791]

Carboxylic acid (0.25 mmol) was dissolved in 3 ml DMF, and TBTU (1.1 eq) and base (K2CO3or DIEA, 1.1 eq.) were added. To the stirred mixture, N-alkylaminomethyl thia(dia)zolylurea was added and stirred overnight. 10 ml of water was added. If the product precipitated from the solution, it was filtered and washed with water and dried. The crude was purified by column chromatography using 0-100% gradient of 10% MeOH/EtOAc and hexanes. If the product remained in the solution, the product was extracted three times with EtOAc and back washed with brine twice. The organic was dried, concentrated and purified by column chromatography using 0-10% gradient of 7 N ammonia/MeOH and DCM.

Method 3: Amide Formation by Condensation of an Acid Chloride and Amine

[0792]

Carboxylic chloride (0.25 mmol) was added to a mixture of 1.0 eq. of N-alkylaminomethylthi(dia)azolylurea and base (K2CO3or DIEA, 1 eq.) in 3 ml DMF. The reaction was stirred overnight. 10 ml of water was added. If the product precipitated from the solution, it was filtered and washed with water and dried. The crude was purified by column chromatography using 0-100% gradient of 10% MeOH/EtOAc and hexanes. If the product remained in the solution, the product was extracted three times with EtOAc and back washed with brine twice. The organic was dried, concentrated and purified by column chromatography using 0-10% 7 N ammonia/MeOH and DCM.

Method 4: TBTU Coupling Followed by Deprotection with HCl

[0793]

Step 1: Thiazole urea intermediate (SM1) and acid (SM2) are coupled following Method 2.

[0794]

Step 2: The protected thiazole urea analog was dissolved in 4.0M HCl in dioxane and the solution is stirred 2-24 hours. Diethyl ether is added. In most cases, product precipitates and is isolated as a solid. If necessary, the product is purified by column chromatography using 0-10% gradient of 7 N ammonia/MeOH and DCM.

Method 5: Sulfonamide Formation by Condensation of a Sulfonyl Chloride and Amine

[0795]

Sulfonyl chloride (SM2, 0.25 mmol) was added to a mixture of an advanced intermediate, N-alkylaminomethylthiazolylurea (SM1, 1.0 eq.) and base (K2CO3or DIEA, 1.0 eq.) in 3 mL inert solvent such as DCM or THF or DMF. The reaction was stirred overnight. 10 mL of water was added. If the product precipitated from the solution, filtered and washed with water and dried. The crude was purified by column chromatography using 0-100% gradient of 10% MeOH/EtOAc and hexanes. If the product remained in the solution, the product was extracted three times with EtOAc and back washed with brine twice. The organic was dried, concentrated and purified by column chromatography using 0-10% gradient of 7 N ammonia/MeOH and DCM.

Method 6: General Method For Removing N-Fmoc Protecting Group

[0796]

The advanced thia(dia)zole intermediate (0.2 mmol) bearing an N-Fmoc (N-9-Fluorenylmethyl Carbamate) protecting group was dissolved in DMF (2 mL) treated with excess morpholine (1 mL). When the reaction was complete the solution was concentrated in vacuo and purified by chromatography to afford the N-deprotected product.

Method 7: Urea Formation by Reaction of an N-Acyl-imidazolide with Amine

[0797]

An N-acyl-imidazolide (SM 1, 1 mmol), typically formed by condensing a 2-aminothiazole derivative with carbonyl diimidazole, is suspended in THF (10 mL) and the amine component (SM2, 1 eq) is added. If the amine (SM2) is used in the form of a salt (ex. hydrochloride), then a base (1 eq) such as DIPEA is also added. The reaction is stirred at 20-50° C. until complete, then concentrated, and purified by chromatography (silica gel, MeOH/EtOAc) to afford the desired thiazole urea product.

Method 8: Urea Formation by Reaction of a Phenyl Carbamate with Amine

[0798]

A phenylcarbamate (SM1, 1 eq.) was taken up in dioxane and the amine (SM2, 1.1 eq.) was added. The reaction was heated in the microwave at 100-140° C. until complete. The solvent was removed and the crude material was purified by column chromatography using 10% saturated ammonia/MeOH in DCM or 10% MeOH/EtOAc in hexanes to give product. In some cases, the HCl salt of the product was prepared by adding HCl in dioxane, followed by the addition of diethyl ether to give a white solid.

Method 9: Carboxylic Acid Formation by Hydrolysis of Corresponding Ester

[0799]

The carboxylic acid ester is saponified with aqueous sodium hydroxide in an alcoholic cosolvent. The carboxylic acid product is isolated by acidification and aqueous work-up.

[0800]

Example: Ethyl 4-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)-carbamoyl)-5-methylisoxazole-3-carboxylate (105 mg) was dissolved in ethanol (5 ml) and 1 N sodium hydroxide (5.0 eq) was added and stirred for 2 hours. The reaction was acidified to pH=2 and concentrated. The precipitate was filtered, washed with water and dried to give 4-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)-5-methylisoxazole-3-carboxylic acid.

Method 10: General DMB Deprotection Method Using TFA

[0801]

The advanced thia(dia)zole intermediate (0.25-0.5 mmol) with a 2,4-dimethoxybenzyl-protecting group (DMB) was dissolved in trifluoroacetic acid (4 ml) with anisole (5 drop) and the reaction was stirred at room temperature overnight. The volatiles were evaporated and the residue was purified by column chromatography using 0-10% gradient of 7 N ammonia/MeOH and DCM to afford the deprotected product.

Method 11: General Deprotection Method For O—Silyl Protecting Groups

[0802]

The advanced thia(dia)zole intermediate (0.25-0.5 mmol) bearing an O-silyl protecting group (such as tert-butyldiphenylsilyl or tert-butyldimethylsilyl) is cleaved by treatment with tetra-n-butylammonium fluoride (TBAF) in THF or ACN solvent (Can. J. Chem. 55, 562 (1977)). The deprotected product is purified by chromatography, if necessary.

Method 12: Reduction of Ester to Alcohol

[0803]

A carboxylic ester is reduced with lithium borohydride in an inert solvent such as THF to afford the corresponding alcohol, after aqueous work-up and chromatography.

[0804]

Example: Ethyl 4-(((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)(methyl)carbamoyl)-5-methylisoxazole-3-carboxylate (60 mg) was suspended in tetrahydrofuran (6 ml) and LiBH4(3.0 mg) was added and stirred at room temperature overnight. Additional LiBH4(6.0 mg) was added and stirred overnight. The reaction was concentrated and the residue was purified by column chromatography using 0-100% gradient of 9:1 EtOAc/MeOH and hexanes.

Method 13: Preparation of 2,4-Dimethoxybenzyl-protected Amines

[0805]

[0806]

Step 1: Aryl aldehyde (10 mmol) was mixed with 2,4-dimethoxybenzylamine (1.0 eq.) in DCM (50 ml) and acetic acid (1.0 ml) was added. To the mixture, sodium triacetoxyborohydride (2.5 eq.) was added the mixture was stirred at room temperature overnight. The mixture was filtered through Celite and washed with DCM. The filtrate was concentrated and purified by column chromatography using 0-10% gradient of 7 N ammonia/MeOH and DCM to afford the 2,4-DMB-protected amine product.

Method 14: Alkylation of Thiazolidine-2,4-Dione

[0807]

[0808]

1-(3-Fluoro-benzyl)-3-(4-iodomethyl-thiazol-2-yl)-urea (Intermediate 7, 0.3 mmol) was taken up in THF (3 ml) and DIPEA (1 eq.) and potassium carbonate (1 eq.) was added, followed by thiazolidine-2,4-dione (1 eq.). The reaction was stirred at room temperature overnight. Solvent is removed in vacuo and the crude material was purified by column chromatography with a gradient of 0-60% of (9:1 EtOAc/MeOH) and hexanes to afford 1-(4-((2,4-dioxothiazolidin-3-yl)methyl)thiazol-2-yl)-3-(3-fluorobenzyl)urea (EX #109) as a white solid.

Method 15: Alkylation of Oxazolidin-2-one

[0809]

[0810]

Step 1: 1-(4-Chloromethyl-thiazol-2-yl)-1-(2,4-dimethoxy-benzyl)-3-(3-fluoro-benzyl)-urea (Intermediate 21, 0.3 mmol) was taken up in DMF (2 ml). A solution of the oxazolidin-2-one (or sultam) (1 eq.) with NaH (1 eq.) in DMF (2 ml) was added. The reaction was allowed to stir at room temperature for 2 hours. An aqueous workup with EtOAc was performed. Purified by column chromatography using a gradient of 0-100% EtOAc/hexanes to give 1-(2,4-dimethoxybenzyl)-3-(3-fluorobenzyl)-1-(4-((2-oxooxazolidin-3-yl)methyl)thiazol-2-yl)urea.

[0811]

Step 2: The 1-(2,4-dimethoxybenzyl)-3-(3-fluorobenzyl)-1-(4-((2-oxooxazolidin-3-yl)methyl)thiazol-2-yl)urea was treated with TFA. Anisole (1 drop) was added. The reaction was stirred for 1 hour. Solvent was removed in vacuo. Purified by column chromatography with a gradient of 0-100% of 9:1 EtOAc/MeOH and hexanes. Resulting solid was triturated with diethyl ether to give the pure urea product.

Method 16: Alkylation of Isothiazolidinine 1,1-Dioxide

[0812]

Intermediate 21 and isothiazolidine 1,1-dioxide were reacted and deprotected following the procedure in Method 15.

Method 17: Bromination of Thiazole 5-Position

[0813]

Bromine (120 μL, 0.12 mmol, 1M in CH2Cl2) was added dropwise to a CH2Cl2(5 mL) solution of the thiazole urea compound (0.1 mmol). The bromination was instantaneous. The mixture was washed with dilute Na2SO3solution, dried and evaporated to afford the 5-bromo-compound.

Method 18: Chlorination of Thiazole 5-Position

[0814]

The thiazole urea compound was taken up in DCM and treated with N-chlror-succinimide (1.2 equiv). The mixture was stirred overnight at ambient temperature. An aqueous work-up was performed with dilute sodium sulfite solution. The organic layer was filtered through a silica plug and eluted with 3% MeOH in DCM to give the 5-chloro-compound.

Method 19: Cyanation of Thiazole 5-Position

[0815]

Example: A mixture of 3,5-dimethyl-isoxazole-4-carboxylic acid {5-bromo-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide (Ex. 151) (100 mg, 0.2 mmol), CuCN (180 mg, 2.0 mmol) and KCN (13 mg, 0.2 mmol) in DMF (1 mL) was heated to 120 C for 5 hours. Upon cooling the mix was diluted with EtOAc (50 mL), filtered, washed with brine, dried and evaporated. Flash chromatography afforded 3,5-dimethyl-isoxazole-4-carboxylic acid {5-cyano-2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide.

Method 20: Hydrolysis of Acetate Protecting Group to Afford Alcohol

[0816]

The acetate thiazole urea (0.5 mmol) was dissolved in ethanol (2 ml) and 1 N sodium hydroxide (2.5 ml) was added and stirred overnight. The ethanol was removed by evaporation. If precipitation occurred, the product was isolated by filtration and washing with water. The product can be isolated by extraction of the mixture three times with EtOAc. The organic was combined and dried over sodium sulfate. The organic was filtered and washed with EtOAc and the filtrate was concentrated to dryness. The residue was purified by column chromatography using gradient of 0-10% gradient of 7 N ammonia/MeOH and DCM.

Method 21-43: Not used

Method 44: Synthesis of 3-chloro-6-methoxypyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide

[0817]

3,6-Dichloro-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide (47 mg) was treated with potassium hydroxide (56 mg) in MeOH (5 mL) over night. The resultant mixture was diluted with water (10 mL) and the pH was adjusted to 9-10 by sodium bicarbonate. After evaporation of MeOH, the resultant precipitate-3-chloro-6-methoxypyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide was collected, briefly rinsed with water and dried. The desired product was confirmed by 1HNMR and LC-MS.

Method 45: Synthesis of 3-chloro-6-hydroxypyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide

[0818]

3,6-Dichloro-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide (150 mg) in acetic acid (10 mL) was heated at reflux for 2 h. The resultant mixture was concentrated and purified by a preparative C-18 reverse phase HPLC. About 15 mg of the desired product-3-chloro-6-hydroxypyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide was obtained. The desired product was confirmed by 1HNMR and LC-MS.

Method 46: Synthesis of tetrahydro-furan-2-carboxylic acid (2-amino-1-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-yl}-ethyl)-methyl-amide

[0819]

Tetrahydro-furan-2-carboxylic acid (cyano-{2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-yl}-methyl)-methyl-amide (420 mg) was dissolved in MeOH (10 mL) and treated with Raney®-Nickel under a pressurized hydrogen (45 psi) over a couple of hours until all starting materials were consumed. The final product was purified by column chromatography. The product was confirmed by1H NMR and LC-MS.

Method 47: Synthesis of 6-methoxy-3-methyl-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide

[0820]

N2was bubbled for 15 minutes through a solution of 1-(3-fluorobenzyl)-3-(4-((3-chloro-6-methoxy-N-methylpyridazine-4-carboxamido)methyl)-thiazol-2-yl)urea (118 mg, 0.25 mmol) in 1,4-dioxane. Pd(PPh3)4(15 mg, 13 μmol) was added followed by AlMe3(250 μl, 2 M in toluene, 0.51 mmol). The mixture was refluxed for 4 hours and MeOH was added. Silica (300 mg) was added and the volatiles were removed in vacuo. The residue was brought on a column and purified by chromatography (CH2Cl2+5% 7N NH3in MeOH) to afford the title product (60 mg, 0.13 mmol) as an off-white solid in 52% yield.

Method 48: Synthesis of 6-hydroxy-3-methyl-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide

[0821]

6-Methoxy-3-methyl-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide was dissolved in DCM and treated with an excess of BBr3 at room temperature for a couple of hours. Column chromatography afforded the title product.

Method 49: Synthesis of 3-(dimethylamino)-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-methoxy-N-methylpyridazine-4-carboxamide

[0822]

3-Chloro-6-methoxypyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide was treated with dimethylamine in 1,4-dioxane to afford the desired product.

Method 50: Synthesis of N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-6-hydroxy-N-methyl-3-(methylamino)pyridazine-4-carboxamide

[0823]

3-(Dimethylamino)-N-((2-(3-(3-fluorobenzyBureido)thiazol-4-yl)methyl)-6-methoxy-N-methylpyridazine-4-carboxamide was treated with BBr3 (12 equivalent) in DCM to afford the title product.

Method 51: Synthesis of 6-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-hydroxy-N-methylpyridazine-4-carboxamide

[0824]

Step 1: Synthesis of 6-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-methoxy-N-methylpyridazine-4-carboxamide. A solution of 3,6-dichloro-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide (235 mg, 0.5 mmol) and MeOH (160 mg, 5 mmol) in 1,4-dioxane (10 mL) was added NaOH (20 mg, 0.5 mmol). The mixture was stirred overnight at room temperature and concentrated in vacuo. The residue was dissolved in CH2Cl2+5% MeOH and filtered over a small plug of silica. The volatiles were evaporated and the desired product (230 mg) was obtained as a 5:1 mixture with starting material-3,6-dichloro-pyridazine-4-carboxylic acid {2-[3-(3-fluoro-benzyl)-ureido]-thiazol-4-ylmethyl}-methyl-amide. This mixture was used as such in the subsequent steps.

[0825]

Step 2: Synthesis of 6-chloro-N-((2-(3-(3-fluorobenzyl)ureido)thiazol-4-yl)methyl)-3-hydroxy-N-methylpyridazine-4-carboxamide. A solution of 6-chloro-N-((2-(3-(3-fluorobenzyBureido)thiazol-4-yl)methyl)-3-methoxy-N-methylpyridazine-4-carboxamide (113 mg, 0.24 mmol) and NaOAc (100 mg, 1.21 mmol) in AcOH (7 mL) was heated at 100° C. overnight. The volatiles were removed in vacuo and the residue was purified by column chromatography (SiO2, CH2Cl2/5% 7N NH3in MeOH). The title product was confirmed by1H-NMR and LC-MS.

[0826]

End of Methods Section.

Example 478

Demonstration of Antibacterial Effect and Mechanism of Action

[0827]

The polC gene from Streptococcus pyogenes was overexpressed and PolC was purified as described in PCT/US05/15548. Primer extension activity of PolC was measured using 1 μM oligonucleotide primer-template (primer strand 5′-ACCAGTGAGACGGGCAACA, template strand 5′-TGAATTATAGGCCCTGTTGCCCGTCTCACTGGT). Reactions contained 10 mM magnesium acetate, 50 mM Tricine/Tris pH 7.8, 2.4% (w/v) polyethylene glycol (8000 MW), 0.024% pluronic F68, 1 mM dithiothreitol, 20 μM dATP, 20 μM dCTP, 0.5 μM dGTP, 0.72 μM dTTP, 0.28 μM 3H-dTTP (0.005 μCi/μL), 8% DMSO and 15 nM PolC. Reactions (25 μL) were incubated for 10 minutes at room temperature and stopped by addition of an equal volume of 100 mM EDTA. Incorporation of radiolabelled dTTP was measured by scintillation proximity assay by addition of 100 μL of 1 mg/mL PEI-PVT beads in 300 mM citrate pH 3.0.

[0828]

Compounds of Formula (I) were tested for inhibition of S. pyogenes PolC activity. Serial 2-fold dilutions of compounds were tested for inhibition of PolC activity and IC50's were determined (XLfit). Compounds described in Examples 1, 3-6, 8, 10-17, 19-21, 24-31, 33, 36, 38, 40, 54, 56-57, 59-71, 74-105, 107-108, 110-112, 114, 117-120, 122-142, 144-159, 162-179, 181-182, 184-225, 227-242, 244-319, 321-355, and 357-475 had IC50's of 0.01-25 μM. These compounds were specific for prokaryotic DNA polymerase, showing little or no inhibition of eukaryotic S. cerevisiae polymerase delta at concentrations up to 160 μM.

[0829]

A subset of these analogs were tested for inhibition of macromolecular biosynthesis in whole cell S. aureus assays as described by Ochsner, et al. (Antimicrob Agents Chemo. 49:4253-62 (2005)). All tested analogs were potent inhibitors of DNA synthesis, with IC50's of <0.06-4.5 μg/mL; the compounds showed little or no inhibition of other macromolecular synthesis pathways (RNA, protein or cell wall biosynthesis) at concentrations as high as 64 μg/mL.

[0830]

Compounds of the present invention were tested for antibacterial activity against a variety of pathogenic organisms including S. aureus, S. pneumoniae, S. pyogenes, E. faecalis, H. influenza and M. catarrhalis using a standard broth microdilution method to determine their minimum inhibitory concentrations (MICs). All compounds were tested using standard methods in accordance with CLSI guidelines (Clinical and Laboratory Standards Institute). Compounds described in Examples 1, 3-6, 8, 10-17, 19-21, 24-31, 33, 36, 38, 40, 54, 56-57, 59-71, 74-105, 107-108, 110-112, 114, 117-120, 122-142, 144-159, 162-179, 181-182, 184-225, 227-242, 244-319, 321-355, and 357-475 had MIC's of <0.12-4.0 μg/mL against some strains of the major Gram-positive organisms S. aureus, S. pneumoniae, S. pyogenes, and E. faecalis. The compounds showed weak Gram-negative activity with MICs of 1->128 μg/mL against some strains of the major Gram-negative organisms E. coli tolC, P. aeruginosa, H. influenze and M. catarrhalis. Compounds described in Examples 11, 54, 60, and 208 shown to be bactericidal in S. aureus, E. faecalis, E. faecium, S. pyogenes, S. epidermidis and S. pneumoniae.

[0831]

Compounds of the present invention were not compromised by existing resistance to all drug classes tested, including β-lactams, glycopeptides, oxazolidinones, macrolides, and fluoroquinolones. In particular, compounds described in Examples 11, 54, 60, and 208 were active against methicillin-(oxacillin-) resistant S. aureus (MRSA), vancomycin-intermediate S. aureus (VISA), linezolid-resistant S. aureus, methicillin-(oxacillin-) resistant and mupirocin resistant S. epidermidis, macrolide-resistant S. pyogenes, macrolide-, penicillin-, and levofloxacin-resistant S. pneumoniae, vancomycin-, macrolide-, and ciprofloxacin-resistant E. faecalis (VRE) and vancomycin-, macrolide-, and ciprofloxacin-resistant E. faecium. MICs were comparable in sensitive versus drug resistant strains, and ranged from 0.25-4 μg/mL in clinically relevant resistant strains.

[0832]

Compounds of the present invention showed broad spectrum antibacterial activity against Gram-positive bacteria. Compounds described in Examples 54, 60, 96, 107, 208, and 214 exhibited MIC90's ranging from 1-4 μg/mL for methicillin-(oxacillin-) resistant S. aureus (MRSA), vancomycin-resistant E. faecalis (VRE), vancomycin-resistant E. faecium, penicillin-intermediate S. pneumoniae and macrolide-resistant S. pyogenes.

[0833]

It will be clear that the invention is well adapted to attain the ends and advantages mentioned as well as those inherent therein. While several presently preferred embodiments have been described for purposes of this disclosure, various changes and modifications may be made which are well within the scope of the invention. Numerous other changes may be made which will readily suggest themselves to those skilled in the art and which are encompassed in the spirit of the invention disclosed herein and as defined in the appended claims.

[0834]

The entire disclosure and all publications cited herein are hereby incorporated by reference.

Как компенсировать расходы
на инновационную разработку
Похожие патенты